

4/10/05 10/511654

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/087368 A2

(51) International Patent Classification⁷: **C12N 15/11**,
A61K 48/00, 31/713, 9/08, C12Q 1/68, C12N 15/12,
C07K 14/47, 16/18, G01N 33/50, 33/68, A01K 67/027

(74) Agent: KNAUTHE EGGERS; Postfach 31 01 40, 80102
München (DE).

(21) International Application Number: PCT/EP03/04003

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 16 April 2003 (16.04.2003)

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

(26) Publication Language: English

— without international search report and to be republished
upon receipt of that report

(30) Priority Data:

02008761.5 18 April 2002 (18.04.2002) EP
60/431,173 5 December 2002 (05.12.2002) US

(71) Applicant (for all designated States except US):
LYNKEUS BIO TECH GMBH [DE/DE]; Friedrich-Bergius-Ring 15, 97076 Würzburg (DE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DRUMM, Karina** [DE/DE]; Innerer Graben 12, 97070 Würzburg (DE). **SCHLÖR, Stefan, Hubert** [DE/DE]; Alfred-Delp-Str. 9c, 97828 Marktheidenfeld (DE). **GÖHRING, Frank** [DE/DE]; Robert-Kirchhoff-strasse 35, 97076 Würzburg (DE).

WO 03/087368 A2

(54) Title: MEANS AND METHODS FOR THE SPECIFIC MODULATION OF TARGET GENES IN THE CNS AND THE EYE AND METHODS FOR THEIR IDENTIFICATION

(57) Abstract: Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the CNS and/or the eye, wherein the composition is designed to be administered outside the blood-CNS and the blood-retina barriers. Furthermore, methods are provided for identifying and obtaining nucleic acid molecules encoding polypeptides involved in CNS disorders or of the eye, methods for diagnosing said disorders as well as transgenic animal deficient in the expression of target genes identified in accordance with the described method. In addition, methods of identifying and isolating drugs that are particularly useful for the treatment of disorders related to the CNS and/or the eye are disclosed.

Means and Methods for the Specific Modulation of Target Genes in the CNS and the Eye and Methods for their Identification

Field of the invention

The present invention relates to methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, the present invention relates to the use of compositions comprising a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of disorders of the CNS and/or the eye, wherein the composition is designed to be administered outside the blood-CNS and the blood-retina barriers. The instant invention further relates to methods of identifying and isolating nucleic acid molecules encoding polypeptides involved in CNS disorders or of the eye, methods for diagnosing said disorders as well as to transgenic animals, wherein the expression of target genes identified in accordance with the method of the invention has been modulated. In addition, the present invention relates to methods of identifying and isolating drugs that are particularly useful for the treatment of disorders related to the CNS and/or the eye.

Several documents are cited throughout the text of this specification. Each of the documents cited herein (including any manufacturer's specifications, instructions, etc.) are hereby incorporated herein by reference; however, there is no admission that any document cited is indeed prior art as to the present invention.

Background art

A variety of approaches currently exist for delivering biologically active agents to the CNS and/or the eye. These include, among possible others, oral administration, intravenous-, intramuscular- and transcutaneous administration as well as intra-bulbous injection or application as eye-drops. If the drug is delivered into the systemic circulation, it is being carried to all internal organs and tissues and it has to pass through the blood-brain and/or blood retina barrier (in order to access the CNS and/or the inner parts of the eye). Obviously, all other organs are being exposed to the drug, which may lead to a high incidence of side

effects, particularly when the drug exerts its effects on target genes or gene products, which are not specific for the disorder to be treated and/or the target cell or tissue.

Another strategy often employed in brain delivery is the use of invasive methods such as intraventricular infusion systems, intracerebral (polymeric) implants, transplantation of genetically engineered protein-secreting cells and cell implants. These methods are unfortunately only effective for drug delivery to the surface of the brain or to cells immediately adjacent to the depot or infusion site and can be used for example in the treatment of carcinomatous infiltration of the meninges. However, these methods have many limitations because effective drug concentrations in brain parenchyma cannot be achieved.

)

Like the human central nervous system the human eye is an organ characterized by high complexity and the coordinated functioning of numerous specific structures and tissues. Both are protected by barriers (tear secretion, enzymes, transport mechanisms, blood-retina and blood-CNS barrier) against harmful environmental influences. Like the blood-brain barrier, the blood-retina barrier also represents a physiological barrier for the uptake of medication by the inner part of the eye, and makes pharmacological therapy of ocular diseases very difficult indeed – if at all possible - at the present state of technology.

Medication currently available on the market for the treatment of disorders of the CNS including ophthalmological diseases is therefore almost exclusively available for treatment of clinical symptoms often associated with side effects due to the high doses necessary. A causal therapy of the CNS, and particularly of the back sections of the eye, was not possible apart from the injections. Furthermore, the current state of information on the complex molecular metabolic interrelationship underlying the etiology of retinal diseases of multi-factorial origin is only limited. Consequently, medicaments available on the market are suitable to treat the symptoms of such diseases only.

In view of the need of therapeutic means for the treatment of diseases related to CNS and/or the eye, the technical problem of the present invention is to provide means and methods for the identification and modulation of genes involved in disorders of the CNS and/or the eye. More specifically, the technical problem of present invention is to provide non-invasive methods for the controlled modulation of target genes and gene products in the mammalian CNS and/or eye while overcoming the blood-brain and/or blood retina barrier without injuring it.

The solution to said technical problem is achieved by providing the embodiments characterized in the claims, and described further below.

5 Summary of the invention

The present invention is directed to a method for the treatment of a disorder of the central nervous system (CNS) and/or the eye comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-brain and/or the blood-retina barriers. In particular, said composition can comprise one or more double-stranded oligoribonucleotides (dsRNA), which mediate an RNA interference of the corresponding mRNA of one or more target genes.

In another aspect, the present invention is directed to a method of identifying and isolating a nucleic acid molecule encoding a polypeptide involved in a disorder of the CNS and/or the eye comprising the steps of:

- (a) culturing a cell, tissue or non-human animal under stress conditions which lead to simulation of a pathological condition related to a CNS or eye disorder;
- (b) isolating nucleic acids and/or proteins from a sample of said cell, tissue or animal;
- 20 (c) comparing the expression or activity profile of at least one of said nucleic acids and/or proteins with that of a corresponding non-treated cell, tissue or animal, and/or with that of a cell, tissue or animal, which has been treated under different stress conditions;
- (d) determining at least one nucleic acid and/or protein which is differentially expressed, whereby a change of expression or of the active amount of said at least one nucleic acid 25 or activity of at least one of said proteins or an altered localization of the protein is indicative for its role in a disorder of the CNS or eye.

The present invention also relates to nucleic acid molecules obtainable by the method described above, particularly if the encoded polypeptide is involved in angiogenesis and/or neovascularization and/or retinal disorder as well as to vectors comprising such nucleic acid molecules and host cells comprising said vector.

The present invention is also directed to a method for the production of a polypeptide capable of inducing a responsive change in a phenotype comprising culturing said host cell under 35 conditions allowing the expression of the polypeptide and recovering the produced

polypeptide from the culture as well as to polypeptides obtainable by said method or encoded by the nucleic acid molecules mentioned above.

Furthermore, the present invention relates to an antibody specifically recognizing such a 5 polypeptide and pharmaceutical and/or diagnostic compositions comprising such an antibody or any one of the above described nucleic acid molecules, nucleic acid molecules which are complementary to such a nucleic acid molecules, vectors, host cells, and/or polypeptides, and optionally a pharmaceutically acceptable carrier and suitable means for detection, respectively.

0

In addition, the present invention is directed to methods for treating a disorder of the CNS and/or the eye comprising administering to the subject said pharmaceutical compositions in an effective dose,

5 Furthermore, the present invention relates to a method for detecting expression of a gene involved in a disorder of the CNS and/or eye comprising:

(a) obtaining mRNA from a cell;
(b) incubating the mRNA so obtained with a probe comprising a nucleic acid molecule described above or a fragment thereof under hybridizing conditions; and

10 (c) detecting the presence of mRNA hybridized to the probe;

or

(a) obtaining a cell sample from the subject;
(b) contacting the cell sample so obtained with an antibody described above; and
(c) detecting the presence of the antibody bound to the protein encoded by said gene.

15

The invention furthermore is directed to a method for diagnosing in a subject said disorder or a predisposition to such disorder which comprises:

(a) isolating DNA from patient suffering from the disorder;
(b) digesting the isolated DNA of step (a) with at least one restriction enzyme;
10 (c) electrophoretically separating the resulting DNA fragments on a sizing gel;
(d) incubating the resulting gel with a probe comprising a nucleic acid molecule of the invention or a fragment thereof labelled with a detectable marker;
(e) detecting labelled bands on a gel which have hybridized to the probe as defined to create a band pattern specific to the DNA of patients of the disorder;
15 (f) preparing subject's DNA by steps (a) to (e) to produce detectable labeled bands on a gel; and

5 (g) comparing the band pattern specific to the DNA of patients of the disorder of step (e) and the subject's DNA of step (f) to determine whether the patterns are the same or different and to diagnose thereby the disorder or a predisposition to the disorder, if the patterns are the same;

0 or

0 (a) analyzing a sample of nucleic acids of a subject by means of a diagnostic chip, primer extension, single nucleotide polymorphisms or sequencing comprising a nucleic acid molecule as described above; and

0 (b) comparing the result with that of a sample obtained from a patient suffering from the disorder;

wherein the identity of expression profil and/or nucleotide sequence is indicative for the disorder.

5 In further embodiment, the present invention relates to a method of determining whether a test substance has an effect on a nucleic acid molecule or polypeptide involved in a CNS or eye disorder comprising the steps:

0 (a) contacting a cell which expresses the target gene or gene product identified and isolated in accordance with the above described method with a compound to be screened; and

0 (b) determining if the compound modulates the expression or the activity of said target gene or gene product.

10 In a further aspect, the present invention relates to a drug or prodrug for the treatment of a disorder as defined above comprising:

15 (a) synthesizing a test substance or a collection of test substances;

(b) subjecting said the test substance or collection of test substances to the screening method of the invention; and

(c) producing a compound identified as a modulator of a target gene or gene product or a derivative thereof.

30 In addition, the present invention is directed to a transgenic non-human animal which displays an aberrant expression or activity of the target gene or gene product defined above and to its use for a process in drug discovery for the treatment of said disorder.

Detailed Description of the Invention

The present invention relates to the use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of a disorder of the central nervous system (CNS) and/or the eye, wherein said composition is 5. designed to be applied outside the blood-CNS and/or blood-retina barriers.

In one aspect, the present invention is based on the surprising finding that the blood-retina barrier could be overcome by the administration of compounds not considered to be capable of doing so in the therapy of ocular diseases by specific modulation of protein function in the tissues of the eye. Due to the functional similarity of the blood-retina barrier to the blood-0. brain barrier, providing an improved method to overcome the blood-retina barrier with the aim to treat a given eye disease is expected to be suitable for the treatment of CNS disorders, too.

Hence, in accordance with the present invention the compositions comprising a compound 5. capable of modulating a target gene or gene product in the CNS or the eye are preferably designed to be administered without any substantial, i.e. substantially effective amount of delivery-enhancing agents facilitating passage of compounds through the blood-brain barrier and/or without the necessity of applying invasive methods and devices; see, e.g., those compounds, methods and devices described in US2002183683 and WO03/000018. However, 10. for some embodiments, which represent independent aspects of the invention, such as the use of compounds mediating RNA interference, the use of such methods and compounds may be encompassed for the enhanced and controlled delivery of a compound capable of modulating a target gene or gene product into the mammalian CNS and/or eye while circumventing the blood-brain and blood-retina barriers.

25. Those later embodiments are based, *inter alia*, on the provision of novel methods that overcome the difficulty of the application of conventional experimental strategies for the identification of genes, which cause CNS disorders and/or eye diseases, and their validation as targets for diagnosis and for pharmacological intervention strategies. This applies especially for AMD, since the symptoms of this disorder appear only late, generally in the 7th 30. decade of life. The current state of knowledge regarding the pathological metabolic interrelationships is not sufficient for the medical treatment of most CNS and eye diseases. Suitable animal or cell culture models are not available for such diseases, due to the complexity of the disease patterns and the lack of appropriate strategies for simple intervention and manipulation in the CNS and at the eye.

Hence, in one important aspect, the present invention relates to a cell, tissue and animal model based assay for the identification and isolation of target genes and gene products involved in disorders of the CNS and/or the eye and their use as targets for therapeutic intervention and/or diagnosis of such disorders.

Examples for CNS disorders are, for example, Alzheimer's disease, Parkinson disease, depression, bipolar disorder, schizophrenia, amnesia, migraine-headache, stroke, insomnia, alcohol abuse, anxiety, obsessive compulsive disorder, cerebral acquired human immunodeficiency syndrome, chronic pain and many others.

The compositions of the invention may be administered locally or systemically e.g., intravenously. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like. Furthermore, the pharmaceutical composition of the invention may comprise further agents such as interleukins or interferons depending on the intended use of the pharmaceutical composition.

In accordance with the present invention the pharmaceutical compositions are administered to a subject in an effective dose of between about 0,1 µg to about 10 mg units/day and/or units/kg body weight; see also infra. Furthermore, the appropriate dosage regimen can be determined according to Example 21.

In a preferred embodiment, the disorder to be treated is related to eye. Such disorders include chorioretinitis and herpes retinitis, which may be considered as acquired forms of retinal disease, the majority of retinal disease disorders are reduced to a genetic predisposition. These include for example primary retinal detachment (ablatio retinae), retinal blastoma, retinal astrocytoma (Bourneville-Pringle), angiomatosis retinae (Hippel-Lindau), Coat's disease

(exudative retinitis), Eale's disease, central serous retinopathy, ocular albinism, retinitis pigmentosa, retinitis punctata albescens, Usher syndrome, Leber's congenital amaurosis, cone dystrophy, vitelliform macular degeneration (Best's disease), juvenile retinoschisis, North Carolina macular dystrophy, Sorsby's fundus dystrophy, Doyne's honey comb retinal dystrophy (Malattia Leventinese), Stargardt's disease, Wagner vitreoretinal degeneration or Age-related macular degeneration (AMD) as well as single-gene retinopathies like Morbus Best or Morbus Stargardt. Various genetic defects are known which lead or predispose to this wide range of eye disease phenotypes.

0 Some of these clinical phenotypes are characterized by a pathological de novo generation of blood vessels, which is called neoangiogenesis or neovascularization. Starting from the choriokapillaris, the growth of new blood vessels into the inner eye then leads to an increasing degeneration of photoreceptor cells in the affected areas of the human retina. In the field of ophthalmology, one can distinguish between two forms of neovascularization: subretinal 5 (choroidal = CNV) neovascularization and retinal neovascularization. Subretinal neovascularization, which is also called subfoveal neovascularization, is associated with degenerative disorders like Makular degeneration and characterized by loss of visual acuity and metamorphopsia. On the other hand, retinal neovascularization, vitreous body or Iris neovascularization is associated with ischemic processes (e.g. retinal vasculitis and diabetic 10 retinopathy). Furthermore, neoangiogenesis is an important pathomechanism in different, non ophthalmological disease patterns such as tumor growth, arthritis and diabetic nephropathy. Therefore, in a preferred embodiment of the methods and uses of the present invention said disorder to be treated is related to angiogenesis and/or neovascularization and particularly 15 preferred to the retinal pigment epithelium (RPE), neurosensory retina and/or choriodea. Most preferred, the disorder is wet age-related macular degeneration (AMD) or diabetic retinopathy.

The following description deals with AMD as example for a complex eye disease with a 10 genetic component. Considering the wet form of AMD, it also serves as an example for a disease pattern, which is characterized by a distinct neovascularization. The example shall illustrate the associated technical problems with reference to the study of molecular causes and the development of diagnostic and pharmacological intervention strategies. AMD, which can be thought as a sub-type of retinal degeneration, is the most common cause 15 of visual morbidity in the developed world with a prevalence increasing from 9% in persons

over 52 years to more than 25% in persons over the age of 75 (Paetkau et al. 1978, Leibowitz et al. 1980, Banks and Hutton 1981, Ghafour et al. 1983, Hyman 1987, Hyman et al. 1983, Grey et al. 1989, Yap and Weatherill 1989, Heiba et al. 1994).

5 An early stage in the evolution of AMD pathology is accompanied by an increasing accumulation of yellowish lipofuscin-like particles within the retinal pigment epithelium (RPE; Feeney 1978). It is thought that these particles represent remnants of undigested phagocytosed photoreceptor outer segment membranes which, in the normal process, are excreted basally through Bruch's membrane into the choriocapillaris. Over time, accumulation
0 of lipofuscin-like particles affect Bruch's membrane and lead to its progressive destruction (Hogan and Alvarado 1967, Sarks 1976, Feeney-Burns and Ellersieck 1985, Pauleikhoff et al. 1990). The deposits in the RPE and Bruch's membrane consists largely of lipids although their exact composition may vary between individuals with some deposits revealing more polar phospholipids while others contain predominantly apolar neutral lipids.

5 These individual differences in drusen composition are thought to be the basis for the clinical heterogeneity in AMD (Green et al. 1985). While some patients present with an ingrowth of vessels from the choriocapillaris through Bruch's membrane (neovascularization) (Bressler et al. 1982), others show pigment epithelial detachment due to exudation underneath the RPE (Gass 1967, Green et al. 1985), and a third group of patients experiences a slow decrease of
0 visual loss due to atrophic changes in the RPE and the overlying sensory neuroretina (Maguire and Vine 1986).

Although much less common the exudative/neovascular form of AMD accounts for more than 80% of blindness with a visual acuity of $\leq 20/200$ (Bressler et al. 2002). In contrast to the
15 above described "dry" form of AMD, the exudative "wet" AMD is associated with a choroidal neovascularization (CNV), leading to blindness and, thus, to a loss of life quality (followed by psychic disorders, increased risk of injury etc; Bressler et al. 2002). There is a high risk of developing ($> 40\%$) CNV in the second eye within 5 years of the development of
30 CNV-AMD in the first eye (Bressler et al. 2002). Neovascular AMD is characterized by choroidal neovascular lesions. These lesions develop when abnormal blood vessels from the choroid grow and proliferate through breaks in the Bruch membrane to beneath the retinal pigment epithelium (Bressler et al. 2002, Campochiaro et al. 1999). The abnormal leakage from these vessels can result in hemorrhage or detachment of the retinal pigment epithelium

or the neurosensory retina (which overlies the retinal pigment epithelium). Accompanying scar formation can replace retinal tissue and result in permanent vision loss.

AMD is a complex disease caused by exogenous as well as endogenous factors (Meyers and 5 Zachary 1988; Seddon et al. 1997). In addition to environmental factors, several personal risk factors such as hypermetropia, light skin and iris colour, elevated serum cholesterol levels, hypertension or cigarette smoking have been suggested (Hyman et al. 1983, Klein et al. 1993, Sperduto and Hiller 1986, The Eye Disease Case-Control Study Group 1992, Bressler and Bressler 1995). A genetic component for AMD has been documented by several groups (Gass 0 1973, Piguet et al. 1993, Silvestri et al. 1994) and has lead to the hypothesis that the disease may be triggered by environmental/individual factors in those persons who are genetically predisposed. The number of genes which, when mutated, can confer susceptibility to AMD is not known but may be numerous.

5 The late onset of symptoms generally in the 7th decade of life as well as the clinical and likely genetic heterogeneity make it difficult to apply conventional approaches for the identification of genes predisposing to AMD. Due to the complexity of the clinical phenotype, it may be assumed that the number of genes is large, which, when mutated contribute to AMD susceptibility.

0 With recent physical approaches for the treatment of AMD such as laser photocoagulation, photodynamic therapy (using verteprofin, trade name Visudyne ®, Novartis), irradiation or surgical therapies, success was only achieved with a moderate percentage of the patients (Bressler et al. 2002, Yuzawa et al. 2001).

15 Hence, the methods, uses and compositions of the present invention described herein represent an important improvement and alternative therapeutic intervention for the treatment of this particular disease as well as of others. For those embodiments the pharmaceutical compositions are preferably designed to be effective in (and applied to) the posterior segment of the eye, preferably in a form designed to be applied outside the retinal region of the blood- 30 retina barrier.

In one embodiment of the invention said compound is an inhibitor/antagonist of said target gene or gene product and preferably inhibits the expression of a gene or the activity of a gene product involved in angiogenesis and/or neovascularization; see supra.

The term "antagonist/inhibitor" in accordance with the present invention includes chemical agents that modulate the action of a gene or the activity of a gene product either through altering its enzymatic activity or through modulation of expression, e.g., by affecting transcription or translation. In some cases the antagonist/inhibitor may also be a substrate of a gene product involved in the disorder or a ligand binding molecule.

5 The term "inhibitor" includes both substances which reduce the activity of the polypeptide and those which nullify it altogether.

An "antagonist" that modulates the activity of the gene product and causes for example a 0 response in a cell based assay described below, refers to a compound that alters directly or indirectly the activity the gene product or the amount of active product. The effect of an antagonist may be observed as a blocking of agonist-induced activation of a target gene. Antagonists include competitive as well as non-competitive antagonists. A competitive antagonist (or competitive blocker) interacts with or near the site specific for agonist binding. 5 A non-competitive antagonist or blocker inactivates the function of the gene product by interacting with a site other than the agonist interaction site. Preferably, the antagonist/inhibitor is small chemical agent which directly interacts with the target gene product involved in the disorder, preferably with a gene product involved in angiogenesis and/or neovascularization. Therefore, there will preferably be a direct relationship between 0 the molar amount of compound required to inhibit or stimulate the target gene activity and the molar amount of gene product present or lacking in the cell. The compounds can be derived from a polypeptide, an anti-polypeptide antibody, an RNA molecule encoding (part of) a polypeptide or its antisense sequence, a transcription regulator, a ligand binding molecule, a polypeptide substrate or a known agonist/activator or antagonist/inhibitor.

25 In a preferred embodiment of the present invention said antagonist is based on nucleic acids, for example a ribozyme, antisense or sense nucleic acid molecules to said gene or gene or dsRNA molecules which are capable of mediating RNA interference. Methods and computer programs for the preparation rational selection of for example antisense oligonucleotide 30 sequences are described in the prior art; see for example Smith, Eur. J. Pharm. Sci. 11 (2000), 191-198; Toschi, Methods 22 (2000), 261-269; Sohail, Adv. Drug Deliv. Rev. 44 (2000), 23-34; Moulton, J. Comput. Biol. 7 (2000), 277-292. These procedures comprise how to find optimal hybridization sites, and secondly on how to select sequences that bind to for example mRNAs overexpressed in a CNS or eye disorder. These methods can include the more

empirical testing of large numbers of mRNA complementary sequences to the more systematic techniques, i.e. RNase H mapping, use of combinatorial arrays and prediction of secondary structure of mRNA by computational methods. Structures that bind to structured RNA, i.e. aptastructures and tethered oligonucleotide probes, and foldback triplex-forming 5 oligonucleotides can also be employed for the purpose of the present invention. Relating to selection of antisense sequences by aid of computational analysis, valuable www addresses are given below.

In a particularly preferred embodiment of the present invention said antagonist/inhibitor 0 substantially consists of ribonucleotides which preferably contain a portion of double-stranded oligoribonucleotides (dsRNA). Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites is described for example in Amarzguioui, Nucleic Acids Res. 28 (2000), 4113-4124. Minimising the secondary structure of DNA targets by incorporation of a modified deoxynucleoside: implications for nucleic acid analysis 5 by hybridisation is described in Nguyen, Nucleic Acids Res. 28 (2000), 3904-3909. dsRNA between 21 and 23 nucleotides in length is preferred. The dsRNA molecule can also contain a terminal 3'-hydroxyl group and may represent an analogue of naturally occurring RNA, differing from the nucleotide sequence of said gene or gene product by addition, deletion, substitution or modification of one or more nucleotides. General processes of 0 introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell comprising RNA with double-stranded structure, i.e. dsRNA or RNAi are known to the person skilled in the art and are described, for in WO99/32619, WO01/68836, WO01/77350, WO00/44895, WO02/055692 and WO02/055693, the disclosure content of which is hereby incorporated by reference.

!5 The target mRNA of said dsRNA is preferably encoded by gene or a cDNA obtained in accordance with the method of the present invention described below. In one embodiment the target nucleotide sequence encodes an amino acid sequence of SEQ ID NO: 2 or 4 and/or comprises a nucleotide sequence of SEQ ID NO: 1 or 3.

30 In one embodiment of the invention the compound to be used in the compositions is a nucleic acid molecule or encoded by a nucleic acid molecule and is designed to be expressed in cells of the CNS and/or eye. For those embodiments gene therapy intervention is envisaged; see also infra.

In a preferred embodiment of the methods and uses of the present invention the composition is in a form designed to be introduced into the cells or tissue of the CNS or eye by a suitable carrier, characterized by the application occurring outside the blood-CNS and/or blood-retina barriers, for instance as eye drops. It can also be administered systemically, iontophoretically or by retrobulbar injection.

Iontophoresis has been defined as the active introduction of ionised molecules into tissues by means of an electric current. The technique has been used to enhance drug delivery into tissues underlying the donor electrode (e.g. skin) as well as to the general blood circulation, thus providing systemic delivery of a drug to the entire body. Iontophoresis devices require at least two electrodes, both being in electrical contact with some portion of a biological membrane surface of the body. One electrode commonly referred to as the "donor" or "active" electrode, is the electrode from which the biologically active substance, such as a drug or prodrug, is delivered into the body. Another electrode having an opposite polarity functions to complete the electric circuit between the body and the electrical power source. This electrode is commonly referred to as the "receptor" or "passive" electrode. During iontophoresis, an electrical potential is applied over the electrodes, in order to create an electrical current to pass through the drug solution and the adjacent tissue. Iontophoresis has been described for the treatment of blood-vessel related disorders (e.g. restenosis), bladder, uterus, urethra and prostate disorders. U.S. Patent Nos. 6,219,557; 5,588,961; 5,843016; 5,486,160; 5,222,936; 5,232,441; 5,401,239 and 5,728,068 disclose different types of iontophoresis catheters for insertion into hollow, tubular organs (bladder, urethra and prostate) or into blood vessels. US 2002183683 suggests the method for delivery of active substances into the CNS.

Numerous active, often specifically expressed genes are required to perform and control the processes in the cells of the CNS and the retina and the metabolic exchanges across the blood-CNS and blood-retina barrier. Specific genetic activity is also necessary for maintaining the structure and functional integrity of numerous components of these complex tissues. As a consequence, this unique and highly evolved system is especially susceptible to various genetic defects, thus leading to a wide range of disease phenotypes. While studying monogenetic disorders is relatively easy, provided the patients are members of a family sufficiently large enough to allow positional cloning, the identification of genes that contribute to multigenic disorders or confer or susceptibility to a disease is far more difficult.

Hence, in another aspect the present invention relates to a method of identifying and isolating a nucleic acid molecule encoding a polypeptide involved in a disorder of the CNS and/or the eye comprising:

- (a) culturing a cell, tissue or non-human animal under stress conditions which lead to simulation of a pathological condition related to a CNS or eye disorder;
- 5 (b) isolating nucleic acids and/or proteins from a sample of said cell, tissue or animal;
- (c) comparing the expression or activity profile of at least one of said nucleic acids and/or proteins with that of a corresponding non-treated cell, tissue or animal, and/or with that of a cell, tissue or animal, which has been treated under different stress conditions;
- 0 (d) determining at least one nucleic acid and/or protein which is differentially expressed, whereby a change of expression or of the active amount of said at least one nucleic acid or activity of at least one of said proteins or an altered localization of the protein is indicative for its role in a disorder of the CNS or eye.

5 First, a cell, tissue or non-human animal is cultured under stress conditions which lead to simulation of a pathological condition related to a CNS or eye disorder. Preferably, said method is a cell culture based method. Preferred cells and tissue investigated (either in culture or comprised in a test animal) are those which belong to the CNS and/or eye, for example neuronal cells, glial cells, retinal cells, etc.

10 In a particular preferred embodiment of the method of the present invention said cell is an RPE cell or an established cell line derived from an RPE cell such as the cell line ARPE-19; see also infra. The isolation of RPE cells is described, e.g., in Example 1 below. ARPE-19 cell line is described in Dunn et al., Exp. Eye Res. 62 (1996), 155-169. For example, ARPE-19 cell line is particularly suitable for mimicking the repair response observed in vivo during

15 proliferative vitreoretinopathy by vitreous treatment.

The mentioned stress condition can be generated by an aberrant supply of the cell, tissue or animal culture conditions and comprise, for example, oxidative stress, hypoxic culture conditions, insufficient nutrition and/or supply with growth factors, change of pH-value and/or pathophysiological concentration of rod outer segments (ROS) and/or A2-E; see also Examples 3 to 10. Preferred stress conditions are those conferred by pathophysiological concentration of rod outer segments (ROS) and/or A2-E. As an example the tissue of the interior segment of the eye can be supplied in an aberrant manner, which is a preferred embodiment of the method of the invention. Table 1 shows commonly marker genes, whose

altered expression indicates apoptosis, hypoxic culture conditions or oxidative stress and which can thereby be used to verify and/or quantify the applied stress and the cellular response, respectively.

- ;) A further step of the method of the present invention involves isolating the nucleic acids and/or proteins from a sample of said cell, tissue or animal and in a further step comparing the expression or activity profile of at least one of said nucleic acids and/or proteins with that of a corresponding non-treated cell, tissue or animal, and/or with that of a cell, tissue or animal, which has been treated under different stress conditions. The isolation of nucleic acids and
- ;) proteins can be done by methods known to the person skilled in the art and described in the cited literature; see also Examples 11 and 12.

In the last step at least one nucleic acid and/or protein which is differentially expressed is determined, whereby a change of expression or of the active amount of said at least one nucleic acid or activity of at least one of said proteins or an altered localization of the protein is indicative for its role in a disorder of the CNS or eye.

In one embodiment of the screening method of the invention the expression of nucleic acids is analyzed with an expression array and/or realtime PCR. Chip and array technology are well known to the person skilled in the art; see also Examples 14 to 20. Advances in approaches to DNA-based diagnostics are reviewed, for example, by Whitcombe et al. in *Curr. Opin. Biotechnol.* 9 (1998), 602-608. Furthermore, DNA chips and microarray technology devices, systems, and applications are described by, e.g. Cuzin, *Transfus. Clin. Biol.* 8 (2001), 291-296 and Heller, *Annu. Rev. Biomed. Eng.* (2002), 129-153. Likewise, biomedical applications of protein chips is known and described in, e.g., Ng, *J. Cell. Mol. Med.* 6 (2002), 329-340.

In another embodiment the protein expression is analyzed with immunoblot or ELISA assay, or 2 D gel electrophoresis or MALDI-TOF and particularly preferred antibodies are used which are specific for proteins involved in angiogenesis and/or neovascularization.

;) Detailed descriptions of conventional methods, such as those employed in the construction of vectors and plasmids, the insertion of genes encoding polypeptides into such vectors and plasmids, the introduction of plasmids into host cells, and the expression and determination thereof of genes and gene products can be obtained from numerous publication, including Sambrook et al., (1989) *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring

Harbor Laboratory Press. Candidate nucleic acids or encoded polypeptides identified in such a manner can be validated by expressing them and observing the phenotype. A further embodiment of the screening method therefore comprises the overexpression or inhibition of expression of the identified candidate nucleic acid or encoded polypeptide in said cell, tissue or animal for their capability of inducing a responsive change in the phenotype of said cell, tissue or animal, wherein said phenotype is related to a disorder of the CNS or eye.

5 The responsive change in the phenotype of said cells can be observed by subjecting the cells, secreted factors thereof, or cell lysates thereof, to endothelial cell cultures; and/or analyzing different parameters like cell proliferation, electrophysiological activity, DNA synthesis, out-
0 growth of cells, cell migration, chemokinesis, chemotaxis, development of vessels, marker gene expression or activity, apoptosis and/or vitality. Examples for such assays are:

Proliferating cell nuclear antigen assay (PCNA) or TUNEL-assay are described in Montesano, R.: Regulation of angiogenesis in vitro. Eur J Clin Invest, 22: 504-515, 1992. Montesano, R.
5 et al.: Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA, 83: 7297-7301, 1986. Holmgren, L. et al.: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med, 1: 149-153, 1995.
10 Boyden chamber assay is described in Holmgren, L. et al.: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med, 1: 149-153, 1995. Albini, A. et al.: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Research, 47: 3239-3245, 1987. Hu, G. et al.: Angiogenen promotes invasiveness of cultured endothelial cells by stimulation of cell-associated
25 proteolytic activities. Proc Natl Acad Sci USA, 91: 12096-12100, 1994. Alessandri, G. et al.: Mobilization of capillary endothelium in vitro induced by effectors of angiogenesis in vivo. Cancer res, 43: 1790-1797, 1983.

Aortic ring angiogenesis assay is described in Zuh, W.H., et al.: Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab Invest, 80: 545-555, 2000. Kruger, EA. et al.: UCN01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. Invasion Metastas, 18: 209-218, 2000. Kruger, E.A. et al.: Endostatin inhibits microvessel formation in the rat aortic ring angiogenesis assay. Biochem Biophys Res Commun, 268: 183-191, 2000. Bauer, K.S. et
35 al.: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species

dependent. Biochem Pharmacol, 55: 1827-1834, 1998. Bauer, K.S. et al.: Carboxyamidotriazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. J Pharmacol Exp Ther, 292: 31-37, 2000. Berger, A.C. et al.: Endothelial monocyte activating polypeptide III induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc Res, 60: 70-80, 2000.

5 Saphenous vein angiogenesis assay is described in Kruger, E.A. et al.: Endostatin inhibits microvessel formation in the rat aortic ring angiogenesis assay. Biochem Biophys Res Commun, 268: 183-191, 2000.

0 Corneal micropocket assay is described in Gimbrone, E.A. et al.: Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst, 52: 413-427, 1974. Kenyon, B.M. et al.: A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci, 37: 1625-1632, 1996. Kenyon, B.M. et al.: Effects of thalidomide and 5 related metabolites in a mouse corneal model of neovascularization. Exp Eye Res, 64: 971-978, 1997. Proia, A.D. et al.: The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res, 57: 693-698, 1993.

0 Chick embryo chorioallantoic membrane assay is described in Knighton, D. et al.: Avascular and vascular phases of tumor growth factor in the chicken embryo. Br J Cancer, 35: 347-356, 1977. Auerbach, R. et al.: A simple procedure for the long-term cultivation of chicken embryos. Dev Biol, 41: 391-394, 1974. Ausprung, D.H. et al.: Differentiation of vascular endothelium in the chick chorioallantois: A structural and autoradiographic study. Dev Biol, 38: 237-248, 1974. Nguyen, M. et al.: Quantitation of angiogenesis and antiangiogenesis in 5 the chick embryo chorioallantoic membrane. Microvasc Res, 47: 31-40, 1994.

Furthermore a sample of said cells can be treated with an inhibitor specific for the candidate nucleic acid or encoded polypeptide to be validated and in a second step it is determined whether said cells, secreted factors thereof or cell lysates thereof have lost their capability of 0 inducing the responsive change in the phenotype observed when no inhibitor is used. In a preferred embodiment the phenotype is angiogenesis and/or neovascularization. As an inhibitor the molecules described above can be used. Preferably, siRNA technique is used for inhibiting the expression of the target gene. A collection of protocols for siRNA-mediated knockdown of mammalian gene expression, which can be adapted to a method of the

invention as mentioned herein is described for example in Elbashir et al., Methods 26 (2002), 199-213 and Martinez et al., Cell 110 (2002), 563-574.

For the development of assays and drugs for treatment of disorders caused by the genes it is
5 often necessary to identify the sequence of those nucleic acids and/or proteins, and optionally
identifying the corresponding encoding gene or cDNA as well. Based on the specific
functions of the cells of the CNS and/or eye specific, it is presumed that genes, the aberrant
function of which cause a CNS or eye disease, are specifically expressed in the respective
tissues and cells, thus representing preferred targets for drug interventions. Therefore, the
0 identified gene, cDNA or a fragment thereof is usually also cloned and nucleic acid molecules
obtainable by the methods described herein form also part of the invention, particularly if they
encode polypeptides involved in angiogenesis and/or neovascularization. Such a nucleic acid
molecule can be DNA or cDNA and be derived from a mammal and in a preferred
embodiment is from a mouse or a human.

5 Hence, in a first set of experiments several nucleic acid molecules could be identified which
indeed were known to be involved in autosomal recessive retinitis pigmentosa (ARRP), which
inter alia is characterized by the degeneration of retinal photoreceptor cells. For example,
0 nucleic acid molecules could be identified corresponding to the gene encoding the human
cyclic nucleotide gated channel alpha 1 (CNGA1, accession No. NM_000087; SEQ ID NO: 1
and 2). Mutations in this gene have been described to be involved in autosomal recessive
retinitis pigmentosa; see Dryja et al., Proc. Nat. Acad. Sci. USA 92 (1995), 10177-10181. In
another experiment, nucleic acid molecules corresponding to the human gene encoding the
beta-subunit of rod cGMP phosphodiesterase (accession No. NM_000283; SEQ ID NO: 3 and
5 4) have been identified. Malfunction of this gene has also been associated with autosomal
recessive retinitis pigmentosa, in particular with congenital stationary night blindness 3,
CSNB3. These results confirm that the method of the present invention works.

0 In another embodiment the nucleic acid molecule specifically hybridizes to one of the nucleic
acid molecules described above wherein the latter encodes a mutated version of the protein
which has lost its capability of inducing a responsive change in a phenotype. In addition or
alternatively, nucleic acid molecules are encompassed of at least 15 nucleotides in length and
able to hybridize specifically to a nucleic acid molecule described above or with a

complementary strand thereof. These nucleic acid molecules are particularly useful as probes; see infra.

The nucleic acid molecules described above can be contained in a vector and preferably be operatively linked to regulatory elements permitting expression in prokaryotic or eukaryotic host cells. Expression of said nucleic acid molecule comprises transcription into a translatable mRNA. Regulatory elements ensuring expression in eukaryotic cells, preferably mammalian cells, are well known to those skilled in the art. They usually comprise regulatory sequences ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as translational enhancers, and/or naturally associated or heterologous promoter regions.

Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the P_L , lac, trp or tac promoter in *E. coli*, and examples for regulatory elements permitting expression in eukaryotic host cells are the AOX1 or GAL1 promoter in yeast or the CMV-, SV40-, RSV-promoter, CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells.

Beside elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk-poly-A site, downstream of the nucleic acid molecule. Furthermore, depending on the expression system used leader sequences capable of directing the polypeptide to a cellular compartment or secreting it into the medium may be added to the coding sequence of the polynucleotide of the invention and are well known in the art. The leader sequence(s) is (are) assembled in appropriate phase with translation, initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein, or a portion thereof, into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including a C- or N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product. In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc/CMV, pcDNA1, pcDNA3 (Invitrogen), or pSPORT1 (GIBCO BRL).

Preferably, the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of 5 the nucleotide sequences, and, as desired, the collection and purification of the protein so produced.

Furthermore, the present invention relates to vectors, particularly plasmids, cosmids, viruses and bacteriophages used conventionally in genetic engineering that comprise a nucleic acid 0 molecule of the invention. Preferably, said vector is an expression vector and/or a gene transfer or targeting vector. Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or bovine papilloma virus, may be used for delivery of the polynucleotides or vector of the invention into targeted cell population. Methods which are well known to those skilled in the art can be used to construct 5 recombinant viral vectors; see, for example, the techniques described in Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1994). Alternatively, the polynucleotides and vectors of the invention can be reconstituted into liposomes for delivery to target cells. The vectors containing the nucleic acid 10 molecules of the invention can be transferred into the host cell by well known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be used for other cellular hosts; see Sambrook, *supra*.

25 Vectors that can be used for therapeutic and/or diagnostic purposes in accordance with the teaching of the present invention are known to the person skilled in the art; see, e.g., heritable and inducible genetic interference by double-stranded RNA encoded by transgenes described in Tavernarakis et al., *Nat. Genet.* 24 (2000), 180-183. Further vectors and methods for gene transfer and generation of transgenic animals are described in the prior art; see, e.g., adeno- 30 associated virus related vectors described in Qing et al., *Virol.* 77 (2003), 2741-2746; human immunodeficiency virus type 2 (HIV-2) vector-mediated *in vivo* gene transfer into adult rabbit retina described in Cheng et al. *Curr. Eye Res.* 24 (2002), 196-201, long-term transgene expression in the RPE after gene transfer with a high-capacity adenoviral vector described in Kreppel et al., *Invest. Ophthalmol. Vis. Sci.* 43 (2002), 1965-1970 and non-invasive

observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo described in Borras et al., J. Gene Med. 3 (2001), 437-449.

CNS gene transfer has also been described in Leone et al., Curr. Opin. Mol. Ther. 1 (1999), 487-492

5

Said vector in turn can be contained in a host cell. A bacterial, fungal, plant or animal cell can be used as a host but mammalian cells are preferred, especially RPE or neurosensory retina 0 cells.

If these host cells are cultured under conditions allowing the expression of the polypeptide and recovering the produced polypeptide from the culture this constitutes a method for the production of a polypeptide capable of inducing a responsive change in a phenotype.

5 Polypeptides encoded by a nucleic acid molecule as defined above or obtainable by this method are therefore preferred embodiments of this invention as well as antibodies specifically recognizing such a polypeptide. Antibodies or fragments thereof to the aforementioned polypeptides can be obtained by using methods which are described, e.g., in Harlow and Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, 1988.

0

Furthermore, the polypeptides encoded by the identified and isolated nucleic acid molecules can be used to identify synthetic chemical peptide mimetics that bind to or can function as a ligand, substrate, binding partner or the receptor of the polypeptide as effectively as does (e.g.) the natural ligand; see, e.g., Engleman, J. Clin. Invest. 99 (1997), 2284-2292. For example, folding

15 simulations and computer redesign of structural motifs of the polypeptide can be performed using appropriate computer programs (Olszewski, Proteins 25 (1996), 286-299; Hoffman, Comput. Appl. Biosci. 11 (1995), 675-679). Computer modeling of protein folding can be used for the conformational and energetic analysis of detailed peptide and protein models (Monge, J. Mol. Biol. 247 (1995), 995-1012; Renouf, Adv. Exp. Med. Biol. 376 (1995), 37-45). In particular, the

20 appropriate programs can be used for the identification of interactive sites of the polypeptide and its ligand or other interacting proteins by computer assisted searches for complementary peptide sequences (Fassina, Immunomethods 5 (1994), 114-120. Further appropriate computer systems for the design of protein and peptides are described in the prior art, for example in Berry, Biochem. Soc. Trans. 22 (1994), 1033-1036; Wodak, Ann. N. Y. Acad. Sci. 501 (1987), 1-13; Pabo,

Biochemistry 25 (1986), 5987-5991. Methods for the generation and use of peptidomimetic combinatorial libraries are described in the prior art, for example in Ostresh, Methods in Enzymology 267 (1996), 220-234 and Dorner, Bioorg. Med. Chem. 4 (1996), 709-715. Furthermore, a three-dimensional and/or crystallographic structure of the polypeptide can be used 5 for the design of mimetic inhibitors of the biological activity of the protein of the invention (Rose, Biochemistry 35 (1996), 12933-12944; Rutenber, Bioorg. Med. Chem. 4 (1996), 1545-1558). The structure-based design and synthesis of low-molecular-weight synthetic molecules that 10 mimic the activity of a native biological polypeptide is further described in, e.g., Dowd, Nature Biotechnol. 16 (1998), 190-195; Kieber-Emmons, Current Opinion Biotechnol. 8 (1997), 435-441; Moore, Proc. West Pharmacol. Soc. 40 (1997), 115-119; Mathews, Proc. West Pharmacol. Soc. 40 (1997), 121-125; Mukhija, European J. Biochem. 254 (1998), 0 433-438.

The nucleic acid molecules identified and isolated by the method of the present invention can 5 also serve as a target for activators and inhibitors. Activators may comprise, for example, proteins that bind to the mRNA of the corresponding gene, thereby stabilizing the native conformation of the mRNA and facilitating transcription and/or translation, e.g., in like manner as Tat protein acts on HIV-RNA. Furthermore, methods are described in the literature 10 for identifying nucleic acid molecules such as an RNA fragment that mimics the structure of a defined or undefined target RNA molecule to which a compound binds inside of a cell resulting in retardation of cell growth or cell death; see, e.g., WO 98/18947 and references cited therein. These nucleic acid molecules can be used for identifying unknown compounds 15 of pharmaceutical and/or agricultural interest, and for identifying unknown RNA targets for use in treating a disease. Alternatively, for example, the conformational structure of the RNA fragment which mimics the binding site can be employed in rational drug design to modify known ligands to make them bind more avidly to the target. One such methodology is nuclear 20 magnetic resonance (NMR), which is useful to identify drug and RNA conformational structures. Still other methods are, for example, the drug design methods as described in WO 95/35367, US-A-5,322,933, where the crystal structure of the RNA fragment can be deduced 25 and computer programs are utilized to design novel binding compounds which can act as 30 antibiotics.

Hence, the antagonist/inhibitor can be, for example, an antibody, an antisense nucleic acid molecule or a ligand binding molecule. Preferably, said antagonist/inhibitor interferes with

change of conformation/function of the polypeptide, most preferably with a biological activity related to angiogenesis and/or neovascularization.

The antibodies, nucleic acid molecules, inhibitors and activators used in the compositions of 5 the present invention preferably have a specificity at least substantially identical to the binding specificity of the natural ligand or binding partner of the protein, in particular if stimulation is desired. An antibody or inhibitor can have a binding affinity to the protein of at 0 least 10^5 M⁻¹, preferably higher than 10^7 M⁻¹ and advantageously up to 10^{10} M⁻¹ in case suppression should be mediated. In a preferred embodiment, a suppressive antibody or inhibitor has an affinity of at least about 10^{-7} M, preferably at least about 10^{-9} M and most preferably at least about 10^{-11} M; and an activator has an affinity of less than about 10^{-7} M, preferably less than about 10^{-6} M and most preferably in order of 10^{-5} M.

In case of antisense nucleic acid molecules it is preferred that they have a binding affinity to those encoding the protein of at most 2-, 5- or 10-fold less than an exact complement of 5 consecutive nucleotides of the coding sequence.

Another embodiment of this invention is a pharmaceutical composition comprising a nucleic acid molecule described above, a vector, a host cell, a polypeptide and/or an antibody as defined above, and optionally a pharmaceutically acceptable carrier; see supra and infra. 0 Those compositions can be used in a method for treating of a disorder of the CNS or the eye comprising administering to the subject such a pharmaceutical compositions in an effective dose.

Similarly the nucleic acid molecule, vector, host cell, polypeptide and/or antibody described 15 above can be used in a diagnostic composition that optionally contains suitable means for detection as well. Expression of a gene involved in a disorder of the CNS or the eye can be detected by obtaining mRNA from a cell; incubating the mRNA so obtained with a probe comprising a nucleic acid molecule as described above or a fragment thereof under hybridizing conditions; and detecting the presence of mRNA hybridized to the probe. On the 30 protein level the method for detecting expression of a gene involves obtaining a cell sample from the subject; contacting the cell sample so obtained with an antibody as defined above; and detecting the presence of antibody so bound. This way the detection of the expression of a protein encoded by a mutated nucleic acid molecule which has lost its capability to induce a responsive change in phenotype is also possible.

The invention also provides a method for diagnosing in a subject a disorder or a predisposition to such disorder of the CNS or the eye which comprises:

- (a) isolating DNA from patient suffering from the disorder;
- 5 (b) digesting the isolated DNA of step (a) with at least one restriction enzyme;
- (c) electrophoretically separating the resulting DNA fragments on a sizing gel;
- (d) incubating the resulting gel with a probe comprising a nucleic acid molecule described above or a fragment thereof labelled with a detectable marker;
- 0 (e) detecting labelled bands on a gel which have hybridized to the probe as defined to create a band pattern specific to the DNA of patients of the disorder;
- (f) preparing subject's DNA by steps (a) to (e) to produce detectable labelled bands on a gel; and
- 15 (g) comparing the band pattern specific to the DNA of patients of the disorder of step (e) and the subject's DNA of step (f) to determine whether the patterns are the same or different and to diagnose thereby the disorder or a predisposition to the disorder, if the patterns are the same.

Another method provided by this invention for diagnosing in a subject a disorder or a predisposition to such disorder of the CNS or the eye comprises:

- 20 (a) analyzing a sample of nucleic acids of a subject by means of a diagnostic chip, primer extension, single nucleotide polymorphisms or sequencing comprising a nucleic acid molecule as defined above, and
- (b) comparing the result with that of a sample obtained from a patient suffering from the disorder,
- 25 wherein the identity of expression profile and/or nucleotide sequence is indicative for the disorder.

In these embodiments, the nucleic acid molecules, (poly)peptide, antibodies or compounds identified above are preferably detectably labeled. A variety of techniques are available for labeling biomolecules, are well known to the person skilled in the art and are considered to be 30 within the scope of the present invention. Such techniques are, e.g., described in Tijssen, "Practice and theory of enzyme immuno assays", Burden, RH and von Knippenburg (Eds), Volume 15 (1985), "Basic methods in molecular biology"; Davis LG, Dibmer MD; Battey Elsevier (1990), Mayer et al., (Eds) "Immunochemical methods in cell and molecular biology" Academic Press, London (1987), or in the series "Methods in Enzymology",

Academic Press, Inc. There are many different labels and methods of labeling known to those of ordinary skill in the art. Commonly used labels comprise, inter alia, fluorochromes (like fluorescein, rhodamine, Texas Red, etc.), enzymes (like horse radish peroxidase, β -galactosidase, alkaline phosphatase), radioactive isotopes (like ^{32}P or ^{125}I), biotin, 5 digoxigenin, colloidal metals, chemi- or bioluminescent compounds (like dioxetanes, luminol or acridiniums). Labeling procedures, like covalent coupling of enzymes or biotinyl groups, iodinations, phosphorylations, biotinylations, random priming, nick-translations, tailing (using terminal transferases) are well known in the art. Detection methods comprise, but are not limited to, autoradiography, fluorescence microscopy, direct and indirect enzymatic reactions, 10 etc.

In addition, the above-described compounds etc. may be attached to a solid phase. Solid phases are known to those in the art and may comprise polystyrene beads, latex beads, magnetic beads, colloid metal particles, glass and/or silicon chips and surfaces, nitrocellulose 5 strips, membranes, sheets, animal red blood cells, or red blood cell ghosts, duracytes and the walls of wells of a reaction tray, plastic tubes or other test tubes. Suitable methods of immobilizing nucleic acids, (poly)peptides, proteins, antibodies, etc. on solid phases include but are not limited to ionic, hydrophobic, covalent interactions and the like. The solid phase can retain one or more additional receptor(s) which has/have the ability to attract and 20 immobilize the region as defined above. This receptor can comprise a charged substance that is oppositely charged with respect to the reagent itself or to a charged substance conjugated to the capture reagent or the receptor can be any specific binding partner which is immobilized upon (attached to) the solid phase and which is able to immobilize the reagent as defined above.

25 Commonly used detection assays can comprise radioisotopic or non-radioisotopic methods. These comprise, inter alia, RIA (Radioisotopic Assay) and IRMA (Immune Radioimmunoassay), EIA (Enzyme Immuno Assay), ELISA (Enzyme Linked Immuno Assay), FIA (Fluorescent Immuno Assay), and CLIA (Chemioluminescent Immuno Assay). 30 Other detection methods that are used in the art are those that do not utilize tracer molecules. One prototype of these methods is the agglutination assay, based on the property of a given molecule to bridge at least two particles.

For diagnosis and quantification of (poly)peptides, polynucleotides, etc. in clinical and/or scientific specimens, a variety of immunological methods, as described above as well as molecular biological methods, like nucleic acid hybridization assays, PCR assays or DNA Enzyme Immunoassays (Mantero et al., Clinical Chemistry 37 (1991), 422-429) have been 5 developed and are well known in the art. In this context, it should be noted that the nucleic acid molecules may also comprise PNAs, modified DNA analogs containing amide backbone linkages. Such PNAs are useful, *inter alia*, as probes for DNA/RNA hybridization.

0 The above-described compositions may be used for methods for detecting expression of a target gene by detecting the presence of mRNA coding for a (poly)peptide which comprises, for example, obtaining mRNA from cells of a subject and contacting the mRNA so obtained with a probe/primer comprising a nucleic acid molecule capable of specifically hybridizing with the target gene under suitable hybridization conditions, and detecting the presence of mRNA hybridized to the probe/primer. Further diagnostic methods leading to the detection of 5 nucleic acid molecules in a sample comprise, e.g., polymerase chain reaction (PCR), ligase chain reaction (LCR), Southern blotting in combination with nucleic acid hybridization, comparative genome hybridization (CGH) or representative difference analysis (RDA). These methods for assaying for the presence of nucleic acid molecules are known in the art and can be carried out without any undue experimentation.

10 Furthermore, the invention comprises methods of detecting the presence of a target gene product, i.e. a protein in a sample, for example, a cell sample, which comprises obtaining a cell sample from a subject, contacting said sample with one of the aforementioned antibodies under conditions permitting binding of the antibody to the protein, and detecting the presence 25 of the antibody so bound, for example, using immuno assay techniques such as radioimmunoassay or enzymeimmunoassay. Furthermore, one skilled in the art may specifically detect and distinguish polypeptides which are functional target proteins from mutated forms which have lost or altered their activity by using an antibody which either 30 specifically recognizes a (poly)peptide which has native activity but does not recognize an inactive form thereof or which specifically recognizes an inactive form but not the corresponding polypeptide having native activity.

The invention also encompasses a method for diagnosing in a subject a predisposition to a CNS and/or eye disorder associated with the expression of a target gene allele; see *supra*. The

detectable markers of the present invention may be labeled with commonly employed radioactive labels, such as, for example, ^{32}P and ^{35}S , although other labels such as biotin or mercury as well as those described above may be employed as well. Various methods well-known to the person skilled in the art may be used to label the detectable markers. For example, DNA sequences and RNA sequences may be labeled with ^{32}P or ^{35}S using the random primer method. Once a suitable detectable marker has been obtained, various methods well-known to the person skilled in the art may be employed for contacting the detectable marker with the sample of interest. For example, DNA-DNA, RNA-RNA and DNA-RNA hybridizations may be performed using standard procedures. Various methods for the detection of nucleic acids are well-known in the art, e.g., Southern and northern blotting, PCR, primer extension and the like. Suitable further DNA amplification techniques are known in the art and comprise, inter alia, Ligase Chain reaction, Strand Displacement Amplification, Nucleic Acid Sequence based Amplification (NASBA), or Q-beta replicase.

Furthermore, the mRNA, cRNA, cDNA or genomic DNA obtained from the subject may be sequenced to identify mutations which may be characteristic fingerprints of target gene mutations in CNS and/or eye disorders such as described above associated with the expression of the target gene or mutated versions thereof. The present invention further comprises methods, wherein such a fingerprint may be generated by RFLPs or AFLP of DNA or RNA obtained from the subject, optionally the DNA or RNA may be amplified prior to analysis, the methods of which are well known in the art. RNA fingerprints may be performed by, for example, digesting an RNA sample obtained from the subject with a suitable RNA-Enzyme, for example RNase T₁, RNase T₂ or the like or a ribozyme and, for example, electrophoretically separating and detecting the RNA fragments on PAGE as described above. Preferably, hybridization (and subsequent washing) is effected under stringent conditions; see, e.g., Sambrook et al., loc. cit and supra.

Furthermore, the present invention relates to a method as described above wherein said sample is or is derived from hair, blood, serum, sputum, feces or another body fluid. The sample to be analyzed may be treated such as to extract, inter alia, nucleic acid molecules, (poly)peptides, or antibodies.

The present invention also relates to kit compositions containing specific reagents such as those described herein-before. Kits containing oligonucleotides, DNA or RNA, antibodies or protein may be prepared. Such kits are used to detect for example DNA which hybridizes to

DNA of the target gene or to detect the presence of protein or peptide fragments in a sample. Such characterization is useful for a variety of purposes including but not limited to forensic analyses, diagnostic applications, and epidemiological studies in accordance with the above-described methods of the present invention. The recombinant target proteins, DNA molecules, 5 RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing of the target gene. Such a kit would typically comprise a compartmentalized carrier suitable to hold in close confinement at least one container. The carrier would further comprise reagents such as recombinant protein or antibodies suitable for detecting the expression or activity of the target gene or gene product. The carrier may also 0 contain a means for detection such as labeled antigen or enzyme substrates or the like.

Another embodiment of this invention comprises the use of an effective dose of a nucleic acid molecule described above or a nucleic acid molecule which is complementary to such a nucleic acid molecule, or a vector as defined previously for the preparation of a composition 5 for treating, preventing and/or delaying a disorder of the CNS and/or the eye in a subject by somatic gene therapy.

As used herein, the term "effective dose" means the total amount of the drug or pro-drug that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of a condition related to the disorder of the CNS, for example 20 neovascularization, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. In addition or alternatively, in particular with respect to pre-clinical testing of the drug the term "effective dose" includes the total amount of the drug or pro-drug that is sufficient to elicit a physiological response in a non-human animal test.

25 As mentioned above, the vectors of the present invention may also be an expression, a gene transfer or gene targeting vector. Gene therapy, which is based on introducing therapeutic genes into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer. Transgenic mice expressing a neutralizing antibody directed against nerve growth factor have been generated using the "neuroantibody" technique; Capsoni, Proc. Natl. 30 Acad. Sci. USA 97 (2000), 6826-6831 and Biocca, Embo J. 9 (1990), 101-108. Suitable vectors, methods or gene-delivering systems for in-vitro or in-vivo gene therapy are described in the literature and are known to the person skilled in the art; see, e.g., Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256 (1992), 808-813, Isner, Lancet 348 (1996), 370-374; Muhlhauser, Circ. Res. 77 (1995), 1077-

1086; Onodua, Blood 91 (1998), 30-36; Verzeletti, Hum. Gene Ther. 9 (1998), 2243-2251; Verma, Nature 389 (1997), 239-242; Anderson, Nature 392 (Supp. 1998), 25-30; Wang, Gene Therapy 4 (1997), 393-400; Wang, Nature Medicine 2 (1996), 714-716; WO 94/29469; WO 97/00957; US 5,580,859; US 5,589,466; US 4,394,448 or Schaper, Current Opinion in 5 Biotechnology 7 (1996), 635-640, and references cited therein. In particular, said vectors and/or gene delivery systems are also described in gene therapy approaches in neurological tissue/cells (see, *inter alia* Blömer, J. Virology 71 (1997) 6641-6649) or in the hypothalamus (see, *inter alia*, Geddes, Front Neuroendocrinol. 20 (1999), 296-316 or Geddes, Nat. Med. 3 (1997), 1402-1404). Further suitable gene therapy constructs for use in neurological 10 cells/tissues are known in the art, for example in Meier (1999), J. Neuropathol. Exp. Neurol. 58, 1099-1110. The nucleic acid molecules and vectors of the invention may be designed for direct introduction or for introduction via liposomes, viral vectors (e.g. adenoviral, retroviral), electroporation, ballistic (e.g. gene gun) or other delivery systems into the cell. The introduction and gene therapeutic approach should, preferably, lead to the expression of a 15 functional copy of the target gene of the invention. On the other hand, if target gene expression should be reduced, the expression of the introduced vector preferably leads to the production of an inhibitor as described above, for example antisense RNA or RNAi molecules. In those embodiments, the nucleic acid molecules are preferably linked to cell and/or tissue specific promoters, particularly preferred to promoters directing the expression in the cells 20 and tissue of the eye. Examples for suitable promoters include the angiopoietin 2 promoter (see in Hackett, J. Cell. Physiol. 184 (2000), 275-284) and particularly preferred promoters which are capable of targeting expression to the retinal pigment epithelium such as the tyrosinase related protein-1 (TyRP1) promoter; see Beermann, Cell Mol. Biol. 45 (1999), 961-968.

25

In a further aspect, the present invention also provides a method for the screening for compounds modulating the expression or the activity of a polypeptide involved in a disorder of the CNS or the eye. This method involves contacting a cell which expresses a polypeptide as described above identified by the methods illustrated previously with a compound to be 30 screened and determining if the expression or the activity is altered.

The amount of time necessary for cellular contact with the compound is empirically determined, for example, by running a time course with a known modulator and measuring cellular changes as a function of time. The measurement means of the method of the present invention can be further defined by comparing a cell that has been exposed to a compound to

an identical cell that has not been similarly exposed to the compound. Alternatively two cells, one containing a functional target gene and a second cell identical to the first, but lacking a functional target gene could be both be contacted with the same compound and compared for differences between the two cells. This technique is also useful in establishing the background noise of these assays. One of average skill in the art will appreciate that these control mechanisms also allow easy selection of cellular changes that are responsive to modulation of the functional target gene or gene product.

The term "cell" refers to at least one cell, but includes a plurality of cells appropriate for the sensitivity of the detection method. Cells suitable for the present invention may be bacterial, yeast, or preferably eukaryotic. The methods of this invention employ certain types of cells, certain observations of changes in aspects of the biological state of a cell, and certain comparisons of these observed changes. Preferred cell lines to be used in the assays of the present invention, especially cells and cell lines derived from the CNS or eye of, for example human, porcine, or murine origin, are described in the examples and in the prior art, for example human retinal pigment epithelial cells (see e.g. Dunaief et al. Curr. Eye Res. 24 (2002), 392-396), immortalized human corneal epithelial cell line (see e.g. Athmanathan et al., BMC Ophthalmol. 30 (2002), 3), and also cells of the CNS, for example human neuronal cell lines (see e.g. Li et al., J. Neurosci. Res. 71 (2003), 559-566), CNS cell line immortalized with an N-terminal fragment of SV40 large T (see e.g. Truckenmiller et al., Exp. Neurol. 175 (2002), 318-337), immortalized Z310 choroidal epithelial cell line from murine choroid plexus (see Zheng and Zhao, Brain Res. 958 (2002), 371-380).

Suitable cell lines, in particular animal and human cell lines as well as technical information on the characteristics of cell lines, cytogenetic analysis, suggestions for handling cell cultures, etc can be obtained from depository institutions, for example the American Type Culture Collection (ATCC), P.O. Box 1549, Manassas, VA 20108, USA and DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, 38124 Braunschweig, GERMANY. Preferred are RPE cells or RPE derived cell lines such as ARPE-19, cells overexpressing or with inhibited expression of candidate genes involved in CNS or eye disorders or host cells as described previously.

In a preferred embodiment said polypeptide is expressed under the control of the GGTB-promoter, which is described in van Bokhoven et al., Genomics 38 (1996), 133-140. The test substance can be a single chemotherapeutic agent or a mixture of chemotherapeutic agents.

The cell that is contacted with the test substance can be derived from a single cell or a multi-cellular organism. Said multi-cellular organism can be selected from the group consisting of a vertebrate animal, a mammal, a primate, an invertebrate animal, an insect and a plant. The 5 above-described cells can also be comprised in a tissue or organism, i.e. non-human animal. General methods for the screening of compounds that have a desired effect on a cell or organism as measured in a specific assay are described in the prior art; see for example US-A-6,165,709 and references cited herein.

Cells, non-human animals and target gene expression and/or knock out systems can be found 0 in the prior art and adapted for the method of the present invention; see for example the documents cited herein.

The cellular changes suitable for the method of the present invention comprise directly measuring changes in the function or quantity of the target gene product, or by measuring 5 downstream effects, for example by measuring secondary messenger concentrations or changes in transcription or by changes in protein levels of genes that are transcriptionally influenced by the target gene product, or by measuring phenotypic changes in the cell. Preferred measurement means include changes in the quantity of protein, changes in the functional activiy, changes in the quantity of mRNA, changes in intracellular protein, changes 10 in cell surface protein, or secreted protein, or changes in Ca^{2+} , cAMP or GTP concentration. Changes in the quantity or functional activity of target gene products are described herein. Changes in the levels of mRNA are detected by reverse transcription polymerase chain reaction (RT-PCR), by differential gene expression or by microarrays. Immunoaffinity, ligand 15 affinity, or enzymatic measurement quantitates changes in levels of protein in host cells. Protein-specific affinity beads or specific antibodies are used to isolate for example ^{35}S - 20 methionine labelled or unlabelled protein. Labelled protein is analyzed by SDS-PAGE. Unlabelled protein is detected by Western blotting, cell surface detection by fluorescent cell sorting, cell image analysis, ELISA or RIA employing specific antibodies. Where the protein 25 is an enzyme, the induction of protein is monitored by cleavage of a flourogenic or 30 colorimetric substrate.

Where the endogenous gene encodes a soluble intracellular protein, changes in the endogenous gene may be measured by changes of the specific protein contained within the cell lysate. The soluble protein may be measured by the methods described herein.

The assays may be simple "yes/no" assays to determine whether there is a change in expression or function, or may comprise any one of the above described methods, for example for the detection of angiogenic activity. The assay may be made quantitative by comparing the expression or function of a test sample with the levels of expression or function in a standard sample. Modulators identified in this process are useful as therapeutic agents.

The above-described methods can, of course, be combined with one or more steps of any of the above-described screening methods or other screening methods well known in the art. Methods for clinical compound discovery comprises for example ultrahigh-throughput screening (Sundberg, Curr. Opin. Biotechnol. 11 (2000), 47-53) for lead identification, and structure-based drug design (Verlinde and Hol, Structure 2 (1994), 577-587) and combinatorial chemistry (Salemme et al., Structure 15 (1997), 319-324) for lead optimization.

- ;) Once a drug has been selected, the method can have the additional step of repeating the method used to perform rational drug design using the modified drug and to assess whether said modified drug displays better affinity according to for example interaction/energy analysis.
- ;) In a preferred embodiment of the method of the present invention, said cell, tissue or non-human animal is a transgenic cell, tissue or non-human animal which displays a substantially reduced or enhanced level of target gene expression and/or gene product activity compared to a corresponding wild-type animal. Usually, said transgenic non-human animal displaying a reduced level of target gene activity comprises at least one mutant allele of the target gene or
- 5) a corresponding trans-dominant allele of a different gene. Preferably, said transgenic non-human animal is a knock-out animal.

- 0) Preferably said substantially reduced or enhanced level of target gene expression and/or gene product activity results in an altered and a phenotypic response of the transgenic cell, tissue or non-human animal. An agonist/activator or antagonist/inhibitor will then be identified by observing whether a candidate compound is able at a certain concentration to revert the phenotypic response of said transgenic cell, tissue or non-human animal back to normal. In a particular preferred embodiment, said transgenic non-human animal displays a CNS and/or eye disorder as defined above.

The assay methods of the present invention can be in conventional laboratory format or adapted for high throughput. The term "high throughput" (HTS) refers to an assay design that allows easy analysis of multiple samples simultaneously, and capacity for robotic manipulation. Another desired feature of high throughput assays is an assay design that is optimized to reduce reagent usage, or minimize the number of manipulations in order to achieve the analysis desired. Examples of assay formats include 96-well, 384-well or more-well plates, levitating droplets, and "lab on a chip" microchannel chips used for liquid handling experiments. It is well known by those in the art that as miniaturization of plastic molds and liquid handling devices are advanced, or as improved assay devices are designed, that greater numbers of samples may be performed using the design of the present invention.

The test substances which can be tested and identified according to a method of the invention may be expression libraries, e.g., cDNA expression libraries, peptides, proteins, nucleic acids, antibodies, small organic compounds, hormones, peptidomimetics, PNAs, aptamers or the like (Milner, *Nature Medicine* 1 (1995), 879-880; Hupp, *Cell* 83 (1995), 237-245; Gibbs, *Cell* 79 (1994), 193-198 and references cited *supra*). The test substances to be tested also can be so called "fast seconds" of known drugs. The invention also relates to further contacting the test cells with a second test substance or mixture of test substances in the presence of the first test substance.

In the method of the invention, said cells are preferably contained in a container, for example in a well in a microtiter plate, which may be a 24, 96, 384 or 1586 well plate. Alternatively, the cells can be introduced into a microfluidics device, such as those provided by Caliper (Newton, MA, USA). In another preferred embodiment, step (b) of the method of the present invention comprises taking 2, 3, 4, 5, 7, 10 or more measurements, optionally at different positions within the container. In some embodiments of the method of the present invention, a compound known to activate or inhibit the target gene or gene product is added to the medium prior to step (b).

30

Preferably, in a first screen said test substance is comprised in and subjected as a collection of compounds. Said collection of compounds may have a diversity of about 10^3 to about 10^5 . Methods for the generation and use of peptidomimetic combinatorial libraries are described in the prior art, for example in Ostresh, *Methods in Enzymology* 267 (1996), 220-234 and

Dorner, Bioorg. Med. Chem. 4 (1996), 709-715. Drug discovery by dynamic combinatorial libraries is described, for example, in Nat. Rev. Drug Discov. 1 (2002), 26-36 and Drug Discov. Today 7 (2002), 117-125.

Furthermore, the above-described methods can, of course, be combined with one or more steps of any of the above-described screening methods or other screening methods well known in the art. Methods for clinical compound discovery comprises for example ultrahigh-throughput screening (Sundberg, Curr. Opin. Biotechnol. 11 (2000), 47-53) for lead identification, and structure-based drug design (Verlinde and Hol, Structure 2 (1994), 577-587) and combinatorial chemistry (Salemme et al., Structure 15 (1997), 319-324) for lead optimization. Once a drug has been selected, the method can have the additional step of repeating the method used to perform rational drug design using the modified drug and to assess whether said modified drug displays better affinity according to for example interaction/energy analysis. The method of the present invention may be repeated one or more times such that the diversity of said collection of compounds is successively reduced. Preferably, the target polypeptide is involved in angiogenesis or neovascularization.

As mentioned above, the present invention provides convenient assays, preferably cell based and in vivo assays for identifying and obtaining drugs capable of modulating the gene activity, thereby being useful as a therapeutic agent for the treatment of diseases related to CNS disorders including (e.g.) Schizophrenia, Parkinson's Disease, Alzheimer's Disease, and eye diseases such as those described above. In accordance with this, the present invention provides also a use for compounds which have been known in the art, properly also known to be able to modulate target gene activity but which hitherto have not been suggested for medical use because of the lack of knowledge of phenotypic responses of an organism evoked by target gene activity or the lack of it.

One embodiment of this invention comprises a method for the production of a drug or prodrug identified by such a screening as a modulator or a derivative thereof, particularly if the substance has hitherto not been known as a drug for the treatment of a disorder of the CNS or the eye.

Substances are metabolized after their in vivo administration in order to be eliminated either by excretion or by metabolism to one or more active or inactive metabolites (Meyer, J. Pharmacokinet. Biopharm. 24 (1996), 449-459). Thus, rather than using the actual compound

or drug identified and obtained in accordance with the methods of the present invention a corresponding formulation as a pro-drug can be used which is converted into its active form in the patient by his/her metabolism. Precautionary measures that may be taken for the application of pro-drugs and drugs are described in the literature; see, for review, Ozama, J. 5 Toxicol. Sci. 21 (1996), 323-329.

Furthermore, the present invention relates to the use of a compound identified, isolated and/or produced by any of these methods for the preparation of a composition for the treatment of said CNS and eye disorders. As a method for treatment the identified substance or the 0 composition containing it can be administered to a subject suffering from such a disorder. Compounds identified, isolated and/or produced by the method described above can also be used as lead compounds in drug discovery and preparation of drugs or prodrugs.

This usually involves modifying the lead compound or a derivative thereof or an isolated 5 compound as a to achieve (i) modified site of action, spectrum of activity, organ specificity, and/or (ii) improved potency, and/or (iii) decreased toxicity (improved therapeutic index), and/or (iv) decreased side effects, and/or (v) modified onset of therapeutic action, duration of effect, and/or (vi) modified pharmokinetic parameters (resorption, distribution, metabolism and excretion), and/or (vii) modified physico-chemical parameters (solubility, hygroscopicity, 10 color, taste, odor, stability, state), and/or (viii) improved general specificity, organ/tissue specificity, and/or (ix) optimized application form and route by (i) esterification of carboxyl groups, or (ii) esterification of hydroxyl groups with carbon acids, or (iii) esterification of hydroxyl groups to, e.g. phosphates, pyrophosphates or sulfates or hemi succinates, or (iv) 15 formation of pharmaceutically acceptable salts, or (v) formation of pharmaceutically acceptable complexes, or (vi) synthesis of pharmacologically active polymers, or (vii) introduction of hydrophilic moieties, or (viii) introduction/exchange of substituents on aromates or side chains, change of substituent pattern, or (ix) modification by introduction of isosteric or bioisosteric moieties, or (x) synthesis of homologous compounds, or (xi) 20 introduction of branched side chains, or (xii) conversion of alkyl substituents to cyclic analogues, or (xiii) derivatisation of hydroxyl group to ketales, acetals, or (xiv) N-acetylation to amides, phenylcarbamates, or (xv) synthesis of Mannich bases, imines, or (xvi) 25 transformation of ketones or aldehydes to Schiff's bases, oximes, acetals, ketales, enolesters, oxazolidines, thiazolidines or combinations thereof; and (b) formulating the product of said modification with a pharmaceutically acceptable carrier.

The various steps recited above are generally known in the art. For example, computer programs for implementing these techniques are available; e.g., Rein, Computer-Assisted Modeling of Receptor-Ligand Interactions (Alan Liss, New York, 1989). Methods for the preparation of chemical derivatives and analogues are well known to those skilled in the art and are described in, for example, Beilstein, Handbook of Organic Chemistry, Springer edition New York Inc., 175 Fifth Avenue, New York, N.Y. 10010 U.S.A. and Organic Synthesis, Wiley, New York, USA. Furthermore, peptidomimetics and/or computer aided design of appropriate derivatives and analogues can be used, for example, according to the methods described above. Methods for the lead generation in drug discovery also include using proteins and detection methods such as mass spectrometry (Cheng et al. J. Am. Chem. Soc. 117 (1995), 8859-8860) and some nuclear magnetic resonance (NMR) methods (Fejzo et al., Chem. Biol. 6 (1999), 755-769; Lin et al., J. Org. Chem. 62 (1997), 8930-8931). They may also include or rely on quantitative structure-action relationship (QSAR) analyses (Kubinyi, J. Med. Chem. 41 (1993), 2553-2564, Kubinyi, Pharm. Unserer Zeit 23 (1994), 281-290) combinatorial biochemistry, classical chemistry and others (see, for example, Holzgrabe and Bechtold, Pharm. Acta Helv. 74 (2000), 149-155). Furthermore, examples of carriers and methods of formulation may be found in Remington's Pharmaceutical Sciences.

Once a drug has been selected in accordance with any one of the above-described methods of the present invention, the drug or a pro-drug thereof can be synthesized in a therapeutically effective amount. As used herein, the term "therapeutically effective amount" means the total amount of the drug or pro-drug that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of a condition related to disorders of the CNS and/or the eye, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. In addition or alternatively, in particular with respect to pre-clinical testing of the drug the term "therapeutically effective amount" includes the total amount of the drug or pro-drug that is sufficient to elicit a physiological response in a non-human animal test.

Furthermore the nucleic acid molecules described above can in turn be used for the validation of test substances, lead compounds, drugs and prodrugs for the treatment of a disorder of the CNS or the eye or for the identification and isolation of downstream genes.

The present invention also relates to a chip or array comprising a solid support and attached thereto one or more of the nucleic acid molecules or encoded (poly)peptides described above, which chip or assay is useful for performing any one of the above described methods. Chip-based or other means for the detection of expression and/or activity of a nucleic acid molecule 5 described above or the respective polypeptides can be provided for in form of a kit, which constitutes a preferred embodiment of the invention. Similarly kit can be developed for the methods for identification, production and screening of active molecules.

In a still further embodiment, the present invention relates to a transgenic non-human animal 0 which displays an aberrant expression or activity of the target gene and/or gene product mentioned previously or identified and obtained by the methods described above, especially when said animal reproduces a disorder of the CNS and/or the eye. Preferably, said animal is a mammal.

A method for the production of a transgenic non-human animal, which is also encompassed 5 by the present invention, for example transgenic mouse, comprises introduction of a polynucleotide or targeting vector encoding said polypeptide into a germ cell, an embryonic cell, stem cell or an egg or a cell derived therefrom. The non-human animal can be used in accordance with a screening method of the invention described herein. Production of transgenic embryos and screening of those can be performed, e.g., as described by A. L. 10 Joyner Ed., Gene Targeting, A Practical Approach (1993), Oxford University Press. A general method for making transgenic non-human animals is described in the art, see for example WO 94/24274. For making transgenic non-human organisms (which include homologously 15 targeted non-human animals), embryonal stem cells (ES cells) are preferred. Murine ES cells, such as AB-1 line grown on mitotically inactive SNL76/7 cell feeder layers (McMahon and Bradley, Cell 62: 1073-1085 (1990)) essentially as described (Robertson, E. J. (1987) in 20 Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. E. J. Robertson, ed. (Oxford: IRL Press), p. 71-112) may be used for homologous gene targeting. Other suitable ES lines include, but are not limited to, the E14 line (Hooper et al., Nature 326: 292-295 25 (1987)), the D3 line (Doetschman et al., J. Embryol. Exp. Morph. 87: 27-45 (1985)), the CCE line (Robertson et al., Nature 323: 445-448 (1986)), the AK-7 line (Zhuang et al., Cell 77: 30 875-884 (1994)). The success of generating a mouse line from ES cells bearing a specific targeted mutation depends on the pluripotence of the ES cells (i. e., their ability, once injected into a host developing embryo, such as a blastocyst or morula, to participate in embryogenesis and contribute to the germ cells of the resulting animal). The blastocysts containing the

5 injected ES cells are allowed to develop in the uteri of pseudopregnant nonhuman females and are born as chimeric mice. The resultant transgenic mice are chimeric for cells having either the recombinase or reporter loci and are backcrossed and screened for the presence of the correctly targeted transgene (s) by PCR or Southern blot analysis on tail biopsy DNA of
5 offspring so as to identify transgenic mice heterozygous for either the recombinase or reporter locus/loci.

10 Methods for producing transgenic flies, such as *Drosophila melanogaster* are also described in the art, see for example US-A-4,670,388, Brand & Perrimon, Development (1993) 118: 401-415; and Phelps & Brand, Methods (April 1998) 14: 367-379. Transgenic worms such as *C. elegans* can be generated as described in Mello, et al., *Embo J.* 10 (1991), 3959-3970, Plasterk, *Methods Cell Biol* 48 (1995), 59-80.

15 Preferably, the transgenic non-human animal comprises at least one inactivated or suppressed wild type allele of the corresponding gene, involved in an CNS and/or eye disorder; see supra. This embodiment allows for example the study of the interaction of various mutant forms of these genes or gene products on the onset of the clinical symptoms and/or may be used to verify the involvement of said gene(s) in the disorder to be studied. All the applications that have been herein before discussed with regard to a transgenic animal also apply to animals
20 carrying two, three or more transgenes. It might be also desirable to inactivate target gene expression or function at a certain stage of development and/or life of the transgenic animal. This can be achieved by using, for example, tissue specific (see supra), developmental and/or cell regulated and/or inducible promoters which drive the expression of, e.g., an antisense or ribozyme directed against the RNA transcript encoding the target gene mRNA; see also supra.
25 A suitable inducible system is for example tetracycline-regulated gene expression as described, e.g., by Gossen and Bujard (Proc. Natl. Acad. Sci. 89 USA (1992), 5547-5551) and Gossen et al. (Trends Biotech. 12 (1994), 58-62). Similar, the expression of a mutant target gene may be controlled by such regulatory elements. Preferably, the presence of the transgenes in cells of the transgenic animals leads to to various physiological, developmental
30 and/or morphological changes, preferably to conditions related to disorders of the CNS and/or eye such as those described above.

In another embodiment said transgenic non-human animal is used for a process in the discovery of drugs for the treatment of a disorder of the CNS and/or the eye. In particular,

mammalian animals are preferred, especially mice and rats. Corresponding animal systems that can be adapted in accordance with the present invention are known to person skilled in the art; see, e.g., molecular biological approaches to neurological disorders including knockout and transgenic mouse models described in Shibata et al., *Neuropathology* 22 (2002), :337-349.

5 However, the widely used zebra fish may also be used since this model system has also been shown to provide valuable predictive results; see, e.g. Gerlai et al., *Pharmacol. Biochem. Behav.* 67 (2000), 773-782.

In a preferred embodiment of the invention the pharmaceutical composition for use in the treatment of the above described CNS and/or eye disorders comprise one or more double-stranded oligoribonucleotides (dsRNA), see supra, which mediate an RNA interference of the corresponding mRNA of one or more nucleic acid molecules which have been shown to be involved in said disorders, and optionally a pharmaceutically acceptable carrier. The method for specific inhibition of genes by double-stranded oligoribonucleotides (dsRNA) is known from WO 01/75164. The disclosure of this application is hereby included in this present description.

This application describes that double-stranded oligoribonucleotides (dsRNA) induce specific degradation of mRNA after delivery to the target cells. The specificity of this process is mediated by the complementarity of one of the two dsRNA strands to the mRNA of the target gene.

The process of gene-specific, post-transcriptional switching off of genes by dsRNA molecules is referred to as RNA interference (RNAi). This term was originally developed by Fire and co-workers to describe the blockage of gene expression observed by delivery of dsRNA molecules to the threadworm *Caenorhabditis elegans* (Fire et al., 1999). Subsequently, RNAi could also be demonstrated in plants, protozoa, insects (Kasschau and Carrington 1998) and recently also in mammalian cells (Caplen et al., 2001; Elbashir et al., 2001). The mechanism by which RNAi suppresses gene expression is not yet fully understood. Studies of non-mammalian cells have shown that dsRNA molecules are transformed into small interfering RNA molecules (siRNA molecules) by endogenous ribonucleases (Bernstein et al., 2001; Grishok et al., 2001; Hamilton and Baulcombe, 1999; Knight and Bass, 2001; Zamore et al., 2000).

Desirably, the region of the double stranded RNA that is present in a double stranded conformation includes at least 5, 10, 20, 30, 50, 75, 100 or 200. Preferably, the double stranded region includes between 15 and 30 nucleotides, most preferably 20 to 25 and particularly preferred 21 to 23 nucleotides, since for the specific inhibition of a target gene, it

5 suffices that a double-stranded oligoribonucleotide exhibits a sequence of 21 to 23 nucleotides (base pairs) in length identical to the target gene; see, e.g., Elbashir et al., Methods 26 (2002), 199-213 and Martinez et al., Cell 110 (2002), 563-574. General means and methods for cell based assays for identifying nucleic acid sequences that modulate the function of a cell, by the use of post-transcriptional gene silencing including definitions, methods for the

0 preparation of dsRNA, vectors, selectable markers, compositions, detection means, etc., and which can be adapted in accordance with the teaching of the present invention are described in European patent application EP 1 229 134 A2, the disclosure content of which is incorporated herein by reference

.5 In contrast to the cited literature in which the use of siRNA and other RNA based molecules is described for cell culture only, experiments performed in accordance with the present invention surprisingly demonstrate that dsRNA molecules of a length of 21 to 23 nucleotides are capable of, after systemic application, for example by intravenous injection, to cross the blood-retina barrier, and specifically inactivate target genes in the tissues of the back of the

10 eye. This overcoming the blood-retina barrier is all the more remarkable, because no experiment could demonstrate overcoming the blood-brain barrier by dsRNA so far. The methods and uses of the invention, explained below by means of examples, are thus suitable for the provision of animal models with which targets, the restricted function of which causing diseases of the eye, can be identified and validated. Those methods are moreover

15 suitable for the specific intervention in CNS and eye diseases on a molecular level, without necessitating direct application to the site of, for example affected cells or tissue. The specificity of selected inhibitors such as preferably RNAi for the inhibition of genes expressed specifically in target cells minimizes the risk of unwanted side effects.

20 The dosage regimen of the pharmaceutical compositions in all of the above described methods and uses of the present invention will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other

drugs being administered concurrently. A typical dose can be, for example, in the range of 0.001 μ g to 10 mg (or of nucleic acid for expression or for inhibition of expression in this range); however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors. Generally, the regimen as a regular administration of 5 the pharmaceutical composition should be in the range of 0.01 μ g to 10 mg units per day. If the regimen is a continuous infusion, it should also be in the range of 0.01 μ g to 10 mg units per kilogram of body weight per minute, respectively. Progress can be monitored by periodic assessment. Dosages will vary but a preferred dosage for intravenous administration of nucleic acids is from approximately 10^6 to 10^{12} copies of the nucleic acid molecule.

0 Therapeutic or diagnostic compositions of the invention are administered to an individual in an effective dose sufficient to treat or diagnose disorders in which modulation of a target gene or gene product is indicated. The effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of 5 administration. The pharmaceutical compositions may be provided to the individual by a variety of routes such as by intracoronary, intraperitoneal, subcutaneous, intravenous, transdermal, intrasynovial, intramuscular or oral routes. In addition, co-administration or sequential administration of other agents may be desirable.

20 A therapeutically effective dose refers to that amount of compounds described in accordance with the present invention needed to ameliorate the symptoms or condition. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The 25 dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50.

These and other embodiments are disclosed and encompassed by the description and Examples of the present invention. Further literature concerning any one of the materials, 30 methods, uses and compounds to be employed in accordance with the present invention may be retrieved from public libraries and databases, using for example electronic devices. For example the public database "Medline" may be utilized, which is hosted by the National Center for Biotechnology Information and/or the National Library of Medicine at the National Institutes of Health. Further databases and web addresses, such as those of the European

Bioinformatics Institute (EBI), which is part of the European Molecular Biology Laboratory (EMBL) are known to the person skilled in the art and can also be obtained using internet search engines. An overview of patent information in biotechnology and a survey of relevant sources of patent information useful for retrospective searching and for current awareness is

5 given in Berks, TIBTECH 12 (1994), 352-364.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples and figure which are provided herein for purposes of illustration only and are not intended to limit the scope of the

0 invention. The contents of all cited references (including literature references, issued patents, published patent applications as cited throughout this application and manufacturer's specifications, instructions, etc) are hereby expressly incorporated by reference; however, there is no admission that any document cited is indeed prior art as to the present invention.

15 The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature; see, for example, DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat.

20 No. 4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J.

25 H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986).

Detailed descriptions of conventional methods, such as those employed in the construction of

30 vectors and plasmids, the insertion of genes encoding polypeptides into such vectors and plasmids, the introduction of plasmids into host cells, and the expression and determination thereof of genes and gene products can be obtained from numerous publication, including Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press.

The figure shows:

Figure 1: eGFP-expression in retina and retinal pigment epithel (RPE) of systemically dsRNA-treated FVB.CG-TG(GFPU)5NAGY mice. The figure shows eGFP-expression in eye 5 paraffin sections of dsRNA-treated FVB.Cg-Tg(GFPU)5Nagy mice. Expression in retina and retinal pigment epithel (RPE) of systemically dsRNA-treated FVB.CG-TG(GFPU)5NAGY mice is highest in the buffer control, slightly decreased in mice treated with non-silencing dsRNA and clearly decreased in eGFP-specific dsRNA treated mice (buffer control > 200 µg/kg BW non-silencing dsRNA > 100 µg/kg BW eGFP-specific dsRNA > 200 µg/kg BW 0 eGFP-specific dsRNA).

EXAMPLES

Example 1 Isolation of primary porcine retinal pigment epithelial cells (RPE cells).
5 The following example describes exemplary the isolation of primary porcine RPE cells which is carried out under sterile conditions. The isolation of RPE-cells from pork, human and cattle is in principal the same.

Porcine eyes were obtained from a local slaughter house. After the eyes were liberated from 0 rests of ocular muscle, they were washed once with sterile ice cold phosphate buffered saline (1xPBS: 1.15g/l Na₂HPO₄, 0.20g/l KH₂PO₄ x H₂O, 8.00 g/l NaCl, 0.20g/l KCl, 0.10g/l MgCl₂, 0.10g/l CaCl₂) containing penicillin (100 U/ml) and streptomycin (100 µg/ml). The eyes were sliced around the ora serrata and the ocular lens and the vitreous were removed. From the eye cups the retinae were carefully detached with a hitch and removed after cutting 5 the optic nerve. The retinae were used for the isolation of the rod outer segments as described in example 2. The remaining eye cup was covered with 1ml 1xPBS to wash the cells. The solution was rejected and the cells were incubated in 1 to 1.5ml of a trypsin/EDTA solution (0.25%/0.02%) for 15 minutes at 37°C. The solution was rejected and the cups were again covered with 1 ml of the trypsin/EDTA solution for 1 hour at 37°C. The RPE cells were 30 carefully removed by pipetting up and down and cells from six eyes were diluted in 20ml cell culture medium (DMEM F12 (Bio Whittaker) with 10% fetal calf serum (FCS), penicillin (100 U/ml) and streptomycin (100 µg/ml), 2mM glutamine, 1.5g/ml sodium bicarbonate). The cells were centrifuged 5 minutes with 120xg at room temperature and washed twice with the cell culture medium. Per T25 cell culture flask, cells according to three retinae were plated. 35 To get rid of cell debris the cells were washed with 1xPBS on the next day. For approximately

one week RPE-cells were cultivated in cell culture medium containing 10% FCS. After they have reached confluence the culture medium was substituted against medium containing 2% FCS. After a further one week-incubation the cells were splitted on cell culture dishes in the ratio 1:2 for further experimental use.

5

Example 2 Isolation of rod outer segments (ROS) from porcine eyes.

The ROS isolation was carried out under sterile conditions. Thirty retinae isolated during the RPE-cell preparation (see example 1) were transferred to 15 ml of a ice cold homogenisation buffer (containing 20 % (w/v) sucrose, 20 mM tris-acetat pH 7.2, 2 mM MgCl₂, 10 mM glucose). The suspension was shaken gently for 1 minute, filtered 3 times through cheesecloth to remove tissue fragments and layered on a 24 ml 25-60% w/v continuous sucrose gradient containing 20 mM Tris acetate pH 7.2, 10 mM glucose. Centrifugation was carried out in a Beckman SW-27 rotor at 24,000 rpm for 1 hour at 4°C. The upper white-yellow band of the gradient was collected, diluted with the same volume of 10 mM Hepes buffer pH 7.4, 115 mM NaCl, 2.5 mM KCl, 1 mM DTT, 1 mM MgCl₂, mixed cautious and centrifuged 10 minutes in a Sigma 4K15 centrifuge, 2989xg, 4°C. The supernatant was removed carefully and the ROS pellet was stored for further use at -20°C. From one retina were approximately 1x10⁷ ROS isolated.

20 **Example 3** Incubation of primary porcine RPE-cells with (physiological concentrations) of ROS.

Since the incubation of RPE-cells from pork, human and cattle with ROS is in principal the same, the following example refers to the incubation of RPE cells isolated from porcine eyes (see example 2).

5

ROS pellet stored at -20°C was warmed-up slowly to room temperature. According to the number of primary RPE-cells, an amount of 10 to 100 ROS per cell was taken from the ROS-suspension. During incubation, the cell culture medium was changed every day and new ROS were added.

0

The phagocytosis of ROS by RPE cells was controlled in parallel by two approaches.

Approach one comprises the detection of ROS covalently labelled with the dual wavelength fluorescent dye SNAFL-2 (Molecular Probes, Leiden Netherlands). The acid form (pH 5) appears green-yellow whereas the alkaline form (pH 9) appears yellow-orange. SNAFL-2

(10 μ g SNAFL-2 in 1 μ l dimethylformimide) was added to isolated ROS in 100 μ l sucrose buffer (20% sucrose, 2mM MgCl₂, 10mM glucose, 20mM tris acetate pH 8.0) and the ROS were labelled for 1 hour at room temperature in the dark with gentle stirring. The labelled ROS were diluted with the same volume of the hepes buffer pH 8.0 spun down for 5 minutes 5 at 2000rpm in a Heraeus Biofuge pico and washed two times with 100 μ l the hepes buffer pH 8.0. The labelled ROS were resuspended in cell culture medium and added to the cells. After an incubation time of 4 to 8 hours cells were washed and cell culture medium pH 9.0 was added for fluorescence microscopy.

In approach two ROS treated cells were washed in 1xPBS (containing Ca²⁺ and Mg²⁺) and 0 analyzed by fluorescence microscopy for autofluorescence-activity of internalized ROS.

Example 4 · Post transcriptional gene silencing (PTGS) of a given target gene.

The following example describes PTGS of a given target gene (growth factor) X in primary cells isolated from different organisms (i.e. pork, human, cattle) or in cell lines (i.e. ARPE-5.19).

After optimizing the experimental conditions with respect to the dsRNA identity, its concentration and the appropriate transfection reagent, PTGS was performed using three (to five) dsRNAs homologous to different regions of the mRNA of the target gene synthesized 10 either by a commercial provider (preferential Proligo) or from corresponding oligonucleotides using a commercially available kit (preferential SilencerTM siRNA Construction Kit, Ambion). 1ng up to 100 μ g of each siRNA was introduced into the cells by commercially available transfection reagents (preferential Gene Eraser/Stratagene, Transmessenger/Qiagen, Oligofectamin/ Invitrogen).
15 Up to five days post transfection cells were harvested for the analysis of mRNA expression profile by real time PCR and up to one week post transfection cells were harvested for the analysis of protein expression by western blot analysis or ELISA.

Example 5 Synthesis and purification of A2-E.

10 A2-E was synthesized from all-trans-retinal and ethanolamine as described from Parish et al. (1998) (Parish CA, Hashimoto M, Nakanishi K, Dillon J, Sparrow J.: Isolation and one-step preparation of A2E and iso-A2E, fluorophores from human retinal pigment epithelium. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14609-13) and purified chromatographically on silica gel 60 thin layer chromatography plates using the primary developing system from

Eldred and Katz (1988) (Eldred GE, Katz ML.: Fluorophores of the human retinal pigment epithelium: separation and spectral characterization. *Exp Eye Res.* 1988 Jul;47(1):71-86). 50-150 mg retinal were dissolved in 1,5-5,5 ml ethanol. 5-15 µl ethanolamine was added and stirred. While stirring 5-15 µl acetic acid were slowly added. The mixture was wrapped in 5 aluminium foil, and stirred for two days at room temperature. The reaction mix was distributed 4 times into four Eppendorf tubes and concentrated to dryness in a speedvac overnight. The content of two Eppendorf reaction tubes was dissolved in a total of 200-600 µl "primary developing system" (14,5 ml heptane, 8,8 ml hexane, 9,8 ml chloroform, 3 ml ether, 3 ml acetone, 14,8 ml iso-propanol, 27 ml ethanol, 2,5 ml methanol, 0,4 ml acetic acid, 7,4 ml 10 H₂O). Then 5-15 aliquots, containing 20-60 µl each, of this solution were applied to a silica chromatography plate that was developed with the "primary developing system" for about 2 hours. A2-E was detected on the plates by their fluorescence upon illumination with 366-nm light. The material containing A2-E was scraped off (A2-E: upper spot; iso-A2-E: lower spot) and eluted 2-3 times with chloroform/methanol/water by vortexing. The supernatants were 15 combined and dried in a speedvac for few hours. The dried material was taken up in 200-600 µl "primary developing system" and rechromatographed. The extraction and the drying were also repeated. The dried material was taken up as a A2-E stock solution in about 1 ml Me₂SO or ethanol and stored at -20°C in the dark. Total A2-E diluted in Me₂SO or ethanol was quantified using a molar extinction coefficient of 36,900 at 439 nm (Parish CA, Hashimoto M, Nakanishi K, Dillon J, Sparrow J.: Isolation and one-step preparation of A2E and iso-A2E, 20 fluorophores from human retinal pigment epithelium. *Proc Natl Acad Sci U S A.* 1998 Dec 8;95(25):14609-13).

Example 6 Incubation of RPE cells with A2-E and the analysis of A2-E accumulation.

25 A2-E was diluted into the RPE cell culture medium to a concentration of 1 to 100 µM A2-E and 0,5% Me₂SO or ethanol. With the aim to find out sub-apoptocidal A2E concentrations, control incubations were done with 0,5% Me₂SO or ethanol in the absence of A2-E as a negative control and with 1 to 200 µM staurosporine as a apoptosis control. Incubation was carried out at 37°C with 5% CO₂ for 24 to 144 h in the darkness (wrapped in aluminium foil) 30 once each day. Cells can also placed under a light source and exposed to light at 390 to 550 nm of various times up to 144 hours. Controls were also run with medium alone. To determine the mean autofluorescence per population of RPE the intracellular fluorescence was assessed using a fluorescence microscope (Nikon; excitation 450-490 nm, emission > 510 nm) and a Safire (Tecan; excitation 456 nm, emission 610 nm) at various times after feeding.

Example 7 Apoptosis assay.

The following example describes the analysis of the induction of apoptosis with the Cell Death Detection ELISA Plus (Roche) (Wyllie AH, Kerr JF, Currie AR.: Cell death: the significance of apoptosis. *Int Rev Cytol.* 1980;68:251-306. Review). The assay based on a quantitative sandwich-enzyme-immunoassay-principle using mouse monoclonal antibodies directed against DNA and histones, respectively. This allows the specific determination of mono- and oligonucleosomes which are released into the cytoplasm of cells which die from apoptosis. The sample (cell-lysate, serum, culture-supernatant etc.) was placed into a streptavidin-coated microplate. Subsequently, a mixture of anti-histone- biotin and anti-DNA-POD was added and incubated for 2 hours. During the incubation period, the anti-histone antibody binds to the histone-component of the nucleosomes and simultaneously fixes the immunocomplex to the streptavidin-coated microplate via its biotinylation. Additionally, the anti-DNA-POD antibody reacts with the DNA-component of the nucleosomes. After removal of unbound antibodies by a washing step, the amount of nucleosomes was quantified by the POD retained in the immunocomplex. POD was determined photometrically with ABTS (2,2'-Azino-di[3-ethyl-benz-thiazolin- sulfonat]) as substrate.

Example 8 Induction of hypoxia

RPE cells were incubated in an incubator (Heracell, Kendro) maintained at 37°C and 95% air, 20 5% CO₂ by vol (normoxic conditions) to 100% confluence (about 10⁷ cells/100-mm plate). Cells were then subjected to hypoxic conditions by placing them in an automatic CO₂/O₂ incubator (B 5061 EC/O₂, Kendro) maintained at 37°C and O₂ levels ranging from 0 to 8%, 5% CO₂, 95 to 87% N₂ (N₂ to balance) for 1 h to 7 days. Uninduced cells remained in normoxic conditions. PO₂ and PCO₂ of the medium were measured in a blood gas analyzer 25 (Corning model 178). Normoxic values were as follows: pH=7.2 +/- 0.1, PO₂=39.3 +/- 0.6 mmHg and PCO₂=131.5 +/- 0.9 mmHg. Hypoxic values were as follows: pH=7.2 +/- 0.1, PO₂=7 to 35 +/- 1.1 mmHg and PCO₂=14.9 +/- 1.2 mmHg (Liu et al., 1995; Palmer et al., 1998) (Liu Y, Cox SR, Morita T, Kourembanas S.: Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. *Circ Res.* 30 1995 Sep;77(3):638-43; Palmer LA, Semenza GL, Stoler MH, Johns RA.: Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. *Am J Physiol.* 1998 Feb;274(2 Pt 1):L212-9).

Example 9 Limitation of essential factors

The following example describes the cultivation of RPE cells in a modified Dulbecco's modified Eagle's medium (high glucose, Life Technologies, Inc.) for inducing stress in RPE cells by lacking essential factors. In normal RPE cell culture the cells grow in a modified Dulbecco's modified Eagle's medium (high glucose, Life Technologies, Inc.) supplemented with 2% heat inactivated fetal calf serum (Roche), 100 units/ml penicillin, 100 µg/ml streptomycin, 1 x non-essential amino acids, 2 mM L-glutamine, and 1 mM sodium pyruvate (all Life Technologies, Inc.) in a humidified atmosphere containing 5% CO₂ at 37°C. Normal cell culture media contains different anorganic salts and is added with vitamins, amino acids, glucose, nucleotides and many other substances. Most cells need for growing blood serum, such as fetal calf serum. The serum supplements proteins, hormones, growth factors, and intermediate products. For limiting these essential factors cells were cultured in a serum free medium. Additionally, a modified Dulbecco's modified Eagle's medium was used. The medium had no anorganic salts (e.g. KCl, NaCl), amino acids (e.g. L-glutamin, L-prolin), vitamins (e.g. biotin, riboflavin, folic acid) or other substances (e.g. glucose, lipon acid, nucleotides).

Example 10 Induction of metabolic acidose

The following example describes the induction of a metabolic acidose (pH<7.2 +/- 0.1) in cultured RPE cells by changing the pH value. Like *in vivo*, mammalia cell cultures need a pH optimum which is ranging from pH 7.2 - 7.4. Growing cells will cause a decrease of the pH-value due to lactate production. The pH value of the medium is measured in a blood gas analyzer (Corning model 178). Two ways were used to induce a metabolic acidose: Changing the CO₂ pressure (from 5% to 0%) in combination with leaking HCO₃⁻ in the culture medium (Palmer et al., 1998) (Palmer LA, Semenza GL, Stoler MH, Johns RA.: Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol. 1998 Feb;274(2 Pt 1):L212-9) and the use of a modified Dulbecco's modified Eagle's medium containing 20 mM Hepes buffer. A Hepes buffer medium can be used for pH stress of cells because a medium buffered with Hepes is acidified in a humidified atmosphere containing 5% CO₂ at 37°C.

Example 11 RNA-preparation from cultured primary RPE cells.

RNA prepared from primary RPE cells served as starting material for expression analyses for both real-time PCR and DNA-microarrays. After stress exposition (like hypoxic culture

conditions, nutrient and/or growth factor deficiencies or pH changes) RPE cells were washed once with PBS prior to cell lysis. Approximately 1×10^6 cells (e.g. one well of a six well cell culture plate) were lysed with 800 μ l of β -mercaptoethanol containing RLT buffer (RNeasy Mini Kit from Qiagen Germany) by softly shaking the plate. Lysates were immediately frozen 5 at -80°C . After thawing for 15 min at 37°C lysates were processed for isolation of total RNA according to the manufacturer's protocol (RNeasy Mini Kit, Qiagen). The RNA on the matrix of one column (according to 1×10^6 cells) was eluted with with a suitable volume (10-100 μ l) RNase free water. RNA from identically cultivated cells was pooled to yield uniform RNA from one culture condition.

10

Example 12 DNase I digestion of contaminating genomic DNA.

For subsequent analysis of RNA care should be taken to eliminate contaminating genomic DNA. Therefore digestion of genomic DNA via enzymatic restriction with DNA polymerase I (RNase free DNase I) was be performed. In brief a 100 μ l reaction volume contained up to 50 15 μ g RNA together with 20 μ l of 25 mM MgSO₄ (final conc. 5 mM), 3.4 μ l 3M NaAc pH 4.7 (final conc. 100 mM) and 20 U DNase I (2 μ l of 10U/ μ l stock e.g. from Roche Diagnostics). Digestion was performed for 1 h at 37°C . Subsequent purification of RNA from DNase and restricted DNA fragments was carried out again by utilizing the RNeasy Mini Kit (Qiagen) according to the supplier's recommendations.

20

Example 13 cDNA synthesis for expression analysis via Real-Time PCR.

Synthesis of cDNA from total RNA is a prerequisite for expression analyses both by real-time PCR and microarray technique. To allow comparison of gene expression between mRNAs derived from different culture conditions the same amount of total RNA (here: e.g. 2 μ g per 25 different RNA) was reversely transcribed to cDNA by the following: 1 μ l oligo-dT-primer (500 μ g/ml, Qiagen-Operon, # 55000142), 2 μ g RNA from porcine RPE cells, 1 μ l 10 mM dNTP-mix (Invitrogen) and RNase-free water (Qiagen) up to 12 μ l in total. The mixture was incubated at 65°C for 5 min followed by 2 min on ice. After brief centrifugation following kit components (Invitrogen, # 18064-014) were added: 4 μ l 5x First Strand buffer, 2 μ l 0,1 M 30 DTT and 1 μ l RNasin (40 U/ μ l, Promega, # N2511). After mixing by pipetting up and down the reaction was incubated for 2 min at 42°C in a water bath. Then 1 μ l reverse transcriptase (Superscript II, Invitrogen kit see above) was added and mixed by pipetting up and down. The reaction was incubated for 50 min at 42°C in water bath and subsequently stopped by

switching the reaction tube for 15 min to a 70 °C heat block. After short incubation on ice the newly synthesized cDNA was centrifuged and stored at – 20 °C until use.

Example 14 Real-Time PCR.

5 Concentrations of cDNA used as template in real-time PCR varied between 100 pg and 100 ng (refering to the original RNA). For each gene of interest and control genes specific TaqMan™ probes (containing a fluorescent dye and a quencher molecule) can be designed. Alternatively, the dye SYBR®-Green can be used, which intercalates in all double stranded DNA molecules, allowing the in process measurement of arising PCR products.

10 Oligonucleotides for PCR amplification (in real-time PCR and microarray analysis) were designed to achieve PCR fragments of usually 150 – 600 base pairs (bp) in size. Along with the gene(s) of interest PCR probes were set up in duplicate or triplicate together with control or housekeeping genes like beta-actin (ACTB), glyceraldehyde 3-phosphate dehydrogenase (GAPD) or hypoxanthine phosphoribosyltransferase (HPRT1). A typical 25 µl PCR reaction

15 was composed like the following: Template cDNA (100 pg – 100 ng), HotStart Taq-polymerase (e.g. Invitrogen) 0.5 U/µl, 1 x polymerase reaction buffer, 0.2 mM of each dNTP (e.g. Invitrogen), 1.5 to 7 mM MgCl₂ (e.g. Invitrogen), oligonucleotides in the range between 50 – 300 nM (e.g. Qiagen-Operon, Germany) and SYBR®-Green (e.g. Bio Whittaker Molecular Applications, # 50512, 10,000 x conc.) 0.1 – 0.5 x (diluted from stock). Typical

20 PCR conditions for real-time PCR were: 5 - 15 min activation step at 95 °C, 45 cycles with each 30 s denaturation at 94 °C, annealing of primers (temperature depending on melting temperature of primers) for 30 s and elongation of primers at 72 °C for up to 1 min. After each cycle the increase in fluorescence of the probe during PCR amplification was determined by the optical unit of the real-time PCR device (e.g. iCycler from BIORAD). The data from

25 real-time PCR generated from control versus treated sample gave a profound information about changes in mRNA expression.

Example 15 PCR amplification of target genes for spotting on microarray slides.

From all selected target genes PCR fragments of 150 – 600 bp were amplified from RPE- /
30 retina- or liver-specific cDNA (as templates) according to the following protocol: PCR reactions were typically set up in a total of 50 µl. They usually contained 1 x polymerase reaction buffer (e.g. Invitrogen), 1.5 – 4 mM (final concentration) MgCl₂ (e.g. Invitrogen), 0.2 mM of each nucleotide (10 mM dNTP stock, e.g. Invitrogen), up to 1 µM of gene specific forward and reverse primer (Qiagen Operon), 0.025 – 1 U Taq polymerase (e.g. Invitrogen), a

suitable amount of template cDNA (1 –10 μ l, depending on cDNA quality) and nuclease free water to a final volume of 50 μ l. Typical conditions for PCR were: a single 5 min denaturation step at 95 °C, 30 cycles with each 30 s denaturation at 94 °C, annealing of primers (usually between 45° - 65° C, temperature depending on melting temperature of primers) for 30 s and elongation of primers at 72 °C for up to 1 min.

5

Example 16 PCR purification.

PCR purification was performed by utilizing the QiaQuick Purification Kit (Qiagen) according to the manufacturer's recommendations.

10

Example 17 Spotting of PCR-products on coated glass-slides.

DNA from PCR products was arrayed with splitted pins (Telechem) on CMT GAPS coated slides (Corning) with a Genepak spotter (Genetix) using 50 % DMSO as spotting buffer. Spotted slides were stored for up to 6 months.

15

Example 18 Labeling of RNAs for hybridization.

For each labeling reaction 5 μ g of RNA (at least 300 ng/ μ l, OD_{260/280} between 1.8 and 2.0) are recommended. Direct labeling of control RNA (from control/untreated cells) and test RNA (from stressed/treated cells) with Cy3 and Cy5 (supplied from Amersham Biosciences or Perkin Elmer) was done with the Qiagen kit 'Label Star' according to the supplier's protocol.

20

Example 19 Hybridization of RNAs with microarray.

Hybridization of mixed RNAs with the spotted DNA on the microarrays was performed at 42 °C overnight on a automated Lucidea Slidepro hybridization station (Amersham Biosciences) under well defined hybridization and washing conditions: Hybridization buffer was composed of 25% formamide, 5x SSC und 0.1% SDS.

25

Example 20 Image processing and data analysis of arrays

30 After hybridization the signals on the microarrays were scanned with a laser scanner (ScanArray 4000, Perkin Elmer) to yield the raw image data. To extract the signal information from above generated images into tab delimited text files software tools like ScanAlyze (Mike Eisen, Stanford University, CA., <http://rana.lbl.gov/EisenSoftware.htm>) were applied. Normalization of data was done by applying Microsoft's Excel and Access programs (part of 35 Microsoft Office packages). Such prepared data were analyzed with software programs like

GeneSpring from Silicon Genetics, which enable e.g. complex cluster analysis to find differentially expressed genes.

Example 21 Inhibition of the expression of green fluorescent protein (eGFP) in the retinal

5 pigment epithelium (RPE) and the retina of transgenic mice by dsRNA molecules.

This example describes specific *post transcriptional gene silencing* by dsRNA of the target gene eGFP in the mouse animal model, during which the optimal dsRNA concentration for

post transcriptional gene silencing on systemic application is to be determined (experimental procedure 1, results see figure 1). The procedure involves the *in vivo* treatment of transgenic

10 mice (FVB.Cg-Tg(GFP)5Nagy, The Jackson Laboratory), which express the *enhanced* form of green fluorescent protein (eGFP) in their body cells, by systemic application of dsRNA oligoribonucleotide molecules against the target gene eGFP. Control animals are also treated

systemically with non-silencing dsRNA molecules. For the purpose of *post transcriptional gene silencing*, the animals not under analgesic or anesthetic influence receive daily i.v. tail

15 vein injections (1st day of treatment: day 0, final day of treatment: day 20) of 100 or 200 µg eGFP-specific dsRNA/kg body weight (BW) and the control group of 200 µg non-silencing dsRNA/kg BW. A control group of animals treated with buffer (daily i.v. injection of 0.1 ml

buffer into the tail vein) is also kept. Each group of experimental animals consists of 8 animals, the maximum injection volume/injection being 0.1 ml. On day 21, the animals are

20 sacrificed by CO₂ inhalation.

The expression of green fluorescent protein in the eye of the mice is examined immunohistologically (spontaneous eGFP fluorescence: fluorescence microscopic evaluation; eGFP-specific immunofluorescence staining: fluorescence microscopic evaluation).

25 dsRNA constructs and plasmids:

For the design of the dsRNA molecules, sequences of the type AA(N19)TT (where N represents any nucleotide) were selected from the sequence of the target mRNA, in order to obtain 21 nucleotide (nt) long sense and antisense strands with symmetrical 3'-overhangs of two nucleotides in length. In the 3'-overhangs, 2'-deoxy-thymidine was used instead of

30 uridine. In order to ensure that the dsRNA molecules are exclusively directed against the target gene, the chosen dsRNA sequences are tested against the mouse genome in a BLAST analysis. The 21-nt RNA molecules are synthesized chemically and purified. For the duplex

formation, 100 µg of the sense and antisense oligoribonucleotides each are mixed in 10 mM Tris/HCl, 20 mM NaCl (pH 7.0) and heated to 95°C and cooled to room temperature over a

period of 18 hours. The dsRNA molecules are precipitated from ethanol and resuspended in sterile buffer (100 mM potassium acetate, 30 mM HEPES-KOH, 2 mM magnesium acetate, pH 7.4). The integrity and double strand character of the dsRNA are verified by gelelectrophoresis. Alternatively, the dsRNA molecules are obtained from commercial 5 suppliers. The sequences of the target genes and the corresponding dsRNA molecules are as follows:

GFP dsRNA

DNA target sequence: 5' G CAA GCT GAC CCT GAA GTT CA (SEQ ID NO 5)
10 Coding region, 121-141 relative to the first nucleotide of the start codon (Acc. No. U55761)
dsRNA (sense) 5' r(GCA AGC UGA CCC UGA AGU U) (SEQ ID NO 6)
dsRNA (antisense) 5' r(AA CUU CAG GGU CAG CUU GC) (SEQ ID NO 7)

15 **non-silencing dsRNA, control**

DNA target sequence: 5' AATTCTCCGAACGTGTCACGT (SEQ ID NO 8)
dsRNA (sense) 5' r(UUCUCCGAACGUGUCACGU)d(TT) (SEQ ID NO 9)
dsRNA (antisense) 5' r(ACGUGACACGUUCGGAGAA)d(TT) (SEQ ID NO 10)

20 Analgesia and anesthesia of the mice:

For systemic application, the animals are immobilized and the dsRNAs are injected i.v. in the tail vein (maximal injection volume: 0.1 ml), where analgesia or anesthesia are refrained from, since this would put more stress on the animals than the i.v. injection itself. For retrobulbar injection (maximal injection volume: 0.005 ml) the animals are however subjected 25 to short-term isofluorane inhalation anaesthesia and provided with Metamizole sodium for analgesic purposes. The animals are then kept in their accustomed animal cage surroundings. After completion of *in vivo* diagnosis (the end of each animal experiment is stated respectively in example 1 - 5) the animals are killed by CO₂ inhalation, enucleated and the eyes are studied histologically (immunohistology).

30

Study of eGFP expression in retinal pigment epithelium and retina:

After removal, the eyes are fixed in 4 % formalin/PBS solution for 24 hours. Using standard methods, the fixed samples are subsequently dehydrated in a series of increasing alcohol and embedded in paraffin. With the aid of a microtome, standard 5 to 12 µm serial slices are

produced, stretched in a heated water bath and transferred to a polylysin-coated cover slip. The sections are then dried in an incubator for 2 hours at a temperature of 52 °C. The dried sections are deparaffinized in xylol, transferred to a decreasing series of alcohol followed by Tris/HCl pH 7.4. After blocking, the sections are incubated for 2 hours with primary anti-
 5 eGFP antiserum (polyclonal goat anti-eGFP antiserum, Santa Cruz No. sc-5384). Detection occurs by means of immunofluorescence staining by using a Cy2-conjugated rabbit anti-goat IgG (Dianova, No. 305-225-045). The samples are embedded and then mounted for microscopy with an Eclipse TE-2000-S microscope (Nikon), equipped with a 20x and 40x/1.3 objective. The spontaneous, eGFP-specific fluorescence in deparaffinized, untreated sections
 10 is analyzed using a fluorescence microscope.

Experimental procedure: Systemic siRNA application. Determination of optimal dsRNA concentration for *post transcriptional gene silencing*.

Group	Substance	Number of animals
Control animals	Buffer	8
Negative control 200 µg dsRNA/kg BW	<i>non-silencing</i> dsRNA	8
200 µg dsRNA/kg BW	eGFP-specific dsRNA	8
100 µg dsRNA/kg BW	eGFP-specific dsRNA	8
Animals per experiment		32

15 For results see figure 1

S/

Gene name	Accession No.	Marker for	CDS	Description	Alternative Symbols	Citation
BAX	NM_138761	apoptosis	53..631	BCL2-associated X protein (BAX), transcript variant alpha	unknown	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
BBC3	NM_014417	apoptosis	1..582	BCL2 binding component 3 (BBC3)	JFY1, PUMA, PUMA/JFY1	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
BCL2	NM_000633	apoptosis	32..751	B-cell CLL/lymphoma 2 (BCL2), transcript variant alpha	unknown	Nicotera. Toxicol Lett. 2002 Feb 28;127(3):189-95.
BIRC2	NM_001166	apoptosis	1160..3016	baculoviral IAP repeat-containing 2 (BIRC2)	API1, MIHB, CIAP1, CIAP2	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
BIRC3	NM_001165	apoptosis	725..2539	baculoviral IAP repeat-containing 3 (BIRC3)	API2, MIHC, CIAP2, HAPI1, HIAPI1	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
BIRC4	NM_001167	apoptosis	34..1527	baculoviral IAP repeat-containing 4 (BIRC4)	ILP, API3, ILP1, MIHA, XIAP, Xiap, hILP, ILP-1	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
CDKN1A	NM_078467	apoptosis	236..730	CDKN1A, transcript variant 2	P21, CIP1, SDI1, WAF1, CAP20, CDKN1, MDA-6	Almond & Cohen. Leukemia. 2002 Apr;16(4):433-43.
ENDOG	NM_004435	apoptosis	167..1060	endo-nuclease G (ENDOG)	unknown	Almond & Cohen. Leukemia. 2002 Apr;16(4):433-43.
HSPD1	NM_002156	apoptosis	25..1746	heat shock 60kDa protein 1 (chaperonin) (HSPD1)	GROEL, HSP60, SPG13	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
HSPE1	NM_002157	apoptosis	42..350	heat shock 10kDa protein 1 (chaperonin 10) (HSPE1)	CPN10, GROES, HSP10	Ravagnan et al. J Cell Physiol. 2002 Aug;192(2):131-7.
LRDD	NM_145886	apoptosis	144..2876	leucine-rich and death domain containing (LRDD), transcript variant 1	PIDD, MGC16925	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
MCL1	NM_021960	apoptosis	64..1116	myeloid cell leukemia sequence 1 (BCL2-related)(MCL1)	EAT	Bae et al. J. Biol. Chem. 275: 25255-25261, 2000.

S6

P53AIP1	AB045830	apoptosis	211..585	for p53AIP1, complete cds	unknown	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
PMAIP1	NM_021127	apoptosis	174..338	phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)	APR, NOXA	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
TNFRSF10B	NM_147187	apoptosis	286..1521	tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B), transcript variant 2	DR5, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
TNFRSF6	NM_000043	apoptosis	347..1354	tumor necrosis factor receptor superfamily, member 6 (TNFRSF6), transcript variant 1..	FAS, APT1, CD95, APO-1, FASTM	Hueber. Nature Cell Biol. 2: E23-E25, 2000.
TOP2B	NM_001068	apoptosis	1..4866	topoisomerase (DNA) II beta 180kDa (TOP2B)	TOP1B	Solovyan et al. J Biol Chem. 2002 Jun 14;277(24):21458-67.
TP53	NM_000546	apoptosis	252..1433	tumor protein p53 (Li-Fraumeni syndrome) (TP53),	p53, TRP53	Almond & Cohen. Leukemia. 2002 Apr;16(4):433-43.
EPO	NM_000799	hypoxic cult.cond	182..763	erythropoietin (EPO), .	EP	Grimm et al. Nature Med. 8: 718-724, 2002.
FGF2	NM_002006	hypoxic cult.cond	302..934	fibroblast growth factor 2 (basic) (FGF2),	BFGF, FGFB, HBGH-2	Grimm et al. Nature Med. 8: 718-724, 2002.
LDHA	NM_005566	hypoxic cult.cond	98..1096	lactate dehydrogenase A	unknown	Semenza et al. J Biol Chem. 1996 Dec 20;271(51):32529-37.
NGB	NM_021257	hypoxic cult.cond	376..831	neuroglobin (NGB), .	unknown	Burmester et al. Nature 407 (6803), 520-523 (2000)
VEGF	NM_003376	hypoxic cult.cond	702..1277	vascular endothelial growth factor (VEGF),	VEGFA	Grimm et al. Nature Med. 8: 718-724, 2002.
AVEN	NM_020371	oxidative stress	53..1141	apoptosis, caspase activation inhibitor (AVEN), .	PDCD12	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
BCL2A1	NM_004049	oxidative stress	184..711	BCL2-related protein A1 (BCL2A1), .	GRS, BFL1, HBPA1, BC12L5	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.

52

CAT	NM_001752	oxidative stress	69..1652	catalase (CAT),	unknown	Cai et al. Prog Retin Eye Res. 2000 Mar;19(2):205-21.
DUSP1	NM_004417	oxidative stress	249..1352	dual specificity phosphatase 1 (DUSP1), .	HVH1, CL100, MKP-1, PTPN10	Wu et al. J Biol Chem. 2002 Nov 15;277(46):44208-13.
GADD45	NM_001924	oxidative stress	296..793	growth arrest and DNA-damage-inducible, alpha (GADD45A), .	DDIT1, GADD45	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
HMOX1	NM_002133	oxidative stress	81..947	heme oxygenase (decycling) 1 (HMOX1),	HO-1, bK286B10	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
IL6	NM_000600	oxidative stress	63..701	interleukin 6 (interferon, beta 2) (IL6)	HGF, HSF, BSF2, IL-6, IFNB2	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
MAP2K6	NM_002758	oxidative stress	341..1345	mitogen-activated protein kinase kinase 6 (MAP2K6), transcript variant 1	MEK6, MKK6, MAPKK6, PRKMK6, SAPKK3	Seger & Krebs. FASEB J. 9: 726-735, 1995.
MAPK8	NM_139049	oxidative stress	18..1301	mitogen-activated protein kinase 8 (MAPK8), transcript variant 1	JNK, JNK1, PRKM8, SAPK1, JNK1A2, JNK2B1/2	Almond & Cohen. Leukemia. 2002 Apr;16(4):433-43.
MAPK9	NM_002752	oxidative stress	50..1324	mitogen-activated protein kinase 9 (MAPK9), transcript variant 1	JNK2, JNK2A, JNK2B, PRKM9, JNK, 55, JNK2BETA, P54ASAPK, p54aSAPK, JNK2ALPHA	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
NFKB2	NM_002502	oxidative stress	164..2965	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) (NFKB2),	LYT10, LYT-10	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
PRDX2	NM_005809	oxidative stress	90..686	peroxiredoxin 2 (PRDX2), .	PRP, TSA, NKEFB, TDPX1	Fujii & Ikeda. Redox Rep. 2002;7(3):123-30. Review.
SFN	NM_006142	oxidative stress	166..912	stratifin (SFN),	unknown	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.

68

SHC1	NM_003029	oxidative stress	195..1946	SHC (Src homology 2 domain containing) transforming protein 1 (SHC1),	SHC, SHCA	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
SOD1	NM_000454	oxidative stress	1..465	superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) (SOD1),	ALS, ALS1, IPOA	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
SOD2	NM_000636	oxidative stress	5..673	superoxide dismutase 2, mitochondrial (SOD2),	IPO-B, MNSOD	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
TNFAIP3	NM_006290	oxidative stress	67..2439	tumor necrosis factor, alpha-induced protein 3 (TNFAIP3),	A20, TNFA1P2	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
TRAF1	NM_005658	oxidative stress	79..1329	TNF receptor-associated factor 1 (TRAF1),	EB16, MGc:10353	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.
TRAF2	NM_021138	oxidative stress	58..1563	TNF receptor-associated factor 2 (TRAF2), transcript variant 1,	TRAP, TRAP3, MGc:45012	Martindale et al. J Cell Physiol. 2002 Jul;192(1):1-15.

50

References

Banks CN, Hutton WK. Blindness in New South Wales: an estimate of the prevalence and some of the contributing causes. *Aust J Ophthalmol* 9:285-288 (1981).

Bohler C, Nielsen PE, Orgel LE. Template switching between PNA and RNA oligonucleotides. *Nature* 376(6541):578-81 (1995).

Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature* 409(6818):363-6 (2001).

Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. *J Am Board Fam Pract*. 15:142-152 (2002).

Bressler NM, Bressler SB. Preventative ophthalmology. Age-related macular degeneration. *Ophthalmology* 102:1206-1211 (1995).

Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. *Surv Ophthalmol* 32:375-413 (1988).

Bressler SB, Bressler NM, Fine SL, Hillis A, Murphy RP, Olk RJ, Patz A. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. *Am J Ophthalmol* 93:157-163 (1982).

Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. *Mol Vis*. 5:34 (1999).

Caplen N.J., Parrish S., Imani F., Fire A., and Morgan R.A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. *Proc. Natl. Acad. Sci.* 98:9742-9747 (2001).

Davis LG, Kuehl M, Kuehl MW, Battey JF. Basic methods in molecular biology. Sec. Ed. Elsevier (1990).

Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschel T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 411: 494-498 (2001).

Feeney L. Lipofuscin and melanin of human retinal pigment epithelium. Fluorescence, enzyme cytochemical, and ultrastructural studies. *Invest Ophthalmol Vis Sci* 17:583-600 (1978).

Feeney-Burns L, Ellersieck MR. Age-related changes in the ultrastructure of Bruch's membrane. *Am J Ophthalmol* 100:686-697(1985).

Finn PJ, Gibson NJ, Fallon R, Hamilton A, Brown T. Synthesis and properties of DNA-PNA chimeric oligomers. *Nucleic Acids Res.* 24: 3357-3363 (1996).

Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* 391:806-811(1998).

Fischer SG, Lerman LS. DNA fragments differing by single base-pair substitutions are separated in denaturing gradient gels: correspondence with melting theory. *Proc Natl Acad Sci U S A*. 80(6):1579-83 (1983).

Gass JD. Drusen and disciform macular detachment and degeneration. *Arch Ophthalmol* 90:206-217 (1973).

Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. *Am J Ophthalmol* 63: Suppl:1-139(1967).

Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. *Br J Ophthalmol* 67: 209-213 (1983).

5 Gossen M, Bonin AL, Freundlieb S, Bujard H. Inducible gene expression systems for higher eukaryotic cells. *Curr Opin Biotechnol*. 5(5):516-20 (1994).

Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc Natl Acad Sci U S A*. 89(12):5547-5551 (1992).

10 Gotoh M, Hasebe M, Ohira T, Totsu M. [Gene diagnosis with an affinity sensor, BIACORE--principle and applications]. *Rinsho Byori*. 45(3):224-8 (1997). Japanese.

Green WR, McDonnell PJ, Yeo JH. Pathologic features of senile macular degeneration. *Ophthalmology* 92:615-27 (1985).

Grey RH, Burns-Cox CJ, Hughes A. Blind and partial sight registration in Avon. *Br J Ophthalmol* 73:88-94(1989).

15 Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, Ruvkun G, Mello CC. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control *C. elegans* developmental timing. *Cell* 106(1):23-34 (2001).

Hamilton AJ and Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. *Science* 286: 950-952(1999).

20 Heiba IM, Elston RC, Klein BE, Klein R. Sibling correlations and segregation analysis of age-related maculopathy: the Beaver Dam Eye Study. *Genet Epidemiol* 11:51-67 (1994).

Hogan MJ, Alvarado J. Studies on the human macula. IV. Aging changes in Bruch's membrane. *Arch Ophthalmol* 77:410-420(1967).

25 Hyman LG, Lilienfeld AM, Ferris FL, Fine SL. Senile macular degeneration: a case-control study. *Am J Epidemiol* 118:213-227 (1983).

Hyman L. Epidemiology of eye disease in the elderly. *Eye* 1: 330-341 (1987).

Jalkanen M, Nguyen H, Rapraeger A, Kurn N, Bernfield M. Heparan sulfate proteoglycans from mouse mammary epithelial cells: localization on the cell surface with a monoclonal antibody. *J Cell Biol*. 101(3):976-984 (1985).

30 Jalkanen M, Rapraeger A, Saunders S, Bernfield M. Cell surface proteoglycan of mouse mammary epithelial cells is shed by cleavage of its matrix-binding ectodomain from its membrane-associated domain. *J Cell Biol*. 105:3087-96 (1987).

Jensen KK, Orum H, Nielsen PE, Norden B. Kinetics for hybridization of peptide nucleic acids (PNA) with DNA and RNA studied with the BIACore technique. *Biochemistry* 36(16):5072-5077 (1997).

35 Joyner A. *Gene Targeting, A Practical Approach*, Second edition, Oxford University Press (1999).

40 Kasschau KD and Carrington JC. A counterdefensive strategy of plant viruses: suppression of posttranscriptional gene silencing. *Cell* 95:461-470(1998).

Klein R, Klein BE, Franke T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. *Ophthalmology* 100:406-414 (1993).

Knight SW and Bass BL. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in *Caenorhabditis elegans*. *Science* 2: 2269-2271(2001).

Koch T, Hansen HF, Andersen P, Larsen T, Batz HG, Otteson K, Orum H. Improvements in automated PNA synthesis using Boc/Z monomers. *J Pept Res.* 49(1):80-8 (1997).

5 Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 256(5517):495-497 (1975).

Leibowitz HM, Krueger DE, Mauder LR, Milton RC, Kini MM, Kahn HA, Nickerson RJ, Pool J, Colton TL, Ganley JP, Loewenstein JI, Dawber TR. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic 10 retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. *Surv Ophthalmol* 24(Suppl): 335-610 (1980).

Le Mouellic H, Lallemand Y, Brulet P. Targeted replacement of the homeobox gene Hox-3.1 by the *Escherichia coli* lacZ in mouse chimeric embryos. *Proc Natl Acad Sci U S A.* 87(12):4712-4716 (1990).

15 Maguire P, Vine AK. Geographic atrophy of the retinal pigment epithelium. *Am J Ophthalmol* 102:621-625 (1986).

Mantero G, Zonaro A, Albertini A, Bertolo P, Primi D. DNA enzyme immunoassay: general method for detecting products of polymerase chain reaction. *Clin Chem.* 37(3):422-429 (1991).

20 Mayer RJ, Walker JH, eds. *Immunochemical methods in cell and molecular biology*. Academic Press, London (1987).

Melani C, Rivoltini L, Parmiani G, Calabretta B, Colombo MP. Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. *Cancer Res.* 51:2897-2901 (1991)

25 Meyers SM, Zachary AA. Monozygotic twins with age-related macular degeneration. *Arch Ophthalmol* 106:651-653 (1988).

Paetkau ME, Boyd TA, Grace M, Bach-Mills J, Winship B. Senile disciform macular degeneration and smoking. *Can J Ophthalmol* 13:67-71 (1978).

30 Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch's membrane. A histochemical and morphologic study. *Ophthalmology* 97:171-178(1990).

Piguet B, Wells JA, Palmvang IB, Wormald R, Chisholm IH, Bird AC. Age-related Bruch's membrane change: a clinical study of the relative role of heredity and environment. *Br J Ophthalmol* 77:400-403 (1993).

35 Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Sarks SH. Ageing and degeneration in the macular region: a clinico-pathological study. *Br J Ophthalmol* 60:324-341 (1976).

Schuler GD. Pieces of the puzzle: expressed sequence tags and the catalog of human genes. *J Mol Med.* 75(10):694-8 (1997)

40 Seddon JM, Ajani UA, Mitchel BD. Familial aggregation of age-related maculopathy. *Am J Ophthalmol* 123: 199-206 (1997).

Smith and Johnson. Single-step purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione S-transferase. *Gene* 67:31-40 (1988)

Silvestri G, Johnston PB, Hughes AE. Is genetic predisposition an important risk factor in age-related macular degeneration? *Eye* 8:564-568 (1994).

5 Sobol RE, Astarita RW, Chisari FV, Griffiths JC, Royston I. Use of immunoglobulin light chain analysis to detect bone marrow involvement in B-cell neoplasms. *Clin Immunol Immunopathol* 24(1):139-144 (1982).

Sobol RE, Dillman RO, Collins H, Griffiths JC, Green MR, Royston I. Applications and 10 limitations of peripheral blood lymphocyte immunoglobulin light chain analysis in the evaluation of non-Hodgkin's lymphoma. *Cancer* 56(8):2005-2010 (1985).

15 Sperduto RD, Hiller R. Systemic hypertension and age-related maculopathy in the Framingham Study. *Arch Ophthalmol* 104:216-219 (1986).

Steinecke, Ribozymes, Methods in Cell Biology 50, Galbraith et al. eds Academic Press, Inc.: 449-460 (1995).

The Eye Disease Case-Control Study Group. Risk factors for neovascular age-related 20 macular. *Arch Ophthalmol* 110:1701-1708 (1992).

15 Tijssen P.; Burden, RH and von Knippenburg (Eds). Practice and theory of enzyme immuno-assays. Elsevier, Amsterdam, Vol. 15 (1985).

Verma R.S.; Babu A. Human chromosomes; Manual of basic techniques. New York, Pergamon Press (1989).

20 Veselkov AG, Demidov VV, Frank-Kamenetskii MD, Nielsen PE. PNA as a rare genome-cutter. *Nature*. 379(6562):214 (1996).

Wahl RL, Parker CW, Philpott GW. Improved radioimaging and tumor localization with 25 monoclonal F(ab')2. *J Nucl Med*. 24(4):316-25 (1983).

Weiler J, Gausepohl H, Hauser N, Jensen ON, Hoheisel JD. Hybridisation based DNA screening on peptide nucleic acid (PNA) oligomer arrays. *Nucleic Acids Res*. 25(14):2792-9 (1997).

25 Yap M, Weatherill J. Causes of blindness and partial sight in the Bradford Metropolitan District from 1980 to 1985. *Ophthalmic Physiol Opt* 9:289-292 (1989).

Yuzawa M, Isomae T, Mori R, Shimada H, Utsunomiya I. Surgical excision versus laser 30 photocoagulation for subfoveal choroidal neovascular membrane with age-related macular degeneration: comparison of visual outcomes. *Jpn J Ophthalmol*. 45(2):192-8 (2001).

Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. *Cell* 101: 25-33(2000).

Claims

1. A method for the treatment of a disorder of the central nervous system (CNS) and/or the eye comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-brain and/or the blood-retina barriers.
2. Use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of a disorder of the central nervous system (CNS) and/or the eye, wherein said composition is designed to be applied outside the blood-brain and/or blood-retina barriers.
3. The method of claim 1 or the use of claim 2, wherein the disorder is related to the eye.
4. The method or use of any one of claims 1 to 3, wherein said disorder is related to angiogenesis and/or neovascularization.
5. The method or use of any one of claims 1 to 4, wherein said disorder is related to the retinal pigment epithelium (RPE), neurosensory retina and/or choriodea.
6. The method or use of any one of claims 1 to 5, wherein said disorder is wet age-related macular degeneration (AMD) or diabetic retinopathy.
7. The method or use of any one of claims 1 to 6, wherein the pharmaceutical composition is designated to be effective in (and applied to) the inner segment of the eye ball.
8. The method or use of any one of claims 1 to 7, wherein the composition is in a form designed to be applied outside the retinal region of the blood-retina barrier.
9. The method or use of any one of claims 1 to 8, wherein said compound is an inhibitor/antagonist of said target gene or gene product.

10. The method or use of claim 9, wherein said antagonist/inhibitor inhibits the expression of a gene or the activity of a gene product involved in angiogenesis and/or neovascularization.
11. The method or use of claim 9 or 10, wherein said antagonist/inhibitor is or is derived from an nucleic acid molecule, polypeptide, antibody, or a ligand binding molecule of said gene or gene product.
12. The method or use of any one of claims 9 to 11, wherein said antagonist/inhibitor is a ribozyme, antisense or sense nucleic acid molecule to said gene or gene product.
13. The method or use of any one of claims 9 to 12, wherein said antagonist/inhibitor substantially consists of ribonucleotides.
14. The method or use of claim 13, wherein said antagonist/inhibitor comprises substantially a portion of double-stranded oligoribonucleotides (dsRNA).
15. The method or use of claim 14, wherein said dsRNA is between 21 and 23 nucleotides in length.
16. The method or use of claim 14 or 15, wherein the dsRNA molecule contains a terminal 3'-hydroxyl group.
17. The method or use of any one of claims 12 to 16, wherein the nucleic acid molecule represents an analogue of naturally occurring RNA.
18. The method or use of claim 17, wherein the nucleotide sequence of the nucleic acid molecule differs from the nucleotide sequence of said gene or gene product by addition, deletion, substitution or modification of one or more nucleotides.
19. The method or use of any one of claims 10 to 18, wherein said gene or a cDNA thereof comprises a nucleotide sequence or encodes an amino acid sequence selected from the group consisting of any one of SEQ ID NOs: 1 to 4.

20. The method or use of any one of claims 1 to 19, wherein said compound is a nucleic acid molecule or encoded by a nucleic acid molecule and is designed to be expressed in cells of the CNS or eye.
21. The method or use of any one of claims 1 to 20, wherein the composition is in a form designed to be introduced into the cells or tissue of the CNS or eye by a suitable carrier, characterized by the application occurring outside the blood-brain or blood-retina barriers.
22. The method or use of any one of claims 1 to 21, wherein the composition is designed for systemic administration or for administration by iontophoresis.
23. The method or use of any one of claims 1 to 21, wherein the composition is designed for retrobulbar application or as eye drops.
24. A method of identifying and obtaining a nucleic acid molecule encoding a polypeptide involved in a disorder as defined in any one of claims 1 to 6 comprising the steps of:
 - (a) culturing a cell, tissue or non-human animal under stress conditions which lead to simulation of a pathological condition related to a CNS or eye disorder;
 - (b) isolating nucleic acids and/or proteins from a sample of said cell, tissue or animal;
 - (c) comparing the expression or activity profile of at least one of said nucleic acids and/or proteins with that of a corresponding non-treated cell, tissue or animal, and/or with that of a cell, tissue or animal, which has been treated under different stress conditions;
 - (d) determining at least one nucleic acid and/or protein which is differentially expressed, whereby a change of expression or of the active amount of said at least one nucleic acid or activity of at least one of said proteins or an altered localization of the protein is indicative for its role in a disorder of the CNS or eye.
25. The method of claim 24, wherein said stress condition is generated by an aberrant supply of the cell, tissue or animal culture conditions.
26. The method of claim 24 or 25, wherein said aberrant supply is an aberrant supply of the interior segment of the eye.

27. The method of any one of claims 24 to 26, wherein the method is a cell culture based method.
28. The method of claim 27, wherein said cell is an RPE cell.
29. The method of claim 28, wherein said cell is derived from an RPE derived cell line such as cell line ARPE-19.
30. The method of any one of claims 24 to 26, wherein said method is performed with a non-human animal.
31. The method of any one of claims 24 to 30, wherein said stress conditions comprise e.g. oxidative stress, hypoxic culture conditions, insufficient nutrition and/or supply with growth factors, change of pH-value and/or pathophysiological concentration of rod outer segments (ROS) and/or A2-E.
32. The method of any one of claims 24 to 31, wherein expression of nucleic acids is analyzed with an expression array and/or realtime PCR.
33. The method of any one of claims 24 to 32, wherein protein expression is analyzed with immunoblot or ELISA assay, or 2D gel electrophoresis or MALDI-TOF.
34. The method of claim 33, wherein antibodies are used which are specific for proteins involved in angiogenesis and/or neovascularization.
35. The method of any one of claims 24 to 34, further comprising overexpression or inhibition of expression of the identified candidate nucleic acid or encoded polypeptide in said cell, tissue or animal for their capability of inducing a responsive change in the phenotype of said cell, tissue or animal, wherein said phenotype is related to a disorder of the CNS or eye.
36. The method of any one of claims 24 to 35, further comprising:
 - (e) subjecting a cell of step (a) or secreted factors thereof, or cell lysates thereof, to

(f) analyzing cell proliferation, electrophysiological activity, DNA synthesis, outgrowth of cells, cell migration, chemokinesis, chemotaxis, development of vessels, marker gene expression or activity, apoptosis and/or vitality.

37. The method of any one of claims 24 to 36, wherein a sample of said cells are treated with an inhibitor specific for said candidate nucleic acid or encoded polypeptide; and further comprising determining whether said cells, secreted factors thereof or cell lysates thereof have lost their capability of inducing said responsive change in said phenotype.

38. The method of any one of claims 35 to 37, wherein said phenotype is angiogenesis and/or neovascularization and/or degenerative retinal disorder.

39. The method of claim 38, wherein said inhibitor is an inhibitor as defined in any one of claims 10 to 19.

40. The method of any one of claims 24 to 39, further comprising identifying the sequence of said at least one nucleic acid and/or protein, and optionally identifying the corresponding encoding gene or cDNA thereof.

41. The method of claims 40, further comprising cloning said gene, cDNA or a fragment thereof.

42. A nucleic acid molecule obtainable by the method of any one of claims 24 to 41.

43. The nucleic acid molecule of claim 42 encoding a polypeptide involved in angiogenesis and/or neovascularization and/or retinal disorder.

44. A nucleic acid molecule which specifically hybridizes to the nucleic acid molecule of claim 42 or 43, which encodes a mutated version of the protein which has lost its capability of inducing a responsive change in a phenotype as defined in any one of claims 35 to 38.

45. The nucleic acid molecule of any one of claims 42 to 44, which is DNA.

47. The nucleic acid molecule of any one of claim 42 to 64, which is derived from a mammal.
48. The nucleic acid molecule of claim 47, wherein the mammal is mouse or human.
49. A nucleic acid molecule of at least 15 nucleotides in length hybridizing specifically with a nucleic acid molecule of any one of claims 42 to 48 or with a complementary strand thereof.
50. A vector comprising a nucleic acid molecule of any one of claims 42 to 49.
51. The vector of claim 50, wherein the nucleic acid molecule is operatively linked to regulatory elements permitting expression in prokaryotic or eukaryotic host cells.
52. A host cell comprising a vector of claim 50 or 51.
53. The host cell of claim 52, which is a bacterial, fungal, plant or animal cell.
54. The host cell of claim 53, which is a mammalian cell.
55. The host cell of claim 54 which is an RPE cell or a neurosensory retina cell.
56. A method for the production of a polypeptide capable of inducing a responsive change in a phenotype as defined in any one of claims 35 to 38 comprising culturing a host cell of any one of claims 52 to 55 under conditions allowing the expression of the polypeptide and recovering the produced polypeptide from the culture.
57. A polypeptide encoded by a nucleic acid molecule of any one of claims 42 to 49 or obtainable by a method according to claim 56.
58. An antibody specifically recognizing a polypeptide of claim 57.
59. A pharmaceutical composition comprising a nucleic acid molecule of any one of

polypeptide of claim 57 and/or an antibody of claim 58, and optionally a pharmaceutically acceptable carrier.

60. A diagnostic composition comprising a nucleic acid molecule of any one of claims 42 to 49, a vector of claim 50 or 51, a host cell of any one of claims 52 to 55, a polypeptide of claim 57 and/or an antibody of claim 58, and optionally suitable means for detection.
61. A method for treating of a disorder as defined in any one of claims 1 to 6 comprising administering to the subject a pharmaceutical compositions of claim 59 in an effective dose.
62. A method for detecting expression of a gene involved in a disorder as defined in any one of claims 1 to 6 comprising
 - (a) obtaining mRNA from a cell;
 - (b) incubating the mRNA so obtained with a probe comprising a nucleic acid molecule of any one of claims 42 to 49 or a fragment thereof under hybridizing conditions; and
 - (c) detecting the presence of mRNA hybridized to the probe.
63. A method for detecting expression of a gene involved in a disorder as defined in any one of claims 1 to 6 comprising
 - (d) obtaining a cell sample from the subject;
 - (e) contacting the cell sample so obtained with an antibody of claim 58; and
 - (f) detecting the presence of the antibody bound to the protein encoded by said gene.
64. The method of claim 62 or 63 for the detection of the expression of a protein encoded by the nucleic acid molecule of claim 44.
65. A method for diagnosing in a subject to disorder as defined in any one of claims 1 to 6 or a predisposition to such disorder which comprises:
 - (a) isolating DNA from patient suffering from the disorder; digesting the isolated DNA of step (a) with at least one restriction enzyme;

- (c) incubating the resulting gel with a probe comprising a nucleic acid molecule of any one of claims 42 to 49 or a fragment thereof labelled with a detectable marker;
- (d) detecting labelled bands on a gel which have hybridized to the probe as defined to create a band pattern specific to the DNA of patients of the disorder;
- (e) preparing subject's DNA by steps (a) to (e) to produce detectable labeled bands on a gel; and
- (f) comparing the band pattern specific to the DNA of patients of the disorder of step (e) and the subject's DNA of step (f) to determine whether the patterns are the same or different and to diagnose thereby the disorder or a predisposition to the disorder, if the patterns are the same.

66. A method for diagnosing a disorder as defined in any one of claims 1 to 6 or a predisposition to such a disorder comprising:

- (a) analyzing a sample of nucleic acids of a subject by means of a diagnostic chip, primer extension, single nucleotide polymorphisms or sequencing comprising a nucleic acid molecule of any one of claims 42 to 49, and
- (b) comparing the result with that of a sample obtained from a patient suffering from the disorder,
wherein the identity of expression profil and/or nucleotide sequence is indicative for the disorder.

67. Use of an effective dose of a nucleic acid molecule of any one of claims 42 to 49, or a nucleic acid molecule which is complementary to such a nucleic acid molecule or a vector of claim 50 to 51 for the preparation of a composition for treating, preventing and/or delaying a disorder as defined in any one of claims 1 to 6 in a subject by somatic gene therapy.

68. A method of determining whether a test substance has an effect on a nucleic acid molecule or polypeptide involved in a disorder as defined in any one of claims 1 to 6, comprising the steps:

- (a) contacting a cell which expresses the polypeptide of claim 57 with a compound to be screened; and
- (b) determining if the compound modulates the expression or the activity of said

69. The method of claim 68, wherein said polypeptide is expressed under the control of the GGTB-promoter.
70. The method of claim 68 or 69, wherein the test substance is a chemotherapeutic agent.
71. The method of any one of claims 68 to 70, wherein the test substance is a mixture of chemotherapeutic agents.
72. The method of any one of claims 68 to 71, wherein said cell is derived from a single cell or a multi-cellular organism.
73. The method of any one of claims 68 to 72, wherein said cell is a cell as defined in any one of claims 28, 29, 35 or 52 to 55.
74. The method of any one of claim 68 to 73, wherein preferably in the first screen said test substance is comprised in and subjected as a collection of test substances.
75. The method of claim 74, wherein said collection of test substances has a diversity of about 10^3 to about 10^5 .
76. The method of claim 74 or 75, wherein the diversity of said collection of test substances is successively reduced.
77. The method of any one of claims 68 to 76, wherein said cell is comprised in a tissue or in a non-human animal.
78. A method for producing a drug or prodrug for the treatment of a disorder as defined in any one of claim 1 to 6 comprising:
 - (a) synthesizing a test substance or a collection of test substances;
 - (b) subjecting said the test substance or collection of test substances to the method of any one of claims 68 to 77; and
 - (c) producing a compound identified as a modulator in step (b) or a derivative thereof.


79. A test substance identified, isolated and/or produced by the method of any one of claims 68 to 78, wherein said test substance has hitherto not been known as a drug for the treatment of a disorder as defined in any one of claims 1 to 6.
80. Use of a compound identified, isolated and/or produced by the method of any one of claims 68 to 78 for the preparation of a composition for the treatment of a disorder as defined in any one of claims 1 to 6.
81. A method for the treatment of a disorder as defined in any one of claims 1 to 6, comprising administering a composition prepared according to the use of claim 80 or the method of claim 78 to a subject suffering from the disorder.
82. A chip comprising a solid support and attached thereto one or more of the nucleic acid molecules of any one of claims 42 to 49.
83. A kit for use in the method of any one of claims 24 to 41 or 62 to 78 comprising a chip of claim 82 or other means for the detection of expression and/or activity of a nucleic acid molecule of any one of claims 42 to 49 or a polypeptide of claim 58.
84. Use of a compound identified, isolated and/or produced by the method of any one of claims 68 to 78 as a lead compound in drug discovery and preparation of drugs or prodrugs.
85. Use of a nucleic acid molecule of any one of claims 42 to 49 or of a polypeptide of claim 57 for the validation of test substances, lead compounds, drugs and prodrugs for the treatment of a disorder as defined in any one of claims 1 to 6 or for the identification and isolation of downstream genes, which respond to modulation of a gene comprising a nucleic acid molecule of any one of claims 42 to 49 or its encoded gene product.
86. A transgenic non-human animal which displays an aberrant expression or activity of the polypeptide of claim 57.
87. The non-human animal of claim 86, wherein said animal reproduces a disorder as

- 73 -

88. The animal of claim 86 or 87 which is a mammal.
89. Use of a transgenic non-human animal of any one of claims 86 to 88 for a process in drug discovery for the treatment of a disorder as defined in any one of claims 1 to 6.
90. A pharmaceutical composition for use in the treatment of a disorder as defined in any one of claim 1 to 6 comprising one or more double-stranded oligoribonucleotides (dsRNA), which mediate an RNA interference of the corresponding mRNA of one or more nucleic acid molecules of any one of claims 42 to 49, and optionally a pharmaceutically acceptable carrier.

1/1

fluorescence



bright-field

Figure 1

SEQUENCE LISTING

<110> Lynkeus Biotech GmbH

<120> Means and Methods for the Specific Modulation of Target Genes in the CNS and the Eye and Methods for Their Identification

<130> LY01A04/P-WO

<150> EP02008761.5

<151> 2002-04-18

<150> US 60/431,173

<151> 2002-12-05

<160> 10

<170> PatentIn version 3.1

<210> 1

<211> 2500

<212> DNA

<213> homo sapiens

<220>

<221> CDS

<222> (25) .. (2097)

<223> Homo sapiens cyclic nucleotide gated channel alpha 1

<400> 1

tatattactt aaacaaccaa agat atg aaa cta tcc atg aag aac aat att
Met Lys Leu Ser Met Lys Asn Asn Ile
1 5

atc aat aca cag cag tct ttt gta acc atg ccc aat gtg att gta cca
Ile Asn Thr Gln Gln Ser Phe Val Thr Met Pro Asn Val Ile Val Pro
10 15 20 25

gat att gaa aag gaa ata cga agg atg gaa aat gga gca tgc agc tcc Asp Ile Glu Lys Glu Ile Arg Arg Met Glu Asn Gly Ala Cys Ser Ser 30 35 40	147
ttt tct gag gat gat gac agt gcc tat aca tct gaa gaa tca gag aat Phe Ser Glu Asp Asp Asp Ser Ala Tyr Thr Ser Glu Glu Ser Glu Asn 45 50 55	195
gaa aac cct cat gca agg ggt tcc ttt agt tat aag tca ctc aga aag Glu Asn Pro His Ala Arg Gly Ser Phe Ser Tyr Lys Ser Leu Arg Lys 60 65 70	243
gga gga cca tca cag agg gag cag tac ctg cct ggt gcc att gcc att Gly Gly Pro Ser Gln Arg Glu Gln Tyr Leu Pro Gly Ala Ile Ala Ile 75 80 85	291
ttt aat gtg aac aac agc agc aat aag gac cag gaa cca gag gaa aaa Phe Asn Val Asn Asn Ser Ser Asn Lys Asp Gln Glu Pro Glu Glu Lys 90 95 100 105	339
aag aaa aag aaa aag gaa aag aag agc aag tca gat gat aaa aac gaa Lys Lys Lys Lys Glu Lys Lys Ser Lys Ser Asp Asp Lys Asn Glu 110 115 120	387
aat aaa aac gac cca gag aag aaa aag aag aaa aag gac aaa gag aag Asn Lys Asn Asp Pro Glu Lys Lys Lys Lys Lys Asp Lys Glu Lys 125 130 135	435
aaa aag aaa gag gag aaa agc aaa gat aag aaa gaa cac cac aag aaa Lys Lys Glu Glu Lys Ser Lys Asp Lys Lys Glu His His Lys Lys 140 145 150	483
gaa gtt gtg gtt att gat ccc tcg gga aac aca tat tac aac tgg ctg Glu Val Val Val Ile Asp Pro Ser Gly Asn Thr Tyr Tyr Asn Trp Leu 155 160 165	531
ttt tgc atc aca tta cct gtt atg tac aac tgg aca atg gtt att gcc Phe Cys Ile Thr Leu Pro Val Met Tyr Asn Trp Thr Met Val Ile Ala 170 175 180 185	579
aga gca tgt ttt gat gaa ctt caa tct gat tac cta gaa tat tgg ctc Arg Ala Cys Phe Asp Glu Leu Gln Ser Asp Tyr Leu Glu Tyr Trp Leu 190 195 200	627
att ttg gat tac gta tca gac ata gtc tat tta atc gat atg ttt gta Ile Leu Asp Tyr Val Ser Asp Ile Val Tyr Leu Ile Asp Met Phe Val 205 210 215	675
cga aca agg aca ggt tac cta gaa caa gga ctg ctg gta aag gaa gaa Arg Thr Arg Thr Gly Tyr Leu Glu Gln Gly Leu Leu Val Lys Glu Glu 220 225 230	723
ctt aaa ctc ata aat aaa tat aaa tcc aac ttg caa ttt aaa ctt gat Leu Lys Leu Ile Asn Lys Tyr Lys Ser Asn Leu Gln Phe Lys Leu Asp 235 240 245	771
gtt ctg tca ctg ata cca act gat ttg ctg tat ttt aag tta ggg tgg Val Leu Ser Leu Ile Pro Thr Asp Leu Leu Tyr Phe Lys Leu Gly Trp 250 255 260 265	819
aac tat cca gaa att aga tta aac agg ttg tta cgg ttc tct cgt atg Asn Tyr Pro Glu Ile Arg Leu Asn Arg Leu Leu Arg Phe Ser Arg Met 270 275 280	867

ttt gag ttc ttc cag aga aca gaa aca agg aca aac tat cca aac atc Phe Glu Phe Phe Gln Arg Thr Glu Thr Arg Thr Asn Tyr Pro Asn Ile 285 290 295	915
ttc agg att tcc aac ctt gtt atg tat atc gtc atc att atc cac tgg Phe Arg Ile Ser Asn Leu Val Met Tyr Ile Val Ile Ile Ile His Trp 300 305 310	963
aat gca tgt gtg ttc tac tct att tct aaa gct att gga ttt gga aat Asn Ala Cys Val Phe Tyr Ser Ile Ser Lys Ala Ile Gly Phe Gly Asn 315 320 325	1011
gat aca tgg gtc tac cct gat att aat gat cct gaa ttt ggc cgt ttg Asp Thr Trp Val Tyr Pro Asp Ile Asn Asp Pro Glu Phe Gly Arg Leu 330 335 340 345	1059
gct aga aaa tac gta tac agc ctt tac tgg tct aca ctg act ttg act Ala Arg Lys Tyr Val Tyr Ser Leu Tyr Trp Ser Thr Leu Thr Leu Thr 350 355 360	1107
acc att ggt gaa aca ccc cct ccc gtc agg gat tct gag tat gtc ttt Thr Ile Gly Glu Thr Pro Pro Val Arg Asp Ser Glu Tyr Val Phe 365 370 375	1155
gtg gtg gtt gat ttc cta att gga gtc tta att ttt gct acc atc gtt Val Val Val Asp Phe Leu Ile Gly Val Leu Ile Phe Ala Thr Ile Val 380 385 390	1203
ggg aac ata ggt tct atg att tcc aac atg aat gca gcc aga gca gaa Gly Asn Ile Gly Ser Met Ile Ser Asn Met Asn Ala Ala Arg Ala Glu 395 400 405	1251
ttt caa gca aga att gat gct atc aag caa tat atg cat ttt cga aat Phe Gln Ala Arg Ile Asp Ala Ile Lys Gln Tyr Met His Phe Arg Asn 410 415 420 425	1299
gta agc aaa gat atg gaa aag agg gtt att aaa tgg ttt gac tac ctg Val Ser Lys Asp Met Glu Lys Arg Val Ile Lys Trp Phe Asp Tyr Leu 430 435 440	1347
tgg acc aac aaa aca gtt gat gag aaa gaa gtc tta aag tat cta Trp Thr Asn Lys Lys Thr Val Asp Glu Lys Glu Val Leu Lys Tyr Leu 445 450 455	1395
cct gat aaa cta aga gca gaa att gcc atc aac gtt cac tta gac aca Pro Asp Lys Leu Arg Ala Glu Ile Ala Ile Asn Val His Leu Asp Thr 460 465 470	1443
tta aaa aag gta cgc att ttt gct gat tgt gaa gct ggt ctg ttg gtc Leu Lys Lys Val Arg Ile Phe Ala Asp Cys Glu Ala Gly Leu Leu Val 475 480 485	1491
gag ttg gtc ttg aaa ttg caa ccc caa gtc tac agt cct gga gat tat Glu Leu Val Leu Lys Leu Gln Pro Gln Val Tyr Ser Pro Gly Asp Tyr 490 495 500 505	1539
att tgc aag aaa ggg gat atc gga cga gag atg tac att atc aag gaa Ile Cys Lys Lys Gly Asp Ile Gly Arg Glu Met Tyr Ile Ile Lys Glu 510 515 520	1587
ggc aaa ctc gct gtg gca gat gat gga gtc act cag ttt gtg gta Gly Lys Leu Ala Val Val Ala Asp Asp Gly Val Thr Gln Phe Val Val	1635

525	530	535	
ttg agc gat ggc agc acc ttc ggt gag atc agc att ctt aac att aaa Leu Ser Asp Gly Ser Thr Phe Gly Glu Ile Ser Ile Leu Asn Ile Lys 540	545	550	1683
ggg agc aaa gct ggc aat cga aga acg gcc aat att aaa agt att ggc Gly Ser Lys Ala Gly Asn Arg Arg Thr Ala Asn Ile Lys Ser Ile Gly 555	560	565	1731
tac tca gac ctg ttc tgt ctc tca aaa gat gac ctc atg gaa gct cta Tyr Ser Asp Leu Phe Cys Leu Ser Lys Asp Asp Leu Met Glu Ala Leu 570	575	580	1779
act gag tac cca gat gcc aaa act atg cta gaa gaa aaa ggg aag caa Thr Glu Tyr Pro Asp Ala Lys Thr Met Leu Glu Lys Gly Lys Gln 590	595	600	1827
att tta atg aaa gat ggt cta ctg gat cta aac att gca aat gct ggc Ile Leu Met Lys Asp Gly Leu Leu Asp Leu Asn Ile Ala Asn Ala Gly 605	610	615	1875
agt gat cct aaa gat ctt gaa gag aag gtt act cga atg gag ggg tca Ser Asp Pro Lys Asp Leu Glu Lys Val Thr Arg Met Glu Gly Ser 620	625	630	1923
gta gac ctc ctg caa acc agg ttt gcc cga atc ttg gct gag tat gag Val Asp Leu Leu Gln Thr Arg Phe Ala Arg Ile Leu Ala Glu Tyr Glu 635	640	645	1971
tcc atg cag cag aaa ctg aaa caa aga tta acc aag gtt gag aaa ttt Ser Met Gln Gln Lys Leu Lys Gln Arg Leu Thr Lys Val Glu Lys Phe 650	655	660	2019
ctg aaa ccg ctt att gac aca gaa ttt tca agt att gag gga cct tgg Leu Lys Pro Leu Ile Asp Thr Glu Phe Ser Ser Ile Glu Gly Pro Trp 670	675	680	2067
agc gaa agt ggg ccc atc gac tct aca tag aaccgaaaag ctggtcattta Ser Glu Ser Gly Pro Ile Asp Ser Thr 685	690		2117
acagggacat gcctcatgat ccttttgcata ctatgactga catcaactaa aatttaaaag aagaggaaga ctcagttggg aaattttcc atgaggaaaa tgtgctttgg tgcaaggtac agcccacacc tctctgagag atactatgat taaaaaagct ttatatctgg gattttcac aactgataat gtgcaaagat ataaactgat taacttgtca gtgtctgtat tttctgattt ttcacatac gctcatttta tgtaatattc ttcataaaaa tgaataagta gcccctcactt tcatgccatt tccatttttg agtgaagcgt atttgaagta actgagaatt accatgtaca tcatatttgg gataacattt tta			2177 2237 2297 2357 2417 2477 2500

<210> 2

<211> 690

<212> PRT

<213> homo sapiens

<400> 2

Met Lys Leu Ser Met Lys Asn Asn Ile Ile Asn Thr Gln Gln Ser Phe
1 5 10 15

Val Thr Met Pro Asn Val Ile Val Pro Asp Ile Glu Lys Glu Ile Arg
20 25 30

Arg Met Glu Asn Gly Ala Cys Ser Ser Phe Ser Glu Asp Asp Asp Ser
35 40 45

Ala Tyr Thr Ser Glu Glu Ser Glu Asn Glu Asn Pro His Ala Arg Gly
50 55 60

Ser Phe Ser Tyr Lys Ser Leu Arg Lys Gly Gly Pro Ser Gln Arg Glu
65 70 75 80

Gln Tyr Leu Pro Gly Ala Ile Ala Ile Phe Asn Val Asn Asn Ser Ser
85 90 95

Asn Lys Asp Gln Glu Pro Glu Glu Lys Lys Lys Lys Lys Glu Lys
100 105 110

Lys Ser Lys Ser Asp Asp Lys Asn Glu Asn Lys Asn Asp Pro Glu Lys
115 120 125

Lys Lys Lys Lys Asp Lys Glu Lys Lys Lys Lys Glu Lys Ser
130 135 140

Lys Asp Lys Lys Glu His His Lys Lys Glu Val Val Val Ile Asp Pro
145 150 155 160

Ser Gly Asn Thr Tyr Tyr Asn Trp Leu Phe Cys Ile Thr Leu Pro Val
165 170 175

Met Tyr Asn Trp Thr Met Val Ile Ala Arg Ala Cys Phe Asp Glu Leu
180 185 190

Gln Ser Asp Tyr Leu Glu Tyr Trp Leu Ile Leu Asp Tyr Val Ser Asp
195 200 205

Ile Val Tyr Leu Ile Asp Met Phe Val Arg Thr Arg Thr Gly Tyr Leu
210 215 220

Glu Gln Gly Leu Leu Val Lys Glu Glu Leu Lys Leu Ile Asn Lys Tyr

6/16

225	230	235	240
Lys Ser Asn Leu Gln Phe Lys Leu Asp Val Leu Ser Leu Ile Pro Thr			
245	250	255	
Asp Leu Leu Tyr Phe Lys Leu Gly Trp Asn Tyr Pro Glu Ile Arg Leu			
260	265	270	
Asn Arg Leu Leu Arg Phe Ser Arg Met Phe Glu Phe Phe Gln Arg Thr			
275	280	285	
Glu Thr Arg Thr Asn Tyr Pro Asn Ile Phe Arg Ile Ser Asn Leu Val			
290	295	300	
Met Tyr Ile Val Ile Ile His Trp Asn Ala Cys Val Phe Tyr Ser			
305	310	315	320
Ile Ser Lys Ala Ile Gly Phe Gly Asn Asp Thr Trp Val Tyr Pro Asp			
325	330	335	
Ile Asn Asp Pro Glu Phe Gly Arg Leu Ala Arg Lys Tyr Val Tyr Ser			
340	345	350	
Leu Tyr Trp Ser Thr Leu Thr Leu Thr Thr Ile Gly Glu Thr Pro Pro			
355	360	365	
Pro Val Arg Asp Ser Glu Tyr Val Phe Val Val Val Asp Phe Leu Ile			
370	375	380	
Gly Val Leu Ile Phe Ala Thr Ile Val Gly Asn Ile Gly Ser Met Ile			
385	390	395	400
Ser Asn Met Asn Ala Ala Arg Ala Glu Phe Gln Ala Arg Ile Asp Ala			
405	410	415	
Ile Lys Gln Tyr Met His Phe Arg Asn Val Ser Lys Asp Met Glu Lys			
420	425	430	
Arg Val Ile Lys Trp Phe Asp Tyr Leu Trp Thr Asn Lys Lys Thr Val			
435	440	445	
Asp Glu Lys Glu Val Leu Lys Tyr Leu Pro Asp Lys Leu Arg Ala Glu			
450	455	460	
Ile Ala Ile Asn Val His Leu Asp Thr Leu Lys Lys Val Arg Ile Phe			
465	470	475	480

7/16

Ala Asp Cys Glu Ala Gly Leu Leu Val Glu Leu Val Leu Lys Leu Gln
485 490 495

Pro Gln Val Tyr Ser Pro Gly Asp Tyr Ile Cys Lys Lys Gly Asp Ile
500 505 510

Gly Arg Glu Met Tyr Ile Ile Lys Glu Gly Lys Leu Ala Val Val Ala
515 520 525

Asp Asp Gly Val Thr Gln Phe Val Val Leu Ser Asp Gly Ser Thr Phe
530 535 540

Gly Glu Ile Ser Ile Leu Asn Ile Lys Gly Ser Lys Ala Gly Asn Arg
545 550 555 560

Arg Thr Ala Asn Ile Lys Ser Ile Gly Tyr Ser Asp Leu Phe Cys Leu
565 570 575

Ser Lys Asp Asp Leu Met Glu Ala Leu Thr Glu Tyr Pro Asp Ala Lys
580 585 590

Thr Met Leu Glu Glu Lys Gly Lys Gln Ile Leu Met Lys Asp Gly Leu
595 600 605

Leu Asp Leu Asn Ile Ala Asn Ala Gly Ser Asp Pro Lys Asp Leu Glu
610 615 620

Glu Lys Val Thr Arg Met Glu Gly Ser Val Asp Leu Leu Gln Thr Arg
625 630 635 640

Phe Ala Arg Ile Leu Ala Glu Tyr Glu Ser Met Gln Gln Lys Leu Lys
645 650 655

Gln Arg Leu Thr Lys Val Glu Lys Phe Leu Lys Pro Leu Ile Asp Thr
660 665 670

Glu Phe Ser Ser Ile Glu Gly Pro Trp Ser Glu Ser Gly Pro Ile Asp
675 680 685

Ser Thr
690

<210> 3

<211> 3231

<212> DNA

<213> homo sapiens

<220>

<221> CDS

<222> (22)..(2586)

<223> Homo sapiens phosphodiesterase 6B, cGMP-specific, rod, beta (congenital stationary night blindness 3, autosomal dominant)

<400>	3														
ctccaggagc	aggcagccac	c	atg	agc	ctc	agt	gag	gag	cag	gcc	cg	agc	51		
			Met	Ser	Leu	Ser	Glu	Glu	Gln	Ala	Arg	Ser			
			1				5			10					
ttt	ctg	gac	cag	aac	ccc	gat	ttt	gcc	cgc	cag	tac	ttt	ggg	99	
Phe	Leu	Asp	Gln	Asn	Pro	Asp	Phe	Ala	Arg	Gln	Tyr	Phe	Gly	Lys	
15							20				25				
ctg	agc	cct	gag	aat	gtt	ggc	cgc	ggc	tgc	gag	gac	ggg	tgc	ccg	147
Leu	Ser	Pro	Glu	Asn	Val	Gly	Arg	Gly	Cys	Glu	Asp	Gly	Cys	Pro	Pro
30							35				40				
gac	tgc	gac	agc	ctc	cg	gac	ctc	tgc	cag	gt	gag	gag	agc	acg	195
Asp	Cys	Asp	Ser	Leu	Arg	Asp	Leu	Cys	Gln	Val	Glu	Ser	Thr	Ala	
45							50				55				
ctg	ctg	gag	ctg	gt	cag	gat	atg	cag	gag	agc	atc	aa	atg	gag	243
Leu	Leu	Glu	Leu	Val	Gln	Asp	Met	Gln	Glu	Ser	Ile	Asn	Met	Glu	Arg
60							65				70				
gt	gt	ttc	aag	gt	ct	cg	cg	ct	tgc	acc	ctc	ct	cag	ggc	91
Val	Val	Phe	Lys	Val	Leu	Arg	Arg	Leu	Cys	Thr	Leu	Leu	Gln	Ala	Asp
75							80				85			90	
cgc	tgc	agc	ctc	ttc	at	tg	cg	cg	aa	gg	gt	gg	cc	ct	339
Arg	Cys	Ser	Leu	Phe	Met	Tyr	Arg	Gln	Arg	Asn	Gly	Val	Ala	Glu	Leu
95							100				105				
gcc	acc	agg	ctt	ttc	agc	gt	cag	cc	gac	agc	gt	ct	gag	gac	387
Ala	Thr	Arg	Leu	Phe	Ser	Val	Gln	Pro	Asp	Ser	Val	Leu	Glu	Asp	Cys
110							115				120				
ctg	gt	ccc	ccc	gac	tcc	gag	atc	gt	ttc	cca	ct	gac	atc	ggg	435
Leu	Val	Pro	Pro	Asp	Ser	Glu	Ile	Val	Phe	Pro	Leu	Asp	Ile	Gly	Val
125							130				135				
gt	gg	cac	gt	gt	gct	cag	acc	aaa	aag	atg	gt	aa	gt	gg	483
Val	Gly	His	Val	Ala	Gln	Thr	Lys	Lys	Met	Val	Asn	Val	Glu	Asp	Val
140							145				150				
gcc	gag	tgc	cct	cac	ttc	agc	tca	ttt	gct	gac	gag	ctc	act	gac	531
Ala	Glu	Cys	Pro	His	Phe	Ser	Ser	Phe	Ala	Asp	Glu	Leu	Thr	Asp	Tyr
155							160				165			170	
aag	aca	aag	aat	atg	ctg	gcc	aca	ccc	atc	atg	aat	ggc	aaa	gac	579
Lys	Thr	Lys	Asn	Met	Leu	Ala	Thr	Pro	Ile	Mét	Asn	Gly	Lys	Asp	Val
175							180				185				

9/16

gtg gcg gtg atc atg gca gtg aac aag ctc aac ggc cca ttc ttc acc Val Ala Val Ile Met Ala Val Asn Lys Leu Asn Gly Pro Phe Phe Thr 190 195 200	627
agc gaa gac gaa gat gtg ttc ttg aag tac ctg aat ttt gcc acg ttg Ser Glu Asp Glu Asp Val Phe Leu Lys Tyr Leu Asn Phe Ala Thr Leu 205 210 215	675
tac ctg aag atc tat cac ctg agc tac ctc cac aac tgc gag acg cgc Tyr Leu Lys Ile Tyr His Leu Ser Tyr Leu His Asn Cys Glu Thr Arg 220 225 230	723
cgc ggc cag gtg ctg ctg tgg tcg gcc aac aag gtg ttt gag gag ctg Arg Gly Gln Val Leu Leu Trp Ser Ala Asn Lys Val Phe Glu Glu Leu 235 240 245 250	771
acg gac atc gag agg cag ttc cac aag gcc ttc tac acg gtg cgg gcc Thr Asp Ile Glu Arg Gln Phe His Lys Ala Phe Tyr Thr Val Arg Ala 255 260 265	819
tac ctc aac tgc gag cgg tac tcc gtg ggc ctc ctg gac atg acc aag Tyr Leu Asn Cys Glu Arg Tyr Ser Val Gly Leu Leu Asp Met Thr Lys 270 275 280	867
gag aag gaa ttt ttt gac gtg tgg tct gtg ctg atg gga gag tcc cag Glu Lys Glu Phe Phe Asp Val Trp Ser Val Leu Met Gly Glu Ser Gln 285 290 295	915
ccg tac tcg ggc cca cgc acg cct gat ggc cgg gaa att gtc ttc tac Pro Tyr Ser Gly Pro Arg Thr Pro Asp Gly Arg Glu Ile Val Phe Tyr 300 305 310	963
aaa gtg atc gac tac atc ctc cac ggc aag gag gag atc aag gtc att Lys Val Ile Asp Tyr Ile Leu His Gly Lys Glu Glu Ile Lys Val Ile 315 320 325 330	1011
ccc aca ccc tca gcc gat cac tgg gcc ctg gcc agc ggc ctt cca agc Pro Thr Pro Ser Ala Asp His Trp Ala Leu Ala Ser Gly Leu Pro Ser 335 340 345	1059
tac gtg gca gaa agc ggc ttt att tgt aac atc atg aat gct tcc gct Tyr Val Ala Glu Ser Gly Phe Ile Cys Asn Ile Met Asn Ala Ser Ala 350 355 360	1107
gac gaa atg ttc aaa ttt cag gaa ggg gcc ctg gac gac tcc ggg tgg Asp Glu Met Phe Lys Phe Gln Glu Gly Ala Leu Asp Asp Ser Gly Trp 365 370 375	1155
ctc atc aag aat gtg ctg tcc atg ccc atc gtc aac aag aag gag gag Leu Ile Lys Asn Val Leu Ser Met Pro Ile Val Asn Lys Lys Glu Glu 380 385 390	1203
att gtg gga gtc gcc aca ttt tac aac agg aaa gac ggg aag ccc ttt Ile Val Gly Val Ala Thr Phe Tyr Asn Arg Lys Asp Gly Lys Pro Phe 395 400 405 410	1251
gac gaa cag gac gag gtt ctc atg gag tcc ctg aca cag ttc ctg ggc Asp Glu Gln Asp Glu Val Leu Met Glu Ser Leu Thr Gln Phe Leu Gly 415 420 425	1299
tgg tca gtg atg aac acc gac acc tac gac aag atg aac aag ctg gag Trp Ser Val Met Asn Thr Asp Thr Tyr Asp Lys Met Asn Lys Leu Glu 430 435 440	1347

aac	cgc	aag	gac	atc	gca	cag	gac	atg	gtc	ctt	tac	cac	gtg	aag	tgc	1395
Asn	Arg	Lys	Asp	Ile	Ala	Gln	Asp	Met	Val	Leu	Tyr	His	Val	Lys	Cys	
445															455	
gac	agg	gac	gag	atc	cag	ctc	atc	ctg	cca	acc	aga	gcg	cgc	ctg	ggg	1443
Asp	Arg	Asp	Glu	Ile	Gln	Leu	Ile	Leu	Pro	Thr	Arg	Ala	Arg	Leu	Gly	
460															470	
aag	gag	cct	gct	gac	tgc	gat	gag	gac	gag	ctg	ggc	gaa	atc	ctg	aag	1491
Lys	Glu	Pro	Ala	Asp	Cys	Asp	Glu	Asp	Glu	Leu	Gly	Glu	Ile	Leu	Lys	
475															490	
gag	gag	ctg	cca	ggg	ccc	acc	aca	ttt	gac	atc	tac	gaa	ttc	cac	ttc	1539
Glu	Glu	Leu	Pro	Gly	Pro	Thr	Thr	Phe	Asp	Ile	Tyr	Glu	Phe	His	Phe	
495															505	
tct	gac	ctg	gag	tgc	acc	gaa	ctg	gac	ctg	gtc	aaa	tgt	ggc	atc	cag	1587
Ser	Asp	Leu	Glu	Cys	Thr	Glu	Leu	Asp	Leu	Val	Lys	Cys	Gly	Ile	Gln	
510															520	
atg	tac	tac	gag	ctg	ggc	gtg	gtc	cga	aag	ttc	cag	atc	ccc	cag	gag	1635
Met	Tyr	Tyr	Glu	Leu	Gly	Val	Val	Arg	Lys	Phe	Gln	Ile	Pro	Gln	Glu	
525															535	
gtc	ctg	gtg	cgg	ttc	ctg	ttc	tcc	atc	agc	aaa	ggg	tac	cgg	aga	atc	1683
Val	Leu	Val	Arg	Phe	Leu	Phe	Ser	Ile	Ser	Lys	Gly	Tyr	Arg	Arg	Ile	
540															550	
acc	tac	cac	aac	tgg	cgc	cac	ggc	ttc	aac	gtg	gcc	cag	acg	atg	ttc	1731
Thr	Tyr	His	Asn	Trp	Arg	His	Gly	Phe	Asn	Val	Ala	Gln	Thr	Met	Phe	
555															570	
acg	ctg	ctc	atg	acc	ggc	aaa	ctg	aag	agc	tac	tac	acg	gac	ctg	gag	1779
Thr	Leu	Leu	Met	Thr	Gly	Lys	Leu	Lys	Ser	Tyr	Tyr	Asp	Leu	Glu		
575															585	
gcc	ttc	gcc	atg	gtg	aca	gcc	ggc	ctg	tgc	cat	gac	atc	gac	cac	cgc	1827
Ala	Phe	Ala	Met	Val	Thr	Ala	Gly	Leu	Cys	His	Asp	Ile	Asp	His	Arg	
590															600	
ggc	acc	aac	aac	ctg	tac	cag	atg	aag	tcc	cag	aac	ccc	ttg	gct	aag	1875
Gly	Thr	Asn	Asn	Leu	Tyr	Gln	Met	Lys	Ser	Gln	Asn	Pro	Leu	Ala	Lys	
605															615	
ctc	cac	ggc	tcc	tcg	att	ttg	gag	cg	cac	cac	ctg	gag	ttt	ggg	aag	1923
Leu	His	Gly	Ser	Ser	Ile	Leu	Glu	Arg	His	His	Ile	Leu	Glu	Phe	Gly	Lys
620															630	
ttc	ctg	ctc	tcg	gag	gag	acc	ctg	aac	atc	tac	cag	aac	ctg	aac	cgg	1971
Phe	Leu	Leu	Ser	Glu	Glu	Thr	Leu	Asn	Ile	Tyr	Gln	Asn	Leu	Asn	Arg	
635															645	
650															650	
cg	cag	cac	gag	cac	gt	atc	cac	ctg	atg	gac	atc	gcc	atc	atc	gcc	2019
Arg	Gln	His	Glu	His	Val	Ile	His	Leu	Met	Asp	Ile	Ala	Ile	Ile	Ala	
655															660	
665															665	
acg	gac	ctg	gcc	ctg	tac	ttc	aag	aag	aga	g	atg	ttt	cag	aag	atc	2067
Thr	Asp	Leu	Ala	Leu	Tyr	Phe	Lys	Lys	Arg	Ala	Met	Phe	Gln	Lys	Ile	
670															675	
680															680	
gtg	gat	gag	tcc	aag	aac	tac	cag	aag	aag	agc	tgg	gtg	gag	tac		2115
Val	Asp	Glu	Ser	Lys	Asn	Tyr	Gln	Asp	Lys	Ser	Trp	Val	Glu	Tyr		

685	690	695	
ctg tcc ctg gag acg acc cg	aatc gtc atg gcc atg atg atg		2163
Leu Ser Leu Glu Thr Thr Arg Lys	Glu Ile Val Met Ala Met Met Met		
700	705	710	
aca gcc tgc gac ctg tct gcc atc acc aag ccc tgg gaa gtc cag agc			2211
Thr Ala Cys Asp Leu Ser Ala Ile Thr Lys Pro Trp Glu Val Gln Ser			
715	720	725	730
aag gtc gca ctt ctc gtg gct gct gag ttc tgg gag caa ggt gac ttg			2259
Lys Val Ala Leu Leu Val Ala Ala Glu Phe Trp Glu Gln Gly Asp Leu			
735	740	745	
gaa agg aca gtc ttg gat cag cag ccc att cct atg atg gac cgg aac			2307
Glu Arg Thr Val Leu Asp Gln Gln Pro Ile Pro Met Met Asp Arg Asn			
750	755	760	
aag gcg gcc gag ctc ccc aag ctg caa gtg ggc ttc atc gac ttc gtg			2355
Lys Ala Ala Glu Leu Pro Lys Leu Gln Val Gly Phe Ile Asp Phe Val			
765	770	775	
tgc aca ttc gtg tac aag gag ttc tct cgt ttc cac gaa gag atc ctg			2403
Cys Thr Phe Val Tyr Lys Glu Phe Ser Arg Phe His Glu Glu Ile Leu			
780	785	790	
ccc atg ttc gac cga ctg cag aac aat agg aaa gag tgg aag gcg ctg			2451
Pro Met Phe Asp Arg Leu Gln Asn Asn Arg Lys Glu Trp Lys Ala Leu			
795	800	805	810
gct gat gag tat gag gcc aaa gtg aag gct ctg gag gag aag gag gag			2499
Ala Asp Glu Tyr Glu Ala Lys Val Lys Ala Leu Glu Glu Lys Glu Glu			
815	820	825	
gag gag agg gtg gca gcc aag aaa gta ggc aca gaa att tgc aat ggc			2547
Glu Glu Arg Val Ala Ala Lys Lys Val Gly Thr Glu Ile Cys Asn Gly			
830	835	840	
ggc cca gca ccc aag tct tca acc tgc tgt atc ctg tga gcactggtcc			2596
Gly Pro Ala Pro Lys Ser Ser Thr Cys Cys Ile Leu			
845	850		
cgtggggacc ctagggctcc ctcaatcttc acccactagg atttgggttc tgcctgtggc			2656
tatttgctac aagaggttag gaagcccaag aaaatgactg aagatcattc tggatatttt			2716
aatttttttt tttttttttt ttttgagatg gagtcttgct ctgtcacccca ggctggagtg			2776
ccgtggcacg atctcagctc actgcaacct ccacccccc ggtcaagcg attctcgtgc			2836
ctcagcctcc ttagtagctg ggactacagg cgccccaccac cacacatgct aattttgt			2896
ttttcagtagc agatgggtt tcaccatatt gggcaggctg gtctcgaact cctgacactca			2956
ggtgatcacc gcctcagctt cctgaagtgc tgggattaca ggcattgagcc accacgccc			3016
gcctgtttt ataaactgaa gccaaactgtg aataaaactgt agcctacatt actcatccat			3076
ttttggatag ttaccactgg gagaccttg aaaagggtcc atgaactctg aaatcactga			3136
gaacatttgc agccacacat gtacatatgt gtacacaggt agacagatgg acacaggccg			3196
tttctcatcc agtttaggaa aacacacatg ctcag			3231

<210> 4

<211> 854

<212> PRT

<213> homo sapiens

<400> 4

Met Ser Leu Ser Glu Glu Gln Ala Arg Ser Phe Leu Asp Gln Asn Pro
1 5 10 15

Asp Phe Ala Arg Gln Tyr Phe Gly Lys Lys Leu Ser Pro Glu Asn Val
20 25 30

Gly Arg Gly Cys Glu Asp Gly Cys Pro Pro Asp Cys Asp Ser Leu Arg
35 40 45

Asp Leu Cys Gln Val Glu Glu Ser Thr Ala Leu Leu Glu Leu Val Gln
50 55 60

Asp Met Gln Glu Ser Ile Asn Met Glu Arg Val Val Phe Lys Val Leu
65 70 75 80

Arg Arg Leu Cys Thr Leu Leu Gln Ala Asp Arg Cys Ser Leu Phe Met
85 90 95

Tyr Arg Gln Arg Asn Gly Val Ala Glu Leu Ala Thr Arg Leu Phe Ser
100 105 110

Val Gln Pro Asp Ser Val Leu Glu Asp Cys Leu Val Pro Pro Asp Ser
115 120 125

Glu Ile Val Phe Pro Leu Asp Ile Gly Val Val Gly His Val Ala Gln
130 135 140

Thr Lys Lys Met Val Asn Val Glu Asp Val Ala Glu Cys Pro His Phe
145 150 155 160

Ser Ser Phe Ala Asp Glu Leu Thr Asp Tyr Lys Thr Lys Asn Met Leu
165 170 175

Ala Thr Pro Ile Met Asn Gly Lys Asp Val Val Ala Val Ile Met Ala
180 185 190

Val Asn Lys Leu Asn Gly Pro Phe Phe Thr Ser Glu Asp Glu Asp Val

13/16

195

200

205

Phe Leu Lys Tyr Leu Asn Phe Ala Thr Leu Tyr Leu Lys Ile Tyr His
210 215 220

Leu Ser Tyr Leu His Asn Cys Glu Thr Arg Arg Gly Gln Val Leu Leu
225 230 235 240

Trp Ser Ala Asn Lys Val Phe Glu Glu Leu Thr Asp Ile Glu Arg Gln
245 250 255

Phe His Lys Ala Phe Tyr Thr Val Arg Ala Tyr Leu Asn Cys Glu Arg
260 265 270

Tyr Ser Val Gly Leu Leu Asp Met Thr Lys Glu Lys Glu Phe Phe Asp
275 280 285

Val Trp Ser Val Leu Met Gly Glu Ser Gln Pro Tyr Ser Gly Pro Arg
290 295 300

Thr Pro Asp Gly Arg Glu Ile Val Phe Tyr Lys Val Ile Asp Tyr Ile
305 310 315 320

Leu His Gly Lys Glu Glu Ile Lys Val Ile Pro Thr Pro Ser Ala Asp
325 330 335

His Trp Ala Leu Ala Ser Gly Leu Pro Ser Tyr Val Ala Glu Ser Gly
340 345 350

Phe Ile Cys Asn Ile Met Asn Ala Ser Ala Asp Glu Met Phe Lys Phe
355 360 365

Gln Glu Gly Ala Leu Asp Asp Ser Gly Trp Leu Ile Lys Asn Val Leu
370 375 380

Ser Met Pro Ile Val Asn Lys Lys Glu Glu Ile Val Gly Val Ala Thr
385 390 395 400

Phe Tyr Asn Arg Lys Asp Gly Lys Pro Phe Asp Glu Gln Asp Glu Val
405 410 415

Leu Met Glu Ser Leu Thr Gln Phe Leu Gly Trp Ser Val Met Asn Thr
420 425 430

Asp Thr Tyr Asp Lys Met Asn Lys Leu Glu Asn Arg Lys Asp Ile Ala
435 440 445

14/16

Gln Asp Met Val Leu Tyr His Val Lys Cys Asp Arg Asp Glu Ile Gln
450 455 460

Leu Ile Leu Pro Thr Arg Ala Arg Leu Gly Lys Glu Pro Ala Asp Cys
465 470 475 480

Asp Glu Asp Glu Leu Gly Glu Ile Leu Lys Glu Glu Leu Pro Gly Pro
485 490 495

Thr Thr Phe Asp Ile Tyr Glu Phe His Phe Ser Asp Leu Glu Cys Thr
500 505 510

Glu Leu Asp Leu Val Lys Cys Gly Ile Gln Met Tyr Tyr Glu Leu Gly
515 520 525

Val Val Arg Lys Phe Gln Ile Pro Gln Glu Val Leu Val Arg Phe Leu
530 535 540

Phe Ser Ile Ser Lys Gly Tyr Arg Arg Ile Thr Tyr His Asn Trp Arg
545 550 555 560

His Gly Phe Asn Val Ala Gln Thr Met Phe Thr Leu Leu Met Thr Gly
565 570 575

Lys Leu Lys Ser Tyr Tyr Thr Asp Leu Glu Ala Phe Ala Met Val Thr
580 585 590

Ala Gly Leu Cys His Asp Ile Asp His Arg Gly Thr Asn Asn Leu Tyr
595 600 605

Gln Met Lys Ser Gln Asn Pro Leu Ala Lys Leu His Gly Ser Ser Ile
610 615 620

Leu Glu Arg His His Leu Glu Phe Gly Lys Phe Leu Leu Ser Glu Glu
625 630 635 640

Thr Leu Asn Ile Tyr Gln Asn Leu Asn Arg Arg Gln His Glu His Val
645 650 655

Ile His Leu Met Asp Ile Ala Ile Ile Ala Thr Asp Leu Ala Leu Tyr
660 665 670

Phe Lys Lys Arg Ala Met Phe Gln Lys Ile Val Asp Glu Ser Lys Asn
675 680 685

Tyr Gln Asp Lys Lys Ser Trp Val Glu Tyr Leu Ser Leu Glu Thr Thr
690 695 700

Arg Lys Glu Ile Val Met Ala Met Met Met Thr Ala Cys Asp Leu Ser
705 710 715 720

Ala Ile Thr Lys Pro Trp Glu Val Gln Ser Lys Val Ala Leu Leu Val
725 730 735

Ala Ala Glu Phe Trp Glu Gln Gly Asp Leu Glu Arg Thr Val Leu Asp
740 745 750

Gln Gln Pro Ile Pro Met Met Asp Arg Asn Lys Ala Ala Glu Leu Pro
755 760 765

Lys Leu Gln Val Gly Phe Ile Asp Phe Val Cys Thr Phe Val Tyr Lys
770 775 780

Glu Phe Ser Arg Phe His Glu Glu Ile Leu Pro Met Phe Asp Arg Leu
785 790 795 800

Gln Asn Asn Arg Lys Glu Trp Lys Ala Leu Ala Asp Glu Tyr Glu Ala
805 810 815

Lys Val Lys Ala Leu Glu Glu Lys Glu Glu Glu Glu Arg Val Ala Ala
820 825 830

Lys Lys Val Gly Thr Glu Ile Cys Asn Gly Gly Pro Ala Pro Lys Ser
835 840 845

Ser Thr Cys Cys Ile Leu
850

<210> 5

<211> 21

<212> DNA

<213> Artificial

<400> 5
gcaagctgac cctgaaggttc a 21

<210> 6

<211> 19

<212> RNA

<213> Artificial

<400> 6
gcaagcugac ccugaaguu 19

<210> 7

<211> 19

<212> RNA

<213> Artificial

<400> 7
aacuuucaggg ucagcuugc 19

<210> 8

<211> 21

<212> DNA

<213> Artificial

<400> 8
aattctccga acgtgtcacg t 21

<210> 9

<211> 21

<212> DNA/RNA

<213> Artificial

<400> 9
uucuccgaac gugucacgut t 21

<210> 10

<211> 21

<212> DNA/RNA

<213> Artificial

<400> 10
acgugacacg uucggagaat t 21

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 2003/087368 A3

(51) International Patent Classification⁷: C12N 15/11, (74) Agent: MÜLLER FOTTNER STEINECKE; Postfach A61K 48/00, 31/713, 9/08, C12Q 1/68, C12N 15/12, 31 01 40, 80102 München (DE).
C07K 14/47, 16/18, G01N 33/50, 33/68, A01K 67/027

(21) International Application Number:
PCT/EP2003/004003

(22) International Filing Date: 16 April 2003 (16.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02008761.5 18 April 2002 (18.04.2002) EP
60/431,173 5 December 2002 (05.12.2002) US

(71) Applicant (for all designated States except US):
LYNKEUS BIO TECH GMBH [DE/DE]; Friedrich-Bergius-Ring 15, 97076 Würzburg (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DRUMM, Karina [DE/DE]; Innerer Graben 12, 97070 Würzburg (DE). SCHLÖR, Stefan, Hubert [DE/DE]; Alfred-Delp-Str. 9c, 97828 Marktheidenfeld (DE). GÖHRING, Frank [DE/DE]; Robert-Kirchhoff-strasse 35, 97076 Würzburg (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
29 April 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2003/087368 A3

(54) Title: MEANS AND METHODS FOR THE SPECIFIC MODULATION OF TARGET GENES IN THE CNS AND THE EYE AND METHODS FOR THEIR IDENTIFICATION

(57) Abstract: Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the CNS and/or the eye, wherein the composition is designed to be administered outside the blood-CNS and the blood-retina barriers. Furthermore, methods are provided for identifying and obtaining nucleic acid molecules encoding polypeptides involved in CNS disorders or of the eye, methods for diagnosing said disorders as well as transgenic animal deficient in the expression of target genes identified in accordance with the described method. In addition, methods of identifying and isolating drugs that are particularly useful for the treatment of disorders related to the CNS and/or the eye are disclosed.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 03/04003

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C12N15/11	A61K48/00	A61K31/713	A61K9/08	C12Q1/68
	C12N15/12	C07K14/47	C07K16/18	G01N33/50	G01N33/68
	A01K67/027				

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K C12Q C07K G01N A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 82900 A (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US); PARTRIDGE WILLIAM M.) 8 November 2001 (2001-11-08)	1,2,9, 11-13, 17,18, 20-22
Y	the whole document ---	14-16
Y	WO 00 63364 A (AMERICAN HOME PRODUCTS CORPORATION; PACHUK CATHERINE SATISHCHANDRAN C.) 26 October 2000 (2000-10-26) page 21 page 39 -page 42; example 3 ---	14-16
A	WO 01 75164 A (WHITEHEAD INST; MAX PLANCK; MIT; MASSACHUSETTS UNIV; TUSCHL; SHARP ET) 11 October 2001 (2001-10-11) cited in the application the whole document ---	15,16
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the International search

20 January 2004

Date of mailing of the International search report

06 FEB 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Macchia, G

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/04003

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1 and 3-23 are directed to a method of treatment of the human/animal body, the search, has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

1-23, all partially insofar as they refer to subject-matter related to the inventions 1, 6 and 7.
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1, 2, 9, 11-18, 20-22 all partially

A method for the treatment of a disorder of the central nervous system (CNS) comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-brain barrier.

Use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of a disorder of the central nervous system (CNS), wherein said composition is designed to be applied outside the blood-brain barrier.

Said method or use wherein said compound is an inhibitor/antagonist of said target gene or gene product, said inhibitor/antagonist being derived from a nucleic acid molecule (ribozyme, antisense).

Methods or uses related thereto.

2. Claims: 1, 2, 9, 11-18, 20-22 all partially,
if and where applicable

A method for the treatment of a disorder of the central nervous system (CNS) comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-brain barrier.

Use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of a disorder of the central nervous system (CNS), wherein said composition is designed to be applied outside the blood-brain barrier.

Said method or use wherein said compound is an inhibitor/antagonist of said target gene or gene product, said inhibitor/antagonist being derived from a nucleic acid molecule (sense nucleic acid molecule).

Methods or uses related thereto.

3. Claims: 1, 2, 9, 11, 20-22 all partially

A method for the treatment of a disorder of the central nervous system (CNS) comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-brain barrier.

Use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

composition for the treatment of a disorder of the central nervous system (CNS), wherein said composition is designed to be applied outside the blood-brain barrier. Said method or use wherein said compound is an inhibitor/antagonist of said target gene or gene product, said inhibitor/antagonist being derived from a polypeptide. Methods or uses related thereto.

4. Claims: 1, 2, 9-11, 20-22 all partially

A method for the treatment of a disorder of the central nervous system (CNS) comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-brain barrier.

Use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of a disorder of the central nervous system (CNS), wherein said composition is designed to be applied outside the blood-brain barrier.

Said method or use wherein said compound is an inhibitor/antagonist of said target gene or gene product, said inhibitor/antagonist being derived from an antibody. Methods or uses related thereto.

5. Claims: 1, 2, 9, 11, 20-22 all partially

A method for the treatment of a disorder of the central nervous system (CNS) comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-brain barrier.

Use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of a disorder of the central nervous system (CNS), wherein said composition is designed to be applied outside the blood-brain barrier.

Said method or use wherein said compound is an inhibitor/antagonist of said target gene or gene product, said inhibitor/antagonist being derived from a ligand binding molecule of said gene or gene product. Methods or uses related thereto.

6. Claims: 1-23 all partially

A method for the treatment of a disorder of the eye comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-retina

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

barrier.

Use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of a disorder of the eye, wherein said composition is designed to be applied outside the blood-retina barrier.

Said method or use wherein said compound is an inhibitor/antagonist of said target gene or gene product, said inhibitor/antagonist being derived from a nucleic acid molecule (ribozyme, antisense).

Methods or uses related thereto.

7. Claims: 1-23 all partially, if and where applicable

A method for the treatment of a disorder of the eye comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-retina barrier.

Use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of a disorder of the eye, wherein said composition is designed to be applied outside the blood-retina barrier.

Said method or use wherein said compound is an inhibitor/antagonist of said target gene or gene product, said inhibitor/antagonist being derived from a nucleic acid molecule (sense nucleic acid molecule).

Methods or uses related thereto.

8. Claims: 1-11, 19-23 all partially

A method for the treatment of a disorder of the eye comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-retina barrier.

Use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of a disorder of the eye, wherein said composition is designed to be applied outside the blood-retina barrier.

Said method or use wherein said compound is an inhibitor/antagonist of said target gene or gene product, said inhibitor/antagonist being derived from a polypeptide.

Methods or uses related thereto.

9. Claims: 1-11, 19-23 all partially

A method for the treatment of a disorder of the eye

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-retina barrier.

Use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of a disorder of the eye, wherein said composition is designed to be applied outside the blood-retina barrier.

Said method or use wherein said compound is an inhibitor/antagonist of said target gene or gene product, said inhibitor/antagonist being derived from an antibody. Methods or uses related thereto.

10. Claims: 1-11, 19-23 all partially

A method for the treatment of a disorder of the eye comprising administering to a subject a composition comprising a compound capable of modulating a target gene or gene product in a therapeutically effective amount, wherein said composition is administered outside the blood-retina barrier.

Use of a compound capable of modulating a target gene or gene product for the preparation of a pharmaceutical composition for the treatment of a disorder of the eye, wherein said composition is designed to be applied outside the blood-retina barrier.

Said method or use wherein said compound is an inhibitor/antagonist of said target gene or gene product, said inhibitor/antagonist being derived from a ligand binding molecule of said gene or gene product. Methods or uses related thereto.

11. Claims: 24-90 all totally

A method as defined in claim 24.

Methods, products, compositions, uses, kits, chips related thereto.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 03/04003

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 20579 A (SMITHKLINE BEECHAM PLC (GB); PRICE JACK) 12 June 1997 (1997-06-12) the whole document	1,2,9, 11-14, 17,18, 20-22
X	WO 01 98522 A (YISSUM RES DEV CO UNIV JERUSALEM; KATZHENDLER SCHLOSSMAN NAJAJREH GIBS) 27 December 2001 (2001-12-27) the whole document	1,2,9, 11,12, 20-22
X	WO 97 18855 A (LERNER EDUARD NAUMOVICH; LERNER LEONID) 29 May 1997 (1997-05-29) the whole document	1,2,22
A	GAN L. ET AL.: "Specific interference of gene function by double-stranded RNA in neuronal cell lines" SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, page 2051 XP002259262 the whole document	14
A	EP 0 308 066 A (HEM RESEARCH, INC. (US); CARTER WILLIAM A.) 22 March 1989 (1989-03-22) page 2, line 40 page 3, line 28-30	14
A	WO 98 22132 A (YISSUM RES DEV CO HEBREW UNIV JERUSALEM; SOREQ FRIEDMAN SEIDMAN KAUFER) 28 May 1998 (1998-05-28) page 15, line 23-26	21
A	DZITOYEVA S. ET AL.: "Intra-abdominal injection of double-stranded RNA into anesthetized adult <i>Drosophila</i> triggers RNA interference in the central nervous system" MOLECULAR PSYCHIATRY, vol. 6, no. 6, November 2001 (2001-11), pages 665-670, XP008023738 the whole document	
A	WO 98 56361 A (MEDINOVA MEDICAL CONSULTING GMBH (DE); SABEL BERNHARD A.; SCHROEDER U.) 17 December 1998 (1998-12-17)	
X	WO 01 83729 A (NOVARTIS AG (CH); SCRIPPS RES INST; NEMEROW; VON SEGGERN; FRIEDLANDER) 8 November 2001 (2001-11-08) the whole document page 17	1-3,7-9, 11,12, 18,20, 21,23

-/-

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 03/04003

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 36646 A (CANCER RES CAMPAIGN TECH LIM (GB) ZERNICKA-GOETZ; WIANNY; EVANS GLOVER) 25 May 2001 (2001-05-25) page 15 -page 18 ---	1-3, 8, 9, 11-18, 21, 23
A	WO 00 44914 A (MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US); LI; FARRELL; KIRBY) 3 August 2000 (2000-08-03) page 47 -page 54; claims ---	
X	US 5 550 289 A (SINTEX USA INC; EPPSTEIN D.A; FELGNER P.L; GADEK T.R; JONES G.H; ROMAN) 27 August 1996 (1996-08-27) column 4, line 12-14 column 8, line 55 column 10, line 34-37 ---	1-3, 7-12, 17, 18, 20, 21, 23
P, X	WO 02 088320 A (UNIVERSITY OF FLORIDA; LEWIN ALFRED S; SHAW LYNN C.; GRANT MARIA B.) 7 November 2002 (2002-11-07) the whole document page 81 -page 82; example 7 page 92 -page 100; claims ---	1-13, 17-23
A	PINEDA D. ET AL.: "The genetic network of prototypic planarian eye regeneration is Pax6 independent" DEVELOPMENT, vol. 129, March 2002 (2002-03), pages 1423-1434, XP002259263 the whole document -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/EP 03/04003

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0182900	A 08-11-2001	US 6372250 B1		16-04-2002
		AU 5364601 A		12-11-2001
		CA 2403501 A1		08-11-2001
		EP 1282403 A1		12-02-2003
		WO 0182900 A1		08-11-2001
		US 2002054902 A1		09-05-2002
WO 0063364	A 26-10-2000	AU 4472100 A		02-11-2000
		BR 0009884 A		08-01-2002
		CA 2370628 A1		26-10-2000
		CN 1375004 T		16-10-2002
		EP 1171586 A2		16-01-2002
		JP 2002542263 T		10-12-2002
		WO 0063364 A2		26-10-2000
WO 0175164	A 11-10-2001	AU 3574402 A		11-06-2002
		AU 4962201 A		15-10-2001
		CA 2404890 A1		11-10-2001
		CA 2429814 A1		06-06-2002
		CZ 20031839 A3		15-10-2003
		WO 0244321 A2		06-06-2002
		EP 1309726 A2		14-05-2003
		HU 0302557 A2		28-10-2003
		JP 2003529374 T		07-10-2003
		NO 20032464 A		21-07-2003
		WO 0175164 A2		11-10-2001
		US 2003108923 A1		12-06-2003
		US 2002086356 A1		04-07-2002
WO 9720579	A 12-06-1997	WO 9720579 A2		12-06-1997
WO 0198522	A 27-12-2001	AU 6778801 A		02-01-2002
		CA 2413556 A1		27-12-2001
		EP 1292606 A2		19-03-2003
		WO 0198522 A2		27-12-2001
WO 9718855	A 29-05-1997	AU 7693296 A		11-06-1997
		CA 2238055 A1		29-05-1997
		WO 9718855 A1		29-05-1997
		EP 0869829 A1		14-10-1998
		JP 2000500999 T		02-02-2000
		US 2002123678 A1		05-09-2002
		US 2003191426 A1		09-10-2003
EP 0308066	A 22-03-1989	AT 132041 T		15-01-1996
		AU 1001595 A		23-02-1995
		AU 1736792 A		30-07-1992
		AU 2053588 A		20-04-1989
		AU 4849897 A		12-03-1998
		CA 1327002 C		15-02-1994
		CN 1032740 A , B		10-05-1989
		DE 3854829 D1		08-02-1996
		DE 3854829 T2		14-08-1996
		DK 449888 A		13-02-1989
		EP 0308066 A2		22-03-1989
		FI 883763 A		13-02-1989
		HU 47854 A2		28-04-1989
		IE 72103 B1		12-03-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/04003

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0308066	A	JP KR NO NZ OA PT SU US ZA	1131119 A 131879 B1 883594 A 225799 A 8901 A 88266 A , B 1834663 A3 5683986 A 8805967 A	24-05-1989 17-04-1998 13-02-1989 26-04-1991 31-10-1989 30-06-1989 15-08-1993 04-11-1997 26-07-1989
WO 9822132	A 28-05-1998	AU CA EP JP WO US US US AU AU EP JP WO US	732043 B2 5364298 A 2272280 A1 0957932 A2 2002512592 T 9822132 A1 6025183 A 6110742 A 6258780 B1 727611 B2 5385698 A 0951536 A1 2001510336 T 9826062 A2 6121046 A	12-04-2001 10-06-1998 28-05-1998 24-11-1999 23-04-2002 28-05-1998 15-02-2000 29-08-2000 10-07-2001 14-12-2000 03-07-1998 27-10-1999 31-07-2001 18-06-1998 19-09-2000
WO 9856361	A 17-12-1998	WO AU EP JP US	9856361 A1 3176097 A 0986373 A1 2001502721 T 2002034474 A1	17-12-1998 30-12-1998 22-03-2000 27-02-2001 21-03-2002
WO 0183729	A 08-11-2001	AU CA WO EP JP US	9519301 A 2407881 A1 0183729 A2 1280929 A2 2003531609 T 2002193327 A1	12-11-2001 08-11-2001 08-11-2001 05-02-2003 28-10-2003 19-12-2002
WO 0136646	A 25-05-2001	AU CA DE EP WO JP NO US ZA	1406501 A 2391622 A1 1230375 T1 1230375 A1 0136646 A1 2003514533 T 20022359 A 2003027783 A1 200203816 A	30-05-2001 25-05-2001 09-01-2003 14-08-2002 25-05-2001 22-04-2003 18-07-2002 06-02-2003 02-01-2003
WO 0044914	A 03-08-2000	AU CA EP WO US	2634800 A 2361201 A1 1147204 A1 0044914 A1 2002114784 A1	18-08-2000 03-08-2000 24-10-2001 03-08-2000 22-08-2002
US 5550289	A 27-08-1996	US US US	5622712 A 5366737 A 5208036 A	22-04-1997 22-11-1994 04-05-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No. ..

PCT/EP 03/04003

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5550289	A	US	5049386 A	17-09-1991
		US	4946787 A	07-08-1990
		US	4897355 A	30-01-1990
		US	6387395 B1	14-05-2002
		US	5545412 A	13-08-1996
		AT	50983 T	15-03-1990
		AU	594654 B2	15-03-1990
		AU	5185386 A	17-07-1986
		CA	1288774 C	10-09-1991
		DE	3669503 D1	19-04-1990
		EP	0187702 A1	16-07-1986
		JP	1935808 C	26-05-1995
		JP	6062517 B	17-08-1994
		JP	61161246 A	21-07-1986
		JP	2546623 B2	23-10-1996
		JP	7070011 A	14-03-1995
		NZ	214716 A	26-04-1989
		ZA	8600081 A	26-08-1987
WO 02088320	A	07-11-2002	WO	02088320 A2
				07-11-2002